Clinical effects of the GLP-1 receptor agonist exenatide in patients with type 2 diabetes by Bunck, M.C.M.
  
 
 
Clinical effects of the 
glucagon-like peptide-1 
receptor agonist exenatide in 
patients with type 2 diabetes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mathijs Christiaan Michaël Bunck 
 Clinical effects of the glucagon-like peptide-1 receptor agonist 
exenatide in patients with type 2 diabetes 
 
PhD-thesis, VU University Medical Center, Amsterdam, the Netherlands 
ISBN: 978-94-91211-91-1 
 
Thesis review committee: 
Prof.dr. J.H. Beijnen, Slotervaart Hospital, Amsterdam 
Prof.dr. H.J.G. Bilo, Isala Clinics, Zwolle 
Prof.dr. H.J. Blom, VU University Medical Center, Amsterdam 
Prof.dr. R.A. DeFronzo, UT Health Science Center at San Antonio 
Prof.dr. S.E. Kahn, VA Puget Sound Health Care System, Seattle 
Dr. E.J.P. de Koning, Leiden University Medical Center 
Prof.dr. P.T.A.M. Lips, VU University Medical Center, Amsterdam 
Prof.dr.ir. J.C. Seidell, VU University Medical Center, Amsterdam 
 
Photo cover: Ragazzo morso da un ramarro (Boy bitten by a lizard) (ca. 
1594), Michelangelo Merisi da Caravaggio (1571 –1610). Image courtesy of 
the National Gallery, London, United Kingdom. 
Cover design: Mathijs C. M. Bunck, Zeist 
Lay-out: Marjolein Driehuis, MIIIH Media, Zeist 
Printed by: Ipskamp Drukkers B.V., Enschede 
 
The studies presented in this thesis were performed in the Diabetes Center, 
Department of Internal Medicine of the VU University Medical Center, 
Amsterdam, the Netherlands. 
 
Copyright © 2011, Mathijs C. M. Bunck, Zeist. 
All rights reserved. No part of this publication may be reproduced or 
transmitted in any form by any means, electronical or mechanical, including 
photocopy, recording or any other information storage and retrieval system, 
without the written permission of the author. 
 
Financial support for this thesis has been kindly provided by: 
 
 
  
  
 VRIJE UNIVERSITEIT 
 
Clinical effects of the GLP-1 receptor agonist exenatide in 
patients with type 2 diabetes 
 
 
 
ACADEMISCH PROEFSCHRIFT 
 
 
ter verkrijging van de graad Doctor aan 
de Vrije Universiteit Amsterdam, 
op gezag van de rector magnificus 
prof.dr. L.M. Bouter, 
in het openbaar te verdedigen 
ten overstaan van de promotiecommissie 
van de faculteit der Geneeskunde 
op vrijdag 9 september 2011 om 15.45 uur 
in de aula van de universiteit, 
de Boelelaan 1105 
 
 
 
 
door 
 
Mathijs Christiaan Michaël Bunck 
 
 
geboren te Amsterdam 
 
  
  
promotoren:  prof.dr. M. Diamant 
   prof.dr. R.J. Heine 
 
  
 “Curiosity is the essence of human existence and exploration has been part 
of humankind for a long time.” 
 
Eugene Andrew Cernan (born March 14, 1934) 
Commander of Apollo 17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aan mijn ouders… 
 Contents 
 
Chapter 1 
General introduction and rationale for this thesis   9 
 
Chapter 2 
One-year treatment with exenatide improves beta-cell function,  35 
compared with insulin glargine, in metformin treated type 2 
diabetes patients: a randomized, controlled trial 
Diabetes Care 2009;32:762-768 
 
Chapter 3 
One-year treatment with exenatide vs. insulin glargine:    53 
effects on postprandial glycemia, lipid profiles, and oxidative stress 
Atherosclerosis 2010;212:223-229 
 
Chapter 4 
One-year exenatide and insulin glargine treatment improves   75 
prandial beta-cell response in metformin treated patients  
with type 2 diabetes 
Diabetes Obes Metab (Submitted for publication) 
 
Chapter 5 
Exenatide affects circulating cardiovascular risk biomarkers   95 
independently of changes in body composition 
Diabetes Care 2010;33:1734-1737 
 
Chapter 6 
Effects of exenatide on measures of beta-cell function after   107 
3-years in metformin-treated patients with type 2 diabetes 
Diabetes Care (Accepted for publication) 
 
Chapter 7 
Exenatide treatment did not affect bone mineral density despite  125 
body weight reduction in patients with type 2 diabetes 
Diabetes Obes Metab 2011;13:374-377 
 
Chapter 8 
Incretin mimetics as a novel therapeutic option for hepatic steatosis 133 
Liver Int 2006;26:1015-1017 
 
 Chapter 9 
Summary and conclusion      139 
 
Chapter 10 
Samenvatting voor de geïnteresseerde leek    166 
List of abbreviations       174 
Affiliation of co-authors       176 
List of publications       178 
Dankwoord/Acknowledgments      181 
Curriculum vitae       185 
 
  
Chapter  1 
General introduction and rationale 
for this thesis 
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Only recently, our appreciation of type 2 diabetes mellitus has evolved from 
‘a relatively benign old people’s condition’ to a disease that globally 
threatens the life and well-being of a growing and ever younger proportion 
of the population (1, 2). Due to changing lifestyles, particularly in the 
developing world, obesity, in adults and children alike, is increasing at an 
alarming rate (3, 4). The World Health Organization has calculated that in 
the year 2030 over 350 million people will be diagnosed with type 2 diabetes 
world wide (3). In the Netherlands this number is expected to increase from 
670.000 people in 2008, to approximately 1.3 million in 2025 (5). 
 
Type 2 diabetes is characterized by progressive pancreatic beta-cell failure 
against a background of obesity-related insulin resistance (6, 7). Data from 
the United Kingdom Prospective Diabetes Study (UKPDS) showed that 
irrespective of the therapy used (8), glycemic control worsens over time as a 
result of progressive loss of pancreatic beta-cell function (9), whereas the 
severity of insulin resistance remains relatively stable (10, 11). The 
aforementioned progressive nature of type 2 diabetes makes the treatment of 
patients with type 2 diabetes challenging (12, 13). In addition to lifestyle 
interventions, that appear most effective but hard to implement and sustain 
(14), oral anti hyperglycemic agents are usually the first pharmacological 
step in the treatment of type 2 diabetes (15, 16). Unfortunately, as 
pancreatic beta-cell function deteriorates at an estimated rate of 
approximately 4% per year (11), a combination of multiple glucose lowering 
agents, and eventually insulin therapy, are often needed to achieve and 
maintain blood glucose at target values (13). Although, traditionally 
available therapeutic options reduce blood glucose concentrations, and 
subsequently improve pancreatic beta-cell function by (temporary) 
alleviating glucose toxicity (17), none of these available anti hyperglycemic 
agents changes the progressive nature of type 2 diabetes (Figure 1.1) (13).  
 
Type 2 diabetes is associated with a high rate of microvascular (18, 19) and 
macrovascular (18, 20-22) morbidity and mortality, which imposes a 
tremendous burden on individuals and societies, with regard to quality of 
life, healthcare resources and socioeconomic aspects (4). Data from the 
UKPDS shows that the development of microvascular disease is reduced 
when glycemic control is improved and has helped establish treatment 
targets for glycemia in type 2 diabetes (23). Current therapeutic 
interventions aim to lower HbA1C concentrations as close as possible to the 
normal, physiological range (approximately less than 6.5%) without 
imposing a high risk of severe hypoglycemia (13). Taken all together, the 
now widely used therapeutic options for patients with type 2 diabetes 
patients make up an unmet medical need. 
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Figure 1.1 Current therapeutic implications of progressively declining beta-cell 
function in type 2 diabetes. At the time of diagnosis, beta-cell function is reduced by 
40–50% in type 2 diabetes and continues to decline over the years (hatched line), 
irrespective of treatment modality. According to the present guidelines, HbA1c 
above 7% (dotted line) should trigger therapeutic action, which may result in 
HbA1c-lowering, however, this effect is only temporary and soon the next 
therapeutic step is needed (solid line). Adapted from Van Genugten (24). 
 
Over the last decade scientific research focusing on the pathophysiology and 
the development of new pharmacotherapeutic options for type 2 diabetes, 
has greatly expanded (25). Traditionally, peripheral insulin resistance, 
increased hepatic gluconeogenesis, and pancreatic beta-cell failure were 
considered core elements in the evolution of type 2 diabetes (1). However, 
the pathophysiology of type 2 diabetes is complex, and disease progression is 
linked to factors independent of insulin deregulation and reduced first-phase 
insulin response (12). New discoveries in both the molecular background of 
type 2 diabetes, and pharmaceutical sciences have provided us with a 
colorful pallet of therapeutic options, in addition to traditionally used agents 
as metformin, sulfonylurea and insulin. These agents target all organs that 
contribute to the complex nature of type 2 diabetes (Figure 1.2) (1, 2, 26). 
In alignment with the changing view on pathophysiology, focus of interest 
has shifted from insulin resistance as a therapeutic target, to deranged islet 
cell homeostasis, in particular the preservation and improvement of 
pancreatic beta-cell mass and progressive loss of beta-cell function (26).  
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Figure 1.2 Pharmacological treatments of type 2 diabetes according to the site of 
action. Adapted from Stumvol (1). 
 
It has been hypothesized that a treatment successfully addressing multiple 
elements of the underlying defects in type 2 diabetes would be an ideal 
intervention (12). To achieve this, a more holistic therapeutic approach may 
be needed enclosing treatment for both the beta-cell function and 
cardiovascular complications. This may involve the early initiation of >1 
pharmacotherapeutic agent to target the underlying defects of the disease 
(13, 27). Additionally, future therapeutic interventions may include 
treatments addressing the decreased activity of incretins, as seen in patients 
with type 2 diabetes (28).  
 
The incretin concept 
During the early days of the 20th century the idea rose that after ingestion 
of a meal, a gastro-intestinal ‘messenger’ stimulated the enhancement of 
carbohydrate processing in the pancreas (29). To test this early hypothesis, 
already then, experiments were conducted studying gut extracts as a 
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possible therapy for diabetes. Moore et al. treated three patients with 
diabetes mellitus with an extract (‘given by the mouth’) derived from the 
mucous surface of the upper three or four feet of the small intestine of a pig 
(30). Shortly afterwards, this presumed endocrine pancreas stimulating, 
gastro-intestinal humoral activity was named ‘incretin’ by La Barre (31). 
Following the discovery of the radio-immunoassay of insulin in 1956 (32), 
the incretin concept (re)gained popularity again. Intravenous glucose 
infusions appeared to result in a smaller pancreatic insulin response 
compared to jejunal infusion of the same amount of glucose (33). The 
connection between the gut and the islets of Langerhans in the pancreas was 
called ‘entero-insular axis’ (34). Finally, Creutzfeldt defined an incretin as a 
substance released upon nutrient ingestion, which at physiological 
concentrations stimulates pancreatic insulin release in the presence of a 
raised blood glucose concentration (35). 
 
The identity of factors responsible for the entero-insular axis remained 
unclear until the identification and characterization, glucose-dependent 
insulinotropic polypeptide (GIP) in the 1970s (36, 37).  Initially, GIP 
appeared to be an inhibitor of gastric acid production; hence it’s early name 
gastric inhibitory polypeptide (38). Due to the fact that the observed increase 
in insulin secretion was only seen in the presence of hyperglycemia, the 
proteins name was changed from gastric inhibitory polypeptide into glucose 
dependent insulinotropic polypeptide (39). Removal of GIP from gut 
extracts by immune-absorption method did not eliminate the incretin effect. 
This gave evidence for the existence of other factors with incretin-like 
activity (40). About a decade later, the second incretin hormone to be 
discovered was glucagon-like peptide-1 (GLP-1). GLP-1 is a product of the 
proglucagon gene and shares a 50% similarity with the amino acid sequence 
of glucagon (41). The proglucagon gene is expressed in the islet of 
Langerhans, the L-cells in the small intestine and specific areas of the central 
nervous system, predominantly the nucleus of the solitary tract (42, 43). L-
cells are specialized entero-endocrine cells, located in ileum and colon, and 
somewhat less frequent in the distal jejunum and duodenum (44, 45). 
Proglucagon is processed in a tissue specific manner: in the pancreas 
predominantly into glucagon and into GLP-1 and GLP-2 in the L-cells, 
brainstem and hypothalamus (42). GLP-1 has 2 bioactive isoforms, GLP-1(7-
37) and GLP-1(7-36)-amide. Both GLP-1 and GIP are part of the glucagon-like 
superfamily and have both structural and functional similarities. GLP-1 
release is regulated by endocrine, neuronal and nutrient related stimuli in a 
biphasic manner. Oral intake of a meal, containing carbohydrates or fat 
results in a rapid increase in the plasma GLP-1 concentration with a peak 
after approximately one hour and account for 50–70% of total meal-related 
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insulin secretion. It is thought that GLP-1 release is under the influence of 
indirect endocrine and nerve induced signals, as the GLP-1 producing L-
cells are predominantly located in the more distal part of the gastrointestinal 
tract, and GLP-1 secretion occurs before nutrients have reached the 
majority of the L-cells in the ileum and colon (44, 46, 47). Taken together 
with the finding that the rapid phase of GLP-1 secretion is preserved in 
patients after ileal resections or proctocolectomy, it is hypothesized that the 
early release of GLP-1, which accounts for the majority of the incretin effect 
in normal individuals, is triggered by local luminal nutrient-sensing pathway 
in addition to neuronal stimuli (48). Biological characteristics of both GIP 
and GLP-1 are shown in Table 1.1.  
 
Glucose-dependent insulinotropic 
polypeptide 
Glucagon-like peptide-1 
42-amino acid peptide released from the 
duodenum 
30/31-amino acid peptide released from 
distal small bowel and colon 
Stimulates insulin secretion Stimulates insulin secretion 
Minimal effect on gastric emptying Inhibits gastric emptying 
Stimulates glucagon secretion Inhibits glucagon secretion 
No regulation of satiety and body weight Inhibits food intake and weight gain 
Promotes expansion of beta-cell mass in 
preclinical models 
Promotes expansion of beta-cell mass in 
preclinical models 
Normal GIP secretion in type 2 diabetes Reduced or normal secretion of GLP-1 in 
type 2 diabetes 
Defective GIP response in type 2 diabetes Preserved but impaired GLP-1 response 
in type 2 diabetes 
Table 1.1 Comparison of the biological properties of glucose-dependent 
insulinotropic polypeptide (GIP) with glucagon-like peptide-1 (GLP-1). Adapted 
from Diamant (49). 
 
The incretin concept, regained focus of interest as a therapeutic option for 
patients with type 2 diabetes over the last decade (44, 50). Nauck and 
coworkers showed, in their landmark study, that the insulin secretory 
response to an oral glucose load was more enhanced when compared to an 
isoglycemic (i.e. in the presence of similar circulating glucose concentrations) 
intravenous glucose infusion. This phenomenon is called the incretin effect  
(51). In patients with type 2 diabetes, the incretin effect is significantly 
impaired and it was shown that postprandial GLP-1, but not GIP, secretion 
is attenuated (51). GLP-1 administration stimulates insulin secretion in both 
healthy and type 2 diabetes individuals, in a glucose-dependent manner, 
whereas the insulinotropic effect of GIP infusion in patients with type 2 
diabetes is lost (44). This observed loss of insulin potentiating effect of GIP 
played an important role in pursuing GLP-1, and not GIP, as an agent for 
the treatment of type 2 diabetes. In addition, in both healthy individuals and 
patients with type 2 diabetes, GLP-1 slows down gastric emptying (52, 53), 
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inhibits glucagon (54) and somatostatin (55) secretion, promotes satiety and 
reduces food intake (56), and reduces body weight (57, 58) (For review see: 
(24, 44, 45, 59)). Experimental data, shows that GLP-1 increases beta-cell 
mass (60-65) and clinical studies show that exogenous GLP-1stimulates 
glucose-dependent insulin secretion by pancreatic beta-cells (41, 66, 67). 
Collectively, these characteristics render GLP-1 as an extremely attractive 
option in the treatment of patients with type 2 diabetes (68-70).  
 
Therapeutic potential of GLP-1 and GLP-1-
based therapies 
GLP-1 exerts its action through G-protein coupled receptors located in the 
islets of Langerhans, gastrointestinal tract, pituitary gland, hepatocytes, and 
heart (28). GLP-1 decreases the blood glucose concentration through 
various mechanisms, which act upon several organs (Figure 1.3).  
 
 
Figure 1.3 The actions of GlP-1 at different organs. Adapted from Drucker (45). 
 
Primarily, GLP-1 potentiates insulin secretion and production by the 
pancreatic beta-cell, in a glucose-dependent manner (28). GLP-1 lowers 
glucagon secretion, slows down gastric emptying and induces satiety, 
resulting in less food intake and a reduction of body weight. Additionally, 
GLP-1 may be beneficial in attenuating the endothelial dysfunction, which 
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underlies many of the cardiovascular complications of diabetes (71). Taken 
together, the biological actions of GLP-1 seem to replenish the phenotype as 
seen in patients with type 2 diabetes (Table 1.2). 
 
Type 2 diabetic phenotype Actions of GLP-1 
Impaired beta-cell function ↑ Insulin secretion and biosynthesis 
Improved beta-cell function 
Up regulated other genes essential for 
beta-cell function 
 
Reduced beta-cell mass ↑Beta-cell proliferation/differentiation  
↓Beta-cell apoptosis   
(shown only in animal studies and in vitro) 
 
Glucagon hyper secretion ↓Glucagon secretion 
 
Overeating, obesity ↓Gastric emptying, ↑satiety, ↓appetite 
→↓Food intake & ↓ body weight 
 
Macrovascular complications Beneficial cardiovascular effects (direct 
and indirect) 
 
Insulin resistance Improvements in insulin sensitivity 
 
Table 1.2 The therapeutic potential of glucagon-like peptide (GLP)-1 in type 2 
diabetes. The various actions of GLP-1 match the defects of the type 2 diabetes 
phenotype. Adapted from Van Genugten (24). 
 
In both healthy subjects and patients with type 2 diabetes, continuous 
subcutaneous and intravenous GLP-1 administration lowers the plasma 
glucose concentration. However, this effect depends on the continuous 
administration of GLP-1 as it disappears 2 hours after cessation of GLP-1 
infusion. In their landmark study, Zander et al compared a 6-week 
continuous subcutaneous GLP-1 (via an insulin-pump) to saline 
administration in a group (n=10) of type 2 diabetic patients. At 6 weeks, 
GLP-1 significantly reduced both fasting and postprandial plasma glucose 
concentrations, as well as the HbA1c value (by 1.3%) from baseline (58). 
Furthermore, GLP-1 reduced appetite and food intake, resulting in 1.9 kg 
weight reduction as compared to placebo. Beta-cell function and insulin 
sensitivity improved during the 6-week treatment period.  
However, circulating GLP-1 is quickly inactivated by the ubiquitous enzyme 
dipeptidyl peptidase (DPP)-4, a proteolytic enzyme that cleaves the two N-
terminal amino acids of biologically active peptides (72-74). After cleaving 
GLP-1 is removed from the circulation by hepatic clearance and renal 
excretion (75, 76). Due to its degradation by DPP-4, GLP-1 only has a half-
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life of several minutes (73). Because of its fast degradation by DPP-4 and its 
short half-life, necessitating continuous infusion, native GLP-1 is not a 
preferred therapeutic option. Therefore, two new pharmacotherapeutic 
approaches have been developed to harness the therapeutic potential of 
GLP-1 in clinical practice: 1) DPP-4 inhibitors which increase the 
circulating concentration of endogenous GLP-1 (77) and 2) DPP-4 resistant 
GLP-1 receptor agonists, which potently stimulate the GLP-1 receptor at 
pharmacological levels (Table 1.3) (78). By now, multiple compounds of 
both these two new classes have been approved by the FDA and the EMA 
and have become available for the treatment of patients with type 2 diabetes 
mellitus over the last years. 
 
Dipeptidyl peptidase-4 inhibitors 
Dipeptidyl peptidase-4 is an enzyme expressed on many cells that rapidly 
degrades circulating endogenous GLP-1 (73). Inhibition of this enzyme has 
the potential to address the abnormal pathophysiology of type 2 diabetes. 
DPP-4 inhibitors increase circulating endogenous GLP-1 concentrations by 
2-fold, changes within the physiologic range. Over the last several years a 
number of oral DPP-4 inhibitors have been developed of which five are 
currently approved for the treatment of patients with type 2 diabetes: 
sitagliptin in 2006, vildagliptin in 2007, saxagliptin in 2009, alogliptin in 
2010 (Japan only), linagliptin in 2011 (77). DPP-4 inhibitors improve 
glycemic control, reduce both fasting and postprandial glucose 
concentrations, and lower the HbA1c concentration, without weight gain 
and with an apparently benign adverse event profile (Table 1.3) (77). As 
DPP-4 inhibitors are not part of this thesis, readers are referred to several 
recently published review papers on DPP-4 inhibitors (77, 80-84). 
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 GLP-1 receptor 
agonists 
DPP-4 inhibitors 
Mode of administration Subcutaneous Oral 
Timing of administration Once/twice daily, once 
weekly 
Once or twice daily 
GLP-1 receptor activation Supra physiological  Close to physiological 
 Continuous Retained diurnal pattern 
Mediators of effect GLP-1 receptor activation GLP-1 receptor activation 
  Other bioactive peptides? 
Insulin secretion Stimulation Stimulation 
Glucagon secretion Inhibition Inhibition 
Gastric emptying Inhibition No effect 
Appetite Induction of satiety No effect 
Fasting glucose* Reduction by ~ 1 mmol/l Reduction by ~ 1 mmol/l 
Prandial glucose Marked reduction Slight reduction 
HbA1c* Reduction by ~ 1% Reduction by ~ 0,8% 
Body weight Reduction No change 
Hypoglycemia Infrequent Comparable to placebo 
Adverse events Nausea, vomiting No, suggestion of higher 
incidence of upper 
respiratory tract infections 
Table 1.3 Characteristics and effects of GLP-1 receptor agonists and DPP-4 
inhibitors. *Absolute numeric reduction dependent on baseline values. Adapted 
from Ahren (79). 
 
Exenatide: a glucagon-like peptide-1 receptor 
agonist  
Exendin-4 is a polypeptide derived from the salivary gland of the Gila 
monster lizard (heloderma suspectum) (85). During its feeding exendin-4 is 
released to the Gila monster’s blood stream where it is thought to play a role 
in energy metabolism and inducing satiety (86). Exendin-4 has a bigger 
effective receptor affinity than GLP-1, and is therefore a potent GLP-1 
receptor agonist (87, 88). Although exendin-4 has a 53% similarity in amino 
acid sequence, it is not strictly regarded a GLP-1 analogue as it is not a 
product of the proglucagon gene. Therefore, the more appropriate name 
GLP-1 receptor agonist (GLP-1RA) has been introduced. Animal and in 
vitro models of type 2 diabetes, exenatide has shown to share the glucose-
regulating properties of GLP-1 (Table 1.4).  
 
Exenatide’s main clinical features are: 1) glucose-dependent increase in 
insulin secretion; 2) suppression of inappropriately high glucagon secretion; 
3) reduction in gastric emptying rate; 4) centrally induced satiety associated 
with lower food intake, and 5) body weight loss. Additionally, animal and in 
vitro studies have shown an increase in pancreatic beta-cell number, as a 
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result of stimulation of cell formation from precursors and inhibition of their 
apoptosis (89). Due to the different amino acid sequence, as compared to 
endogenous GLP-1, exendin-4 is not degraded by the enzyme DPP-4. As  a 
result exenatide has a longer half life (2.4 hours vs. a few minutes) which 
enables its therapeutic use (85). 
 
 GLP-1  Exenatide 
Insulin secretion ! ! 
Insulin gene expression* ! ! 
Glucagon secretion " " 
Gastric emptying " " 
Food intake " " 
Body weight " " 
Glucose utilization ! ! 
Beta-cell neogenesis* ! ! 
Beta-cell proliferation* ! ! 
Beta-cell differentiation* ! ! 
Neuro endocrine effects* ! ! 
Table 1.4 Biological characteristics of glucagon-like peptide-1 (GLP-1) and the 
GLP-1RA exenatide. Adapted from Diamant (49). *Only in the preclinical models. 
 
Synthetic exendin-4 is commercially available as exenatide (brand name: 
βyetta®). This compound requires to be injected subcutaneously using a 
pen device approximately one-hour prior to a major meal, twice daily. 
Exenatide was approved by the FDA in 2005, and the EMA in 2006 for use 
as an adjunctive therapy, exenatide is indicated to improve glycemic control 
in patients with type 2 diabetes not well-controlled with metformin, a 
sulfonylurea, thiazolidinediones, or a combination of metformin and 
sulfonylurea or thiazolidinediones, but who have not been able to achieve 
adequate control of blood glucose levels (Table 1.5). 
 
Placebo and comparator-controlled clinical studies have demonstrated that 
10 µg exenatide twice daily improves glycemic control and reduces body 
weight in patients with type 2 diabetes (Table 1.6 and Table 1.7) (90-100). 
Some of these studies also showed amelioration of surrogate measures of 
beta-cell function such as fasting pro-insulin to insulin ratio in post-hoc 
analysis (92, 95, 96). In a subset of the studied population, additional beta-
cell parameters were obtained from modeling analysis of glucose and C-
peptide concentrations during standardized mixed-meal tests. Exenatide 
improved a number of beta-cell function parameters, including glucose 
sensitivity (101). In the open-label extension of the 3 pivotal trials, exenatide 
treatment was associated with an increase in HOMA-B from baseline by 
approximately 50% at 2 year and by approximately 70% at 3 years (102, 
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103). Accordingly, improvements have been demonstrated in first and 
second phase glucose-stimulated insulin secretion (104). 
 
 Exenatide Liraglutide Sitagliptin Vildagliptin Saxagliptin 
Monotherapy No No Yes No No 
Add-on to 
metformin 
Yes Yes Yes Yes Yes 
Add-on to 
sulfonylurea 
Yes Yes Yes Yes Yes 
Add-on to 
thiazolidinediones 
Yes No Yes Yes Yes 
Triple therapy 
with metformin 
and sulfonylurea 
Yes Yes Yes No No 
Triple therapy 
with metformin 
and 
thiazolidinediones 
Yes Yes Yes No No 
Add-on to insulin No No Yes No No 
Table 1.5 Indications of approved incretin-based therapies (EMA). Table with 
courtesy of prof. M. Diamant 
General introduction and rationale 
 
21 
  
  
A
ut
ho
r 
 
Y
ea
r 
(R
ef
.) 
T
re
at
m
en
t 
n 
Fo
llo
w
-u
p 
(w
ee
k)
 
A
ge
 (y
) 
B
W
 (K
g)
 
B
M
I 
(K
g/
m
2)
 
D
ia
be
te
s 
du
ra
tio
n 
(y
) 
H
bA
1c
 (%
) 
FP
G
 
(m
m
ol
/L
) 
C
om
m
en
ts
 
B
us
e 
20
04
 (9
2)
 
Pl
ac
eb
o 
B
ID
 
12
3 
30
 
55
±1
1 
99
±1
8 
34
±5
 
6±
5 
8.
7±
1.
2 
10
.8
±3
.2
 
A
dd
ed
 to
 S
U
 a
lo
ne
 
E
xe
na
tid
e 
B
ID
 
12
9 
 
56
±1
1 
95
±1
8 
33
±6
 
7±
7 
8.
6±
1.
2 
9.
9±
2.
8 
D
eF
ro
nz
o 
20
05
 (9
4)
 
Pl
ac
eb
o 
B
ID
 
11
3 
30
 
54
±9
 
10
0±
19
 
34
±6
 
7±
6 
8.
2±
1.
0 
9.
4±
2.
2 
A
dd
ed
 to
 M
E
T
 a
lo
ne
 
E
xe
na
tid
e 
B
ID
 
11
3 
 
52
±1
1 
10
1±
20
 
34
±6
 
5±
5 
8.
2±
1.
0 
9.
3±
2.
6 
K
en
da
ll 
20
05
 (9
6)
 
Pl
ac
eb
o 
B
ID
 
24
7 
30
 
56
±1
0 
99
±1
9 
34
±5
 
9±
6 
8.
5±
1.
0 
10
.0
±2
.7
 
A
dd
ed
 to
 M
E
T
 a
nd
 S
U
 
E
xe
na
tid
e 
B
ID
 
24
1 
 
55
±1
0 
98
±2
1 
34
±6
 
9±
6 
8.
5±
1.
1  
9.
9±
2.
4 
H
ei
ne
 
20
05
 (9
5)
 
In
su
lin
 G
la
rg
in
e 
Q
D
 
26
7 
26
 
58
±1
0 
88
±1
8 
31
±5
 
9±
6 
8.
3±
1.
0 
10
.4
±2
.9
 
A
dd
ed
 to
 M
E
T
 a
nd
 S
U
 
E
xe
na
tid
e 
B
ID
 
28
2 
 
60
±9
 
88
±1
7 
31
±4
 
10
±6
 
8.
2±
1.
0 
10
.1
±2
.6
 
Z
in
m
an
 
20
07
 (1
00
) 
Pl
ac
eb
o 
11
2 
16
 
57
±
10
 
97
±
19
 
34
±
5 
8±
6 
7.
9±
0.
8 
8.
8±
1.
9 
A
dd
ed
 to
 T
Z
D
/M
E
T
 o
r 
M
E
T
  
E
xe
na
tid
e 
B
ID
 
12
1 
 
56
±
11
 
98
±
19
 
34
±
5 
7±
5 
7.
9±
0.
9 
9.
1±
2.
6 
B
ar
ne
tt
 
20
07
 (9
0)
 
In
su
lin
 g
la
rg
in
e 
Q
D
 
68
 
16
 
55
±
8 
86
±
16
 
31
±
4 
7±
5 
8.
9±
1.
0 
11
.8
±
3.
2 
C
ro
ss
-o
ve
r 
de
si
gn
 
A
dd
ed
 to
 M
E
T
 o
r 
SU
 
E
xe
na
tid
e 
B
ID
 
70
 
 
55
±
8 
84
±
16
 
31
±
4 
8±
5 
9.
0±
1.
0 
12
.2
±
3.
2 
N
au
ck
 
20
07
 (9
8)
 
In
su
lin
 a
sp
ar
t B
ID
 
24
8 
52
 
58
±9
 
83
±1
6 
30
±4
 
10
±6
 
8.
6±
1.
1 
11
.3
±2
.8
 
A
dd
ed
 to
 M
E
T
 a
nd
 S
U
 
E
xe
na
tid
e 
B
ID
 
25
3 
 
59
±9
 
86
±1
6 
30
±4
 
10
±6
 
8.
6±
1.
0 
11
.0
±2
.7
 
B
er
ge
ns
ta
l 
20
09
 (9
1)
 
In
su
lin
 a
sp
ar
t Q
D
 
12
4 
24
 
52
±
11
 
97
±
25
 
34
±
7 
8±
6 
10
.1
±
1.
8 
10
.9
±
3.
7 
A
dd
ed
 to
 M
E
T
 a
nd
 S
U
 
  
In
su
lin
 a
sp
ar
t B
ID
 
12
4 
53
±
10
 
94
±
24
 
34
±
7 
10
±
6 
10
.3
±
1.
9 
11
.2
±
4.
2 
E
xe
na
tid
e 
B
ID
 
12
4 
53
±
1 
97
±
24
 
34
±
7 
9±
6 
10
.2
±
1.
5 
11
.7
±
3.
7 
L
iu
tk
us
 
20
10
 (9
7)
 
Pl
ac
eb
o 
54
 
26
 
54
±
9 
93
±
18
 
33
±
5 
6±
5 
8.
3±
0.
9 
9.
0±
2.
0 
A
dd
ed
 to
 T
Z
D
/M
E
T
 o
r 
M
E
T
  
E
xe
na
tid
e 
B
ID
 
11
1 
 
55
±
8 
95
±
18
 
34
±
6 
6±
4 
8.
2±
0.
9 
9.
2±
2.
8 
B
us
e 
20
11
 (9
3)
 
Pl
ac
eb
o 
12
2 
30
 
59
±
10
 
93
±
21
 
33
±
6 
12
±
7 
8.
5±
1.
0 
8.
3±
2.
3 
A
dd
ed
 to
 I
G
 a
lo
ne
; 
IG
/T
Z
D
/M
E
T
; I
G
/M
E
T
 
E
xe
na
tid
e 
B
ID
 
13
7 
 
59
±
9 
95
±
20
 
34
±
6 
12
±
7 
8.
3±
0.
9 
7.
9±
2.
1 
B
W
 =
 b
od
yw
ei
gh
t; 
B
ID
 =
 tw
ic
e 
da
ily
; F
PG
 =
 fa
st
in
g 
pl
as
m
a 
gl
uc
os
e;
 H
bA
1c
 =
 g
ly
ca
te
d 
he
m
og
lo
bi
n;
 n
 =
 n
um
be
r 
of
 p
at
ie
nt
s;
 N
R
 =
 n
ot
 r
ep
or
te
d;
 Q
D
 =
 o
nc
e 
da
ily
; Q
W
 =
 o
nc
e 
w
ee
kl
y;
 S
U
 =
 
su
lp
ho
ny
lu
re
a.
; M
E
T
 =
 m
et
fo
rm
in
; T
Z
D
 =
 th
ia
zo
lid
in
ed
io
ne
; I
G
 =
 in
su
lin
 g
la
rg
in
e 
T
ab
le
 1
.6
 P
at
ie
nt
 c
ha
ra
ct
er
is
tic
s 
of
 c
on
tr
ol
le
d 
cl
in
ic
al
 tr
ia
ls
 w
ith
 1
0 
µg
 e
xe
na
tid
e 
B
ID
 in
 p
at
ie
nt
s 
w
ith
 ty
pe
 2
 d
ia
be
te
s 
m
el
lit
us
. 
 
Chapter 1 
 
22 
  
 
A
ut
ho
r 
Y
ea
r 
(R
ef
.) 
T
re
at
m
en
t 
n 
Fo
llo
w
-
up
 
(w
ee
k)
 
M
ea
n 
!
H
ba
1c
 
(%
) 
H
ba
1c
  
<
 7
,0
 
(%
) 
M
ea
n 
!
FP
G
  
(m
m
ol
/L
) 
M
ea
n 
!
B
W
  
(K
g)
 
V
s 
co
nt
ro
l 
V
s 
ba
se
lin
e 
V
s 
co
nt
ro
le
 
V
s 
ba
se
lin
e 
V
s 
co
nt
ro
le
 
V
s 
ba
se
lin
e 
B
us
e 
20
04
 (9
2)
 
Pl
ac
eb
o 
B
ID
 
12
3 
30
 
 
+
0.
1±
1.
0 
9 
 
+
0.
4±
3.
3 
 
-0
.6
±
3.
3 
E
xe
na
tid
e 
B
ID
 
12
9 
 
N
R
 
-0
.9
±
1.
2a
 
41
a  
N
R
 
-0
.6
±
3.
4a
 
N
R
 
-1
.6
±
3.
4a
 
D
eF
ro
nz
o 
20
05
 (9
4)
 
Pl
ac
eb
o 
B
ID
 
11
3 
30
 
 
+
0.
1±
1.
1 
13
 
 
+
0.
8±
2.
1 
 
-0
.3
±
3.
2 
E
xe
na
tid
e 
B
ID
 
11
3 
 
N
R
 
-0
.8
±
1.
1a
 
46
a  
-1
.4
 (N
R
)a  
-0
.6
±
2.
1a
 
N
R
 
-2
.8
±
5.
3a
 
K
en
da
ll 
20
05
 (9
6)
 
Pl
ac
eb
o 
B
ID
 
24
7 
30
 
 
+
0.
23
±
1.
1 
9 
 
+
0.
8±
3.
1 
 
-0
.9
±
3.
1 
E
xe
na
tid
e 
B
ID
 
24
1 
 
N
R
 
-0
.7
7±
1.
2a
 
34
a  
N
R
 
-0
.6
±
3.
1a
 
N
R
 
-1
.6
±
3.
1a
 
H
ei
ne
 
20
05
 (9
5)
 
In
su
lin
 G
la
rg
in
e 
Q
D
 
26
7 
26
 
 
-1
.1
1±
N
R
b  
48
 
 
-2
.9
±
N
R
b  
 
+
1.
8±
N
R
 
E
xe
na
tid
e 
B
ID
 
28
2 
 
+
0.
02
 (-
0.
12
 to
 0
.1
6)
 
-1
.1
1±
N
R
b  
46
 
1.
5 
(1
.1
 to
 1
.5
)a  
-1
.4
±
N
R
b  
-4
.1
 (-
4.
6 
to
 -3
.5
)a  
-2
.3
±
N
R
 
Z
in
m
an
 
20
07
 (1
00
) 
Pl
ac
eb
o 
11
2 
16
 
 
+
0.
1±
N
R
 
16
 
 
+
0.
1±
2.
1 
 
-0
.2
±
N
R
 
E
xe
na
tid
e 
B
ID
 
12
1 
 
-1
.0
 (-
1.
2 
to
 -0
.7
)a  
-0
.9
±
N
R
 
62
a  
-1
.7
 (-
2.
2 
to
 1
.2
) 
-1
.6
±
2.
2 
-1
.5
 (-
2.
2 
to
 -0
.9
)a  
-1
.8
±
N
R
 
B
ar
ne
tt
 
20
07
 (9
0)
 
In
su
lin
 g
la
rg
in
e 
Q
D
 
68
 
16
 
 
-1
.3
6±
0.
84
b  
38
 
 
-4
.1
±
1.
7 
 
+
1.
0±
0.
4 
E
xe
na
tid
e 
B
ID
 
70
 
 
-0
.0
1 
(-0
.1
7 
to
 0
.1
5)
 
-1
.3
6±
0.
84
b  
40
 
+
1.
2 
(+
0.
7 
to
 +
1.
7)
a  
-2
.9
±
1.
7 
-2
.2
 (-
2.
8 
to
 -1
.7
)a  
-2
.0
±
0.
4 
N
au
ck
 
20
07
 (9
8)
 
In
su
lin
 a
sp
ar
t B
ID
 
24
8 
52
 
 
-0
.8
9±
0.
9 
24
 
 
-1
.7
±
0.
2 
 
+
2.
9±
3.
1 
E
xe
na
tid
e 
B
ID
 
25
3 
 
-0
.2
 (-
0.
3 
to
 +
0.
0)
 
-1
.0
4±
1.
1 
32
a  
-0
.1
 (-
0.
6 
to
 +
0.
4)
 
-1
.8
±
0.
2 
-5
.4
 (-
5.
9 
to
 -5
.0
)a  
-2
.5
±
3.
2 
B
er
ge
ns
ta
l 
20
09
 (9
1)
 
In
su
lin
 a
sp
ar
t Q
D
 
12
4 
24
 
+
0.
7(
-1
.0
 to
 -0
.3
)a  
-2
.3
±
1.
5 
26
 
N
R
 
-2
.9
±
0.
3a
 
N
R
 
+
2.
8±
3.
6 
In
su
lin
 a
sp
ar
t B
ID
 
12
4 
+
0.
9(
-1
.2
 to
 -0
.6
)a  
-2
.8
±
1.
8 
37
a  
N
R
 
-3
.5
±
0.
3a
 
N
R
 
+
4.
1±
5.
4 
E
xe
na
tid
e 
B
ID
 
12
4 
 
-1
.8
±
1.
6 
20
 
 
-1
.2
±
0.
3 
 
-1
.9
±
3.
8 
L
iu
tk
us
 
20
10
 (9
7)
 
Pl
ac
eb
o 
54
 
26
 
 
-0
.1
±
1.
7 
36
 
 
N
R
 
 
-0
.8
±
5.
1 
E
xe
na
tid
eB
ID
 
11
1 
 
-0
.7
 (-
1.
1 
to
 -0
.4
)a  
-0
.8
±
2.
1 
49
 
-1
.0
 (-
1.
8 
to
 -0
.3
)a  
N
R
 
-0
.7
 (-
1.
7 
to
 0
.3
) 
-1
.4
±
6.
3 
B
us
e 
20
11
 (9
3)
 
Pl
ac
eb
o 
12
2 
30
 
 
-1
.0
 (-
1.
2 
to
 -0
.9
) 
35
 
 
-1
.5
 (-
1.
8 
to
 -1
.2
) 
 
+
1.
0 
(+
0.
2 
to
 +
1.
7)
 
E
xe
na
tid
e 
B
ID
 
13
7 
 
-0
.7
 (-
0.
9 
to
 -0
.5
)a  
-1
.7
 (-
1.
9 
to
 -1
.6
) 
60
a 
-0
.1
 (-
0.
5 
to
 0
.3
)a  
-1
.6
 (-
1.
9 
to
 -1
.3
) 
-2
.7
 (-
3.
7 
to
 -1
.4
)a  
-1
.8
 (-
2.
5 
to
 -1
.1
) 
* 
St
at
is
tic
al
ly
 s
ig
ni
fic
an
t d
iff
er
en
t f
ro
m
 c
on
tr
ol
. B
W
 =
 b
od
yw
ei
gh
t; 
B
ID
 =
 tw
ic
e 
da
ily
; F
PG
 =
 fa
st
in
g 
pl
as
m
a 
gl
uc
os
e;
 F
SI
 =
 fa
st
in
g 
se
ru
m
 in
su
lin
; F
SP
 =
 fa
tin
g 
se
ru
m
 p
ro
in
su
lin
; H
bA
1c
 =
 g
ly
ca
te
d 
he
m
og
lo
bi
n;
 n
 =
 n
um
be
r 
of
 p
at
ie
nt
s;
 N
A
 =
 n
ot
 a
pp
lic
ab
le
; N
R
 =
 n
ot
 r
ep
or
te
d;
 Q
D
 =
 o
nc
e 
da
ily
; Q
W
 =
 o
nc
e 
w
ee
kl
y;
 S
U
 =
 s
ul
ph
on
yl
ur
ea
.; 
M
E
T
 =
 m
et
fo
rm
in
; T
Z
D
 =
 th
ia
zo
lid
in
ed
io
ne
; I
G
 =
 in
su
lin
 
gl
ar
gi
ne
 
T
ab
le
 1
.7
. E
ffe
ct
s 
of
 1
0 
µg
 e
xe
na
tid
e 
B
ID
 o
n 
gl
yc
em
ia
 a
nd
 b
od
yw
ei
gh
t i
n 
pa
tie
nt
s 
w
ith
 ty
pe
 2
 d
ia
be
te
s 
m
el
lit
us
. D
at
a 
re
pr
es
en
t m
ea
n±
SD
 o
r 
95
%
 c
on
fid
en
ce
 in
te
rv
al
 
General introduction and rationale 
 
23 
 
Summary and rationale for conduct of the 
core studies and outline of this thesis 
The core study presented in this thesis was collectively initiated and 
designed by the investigators from the three study sites: 1) Diabetes Center, 
Department of Internal Medicine, VU University Medical Center, 
Amsterdam, the Netherlands; 2) Lundberg Laboratory for Diabetes 
Research, Sahlgrenska University Hospital, Göteborg, Sweden; 3) 
Department of Medicine, Helsinki University Central Hospital, Helsinki, 
Finland. The study was performed between September 2004 and December 
2009. 
 
Type 2 diabetes mellitus is characterized by insulin resistance and by a 
progressive beta-cell defect. The latter abnormality is thought to be 
primarily responsible for the progressive nature of the disease. The decline 
in insulin secretory capacity requires periodic adjustment of blood glucose 
lowering therapy. The management of hyperglycemia in type 2 diabetes 
starts with education, whereby advice is provided to facilitate patients to 
change their dietary habits and increase their physical activity and reduce 
body weight. When these measures fail, and patients do not achieve 
adequate blood glucose control, oral blood-glucose lowering agent 
monotherapy with metformin is usually begun. It has become increasingly 
common to combine two or more oral blood-glucose lowering agents for 
patients who fail to achieve adequate glycemic control on monotherapy. At 
the point glycemic control cannot be achieved or maintained with one or 
more oral blood-glucose lowering agents, the addition of insulin therapy is 
generally accepted as the next step. Although the long duration of action of 
insulin glargine supports convenient, once-daily administration with 
improvement in overall glycemic control, insulin glargine use (as well as 
other forms of insulin therapy) still has negative aspects, such as the 
potential for overall increase in hypoglycemia over that observed with oral 
blood-glucose lowering agent therapy alone, and weight gain (105). In 
addition, insulin glargine does not target postprandial hyperglycemia 
and/or dyslipidemia (105) that may be associated with accelerated 
development of cardiovascular disease (CVD) (106). The potential beneficial 
effects of exenatide make it a promising candidate to improve glycemic 
control in patients with type 2 diabetes inadequately controlled on 
metformin with a reduction in the known side effects of weight gain and 
hypoglycemia associated with insulin therapy. 
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At present, there are no pharmacological therapies available that have been 
demonstrated to slow the decline of beta-cell function in patients with 
established type 2 diabetes. However, data exist from a number of 
preclinical studies supporting the premise that exenatide and/or GLP-1 
have effects on beta-cells that go beyond the acute effects of enhancing 
glucose-dependent insulin secretion (79). The published scientific literature 
examining both in vitro and in vivo actions of exenatide and GLP-1-related 
peptides, now provides strong support that these peptides play an important 
role in the maintenance of beta-cell mass and function, through 
complementary actions to stimulate beta-cell proliferation and neogenesis, 
together with inhibition of beta-cell apoptosis (45). These findings are also 
consistent with work performed in a number of animal models, in which 
exenatide or GLP-1 have been shown to increase beta-cell mass and/or 
function (45). This leads to the important question of whether long-term 
exenatide usage in patients with type 2 diabetes may have similar effects, 
and if so, may restore some of the beta-cell functionality (or slow the 
progression of further loss) that is lost as part of the progression of the 
disease. The present study is designed to test this possibility; utilizing stepped 
euglycemic/hyperglycemic clamp experiments to assess beta- cell responses 
to glucose and arginine, a non-glucose insulin secretagogue. 
 
The primary purpose of the study presented in this thesis is to 
assess the effects of long-term treatment period with exenatide 
or insulin glargine in modifying the parameters of beta-cell 
function in patients with type 2 diabetes who have not achieved a 
goal HbA1c of ≤ 6.5% using metformin. 
 
In addition to its effects on the beta-cell and enhanced glucose-dependent 
insulin secretion, exenatide also slows gastric emptying. This slowing may be 
beneficial in terms of postprandial glucose and lipid control, which may be 
important in decreasing the development of CVD in this population. 
Clinical, epidemiological and experimental evidence indicates that 
postprandial plasma glucose- and triglyceride responses, which are 
abnormally elevated and prolonged in patients with type 2 diabetes, are 
associated with increased CVD risk (107). In particular, postprandial 
triglyceride-rich lipoproteins seem to activate coagulation and inflammation, 
both of which have been implicated in the development of atherosclerosis 
(108). Therefore, the ability of exenatide to decrease the postprandial 
elevations in glucose and lipids may represent a key benefit differentiating 
exenatide and insulin glargine for patients who are not adequately 
controlled with oral blood-glucose lowering agents alone. 
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The general outline of this thesis is as follows: chapter 2 describes the 
effects on hyperglycemic clamp derived measures of beta-cell function, 
glycemic efficacy, body weight following one-year of treatment, and during 
the course of a 12-week off-drug period. In chapter 3 the effects of one-
year treatment on postprandial glycemia, lipid profiles, and oxidative stress 
are shown. The effects on the postprandial beta-cell response, measured 
using mathematical modeling, are given in chapter 4. The effects of one-
year treatment with either exenatide or insulin glargine on body 
composition, and circulating CVD risk markers are presented in chapter 
5. Chapter 6 gives the results on hyperglycemic clamp derived measures of 
beta-cell function, glycemic efficacy, body weight following the total 3.5-
year duration of the study. Effects on bone mineral density and measures of 
calcium homeostasis are depicted in chapter 7. In chapter 8 we 
demonstrate that exenatide treatment may play a beneficial role in the 
treatment of non-alcoholic liver steatosis. 
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Abstract 
Background: Traditional blood glucose lowering agents do not sustain 
adequate glycemic control in most type 2 diabetic patients. Preclinical 
studies with exenatide have suggested sustained improvements in beta-cell 
function. We investigated the effects of 52-weeks treatment with exenatide 
or insulin glargine followed by an off-drug period on hyperglycemic clamp 
derived measures of beta-cell function, glycemic control and body weight. 
Methods: Sixty-nine metformin-treated patients with type 2 diabetes were 
randomized to exenatide (n=36) or insulin glargine (n=33). Beta-cell 
function was measured during an arginine stimulated hyperglycemic clamp 
at week 0, week 52 and after a 4-week off-drug period. Additional endpoints 
included effects on glycemic control, body weight, and safety.  
Results: Treatment induced change in combined glucose and arginine 
stimulated C-peptide secretion was 2.46 fold (95% CI 2.09 to 2.90, 
p<0.0001) greater following 52-week exenatide treatment as compared to 
insulin glargine. Both exenatide and insulin glargine reduced hemoglobin 
(Hb) A1C similarly: -0.8±0.1% and -0.7±0.2% respectively (P=0.55). 
Exenatide reduced body weight compared to insulin glargine (difference -4.6 
kg, p<0.0001). Beta-cell function measures returned to pre-treatment values 
in both groups after 4-week off-drug. HbA1c and body weight rose to pre-
treatment values 12-weeks after discontinuing either exenatide or insulin 
glargine therapy. 
Conclusions: Exenatide significantly improves beta-cell function during 1-year 
of treatment as compared to titrated insulin glargine. Following cessation of 
both exenatide and insulin glargine therapy beta-cell function and glycemic 
control returned to pre-treatment values, suggesting that ongoing treatment 
is necessary to maintain the beneficial effects of either therapy. 
Exenatide and beta-cell function 
 
 
37 
Introduction 
Type 2 diabetes mellitus is characterized by beta-cell dysfunction against a 
background of obesity-related insulin resistance (1). When lifestyle measures 
and oral blood glucose lowering medications fail to sustain glycemic control, 
current guidelines advise the use of basal insulin (2). Data from the United 
Kingdom Prospective Diabetes Study suggest that glycemic control 
progressively worsens over time and this deterioration has been attributed to 
a progressive loss of beta-cell function which occurs irrespective of whether 
metformin, sulfonylureas or insulin are used (3). Therefore, therapeutic 
approaches, which may prevent or delay the decline of beta-cell function in 
type 2 diabetes are eagerly awaited. 
 
Exenatide is synthetic exendin-4, first identified and isolated from the 
salivary secretions of the Gila monster (heloderma suspectum). Exendin-4 shares 
53% amino acid sequence identity with human glucagon-like peptide (GLP)-
1 and binds directly to GLP-1 receptors. Placebo- (4-7) and comparator-
controlled (8-10) clinical studies have demonstrated that exenatide improves 
glycemic control and reduces body weight in patients with type 2 diabetes. 
These studies also showed amelioration of surrogate measures of beta-cell 
function (4-6, 8). Accordingly, improvements have been demonstrated in 
first and second phase glucose-stimulated insulin secretion, and in meal-
derived indices of beta-function compared to placebo (11, 12). In animals 
exenatide has shown to sustain improvements in beta-cell function or even 
increase beta-cell mass (13). 
 
Previously, we showed that 26-week exenatide therapy lowered hemoglobin 
(Hb) A1c similarly to insulin glargine in patients with type 2 diabetes who 
were treated with metformin and a sulfonylurea (8). However, at present, no 
data exist regarding the relative effects of these treatments on beta-cell 
function, nor is it known whether the effects of either therapy are sustained 
after discontinuation.  
 
The aim of the current study, was to assess the effects of treatment with 
exenatide or insulin glargine on beta-cell function, glycemic control, body 
weight, and safety, after 52-weeks of treatment and during a 12-week off-
drug period. 
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Research design and methods 
The study was performed between September 27th 2004 and September 13th 
2007 at three study sites, in Sweden, Finland and the Netherlands. In total, 
69 patients were randomized using a permutated block randomization 
scheme stratified by site and screening HbA1c to receive exenatide or insulin 
glargine, in addition to ongoing metformin treatment (Figure 2.1).  
 
Figure 2.1 Protocol flow chart and baseline characteristics of the study population. 
Data represent mean±SEM. 
 
Inclusion criteria were: age 30-75 years, HbA1c 6.5-9.5%, body mass index 
25-40 kg/m2, and metformin treatment at a stable dose for at least 2 
months. No other blood glucose lowering agents were allowed within 3 
months prior to screening. No changes in other agents known to affect beta-
cell function (such as ACE inhibitors and angiotensin receptor blockers) 
were allowed during the study. The study protocol was approved by each 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Randomized 
69 
 
 
(N = 45) 
Completed On-Drug Period 30 (83.3%) 
Withdrew prior to week 52   6 (16.7%) 
Withdrawal of consent   1   (2.8%) 
Adverse event    5 (13.9%) 
 
Completed Off-Drug Period 25 (69.4%) 
Withdrew between week 52-64   5 (30.6%) 
Withdrawal of consent   2   (5.6%) 
Loss of glucose control   3   (8.3%) 
 
Exenatide 
Intent-to-treat (ITT) 36 
Insulin glargine 
Intent-to-treat (ITT) 33 
Completed On-Drug Period 30 (90.9%) 
 Withdrew prior to week 52   3  (9.1%) 
Withdrawal of consent   1  (3.0%) 
Investigator decision   1  (3.0%) 
Lost to follow-up   1  (3.0%) 
 
Completed Off-Drug Period 26 (78.8%) 
Withdrew between week 52-64   4 (21.2%) 
Withdrawal of consent   1   (3.0%) 
Loss of glucose control   2   (6.1%) 
Investigator decision   1   (3.0%) 
 
 
Screened 
150 
 
 
(N = 45) 
Screen failure   76  (50.6%) 
 
Did not meet inclusion criteria 71   (47.3%) 
Withdrawal of consent    1     (0.7%) 
Protocol violation    3     (2.0%) 
Lost to follow-up    1     (0.7%) 
 
  
Early term prior to randomization  5 (3.3%) 
 
Withdrawal of consent      3 (2.0%) 
Investigator decision      2 (1.3%) 
 
Demographics 
Male Sex (%)    63.9 
Age (y):     58.4±1.4 
Weight (kg)    90.6±2.1 
Body-Mass Index (kg/m
2
)   30.9±0.7 
Duration of diabetes (y)      5.7±0.8 
Daily metformin dose (mg)              2094±120 
HbA1c         7.6±0.1 
Fasting Plasma Glucose (mmol/L)   9.4±0.4 
Fasting Insulin (pmol/L)       87±12 
Fasting C-peptide (nmol/L)     0.9±0.1 
C-peptide response to arginine 
at 15 mmol/L glucose (nmol*min/L)  19.7±2.1 
Demographics 
Male Sex (%)    66.7 
Age (y):     58.3±1.3 
Weight (kg)    92.4±2.4 
Body-Mass Index (kg/m
2
)   30.1±0.6 
Duration of diabetes (y)      4.0±0.6 
Daily metformin dose (mg)              1768±149 
HbA1c         7.4±0.1 
Fasting Plasma Glucose (mmol/L)    8.9±0.4 
Fasting Insulin (pmol/L)       76±12 
Fasting C-peptide (nmol/L)     0.8±0.1 
C-peptide response to arginine 
at 15 mmol/L glucose (nmol*min/L)  20.0±2.5 
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site’s ethics review committee and was in accordance to the principles 
described in the declaration of Helsinki. All participating patients gave their 
written informed consent prior to screening. 
 
Patients randomized to exenatide (n=36) initiated treatment at a dose of 5 
µg twice daily (BID), injected 15-min before breakfast and dinner, for a 
period of 4 weeks, followed by dose increase to 10 µg BID. Exenatide was 
titrated to a maximum dose of three times (TID) 20 µg, or the maximum 
tolerated dose, when HbA1c ranged 7.1-7.5% at two consecutive visits, or 
when HbA1c was !7.6% at any given visit. Patients randomized to insulin 
glargine (n=33) started at an initial dose of 10 IU once daily (QD), injected 
at bedtime. Patients were instructed to increase the daily dose based on their 
fasting self-monitored blood glucose (SMBG) levels, according to a pre-
specified algorithm (14). When fasting SMBG was !5.6 mmol/L on three 
consecutive days the insulin dose was increased by 2 units until finally fasting 
SMBG would range between 4.5 and 5.5 mmol/L. If a hypoglycemic event 
(<3.3 mmol/L) occurred, patients were instructed to refrain from increasing 
insulin glargine dose for seven days and to contact the study physician. 
When necessary, the importance of proper titration of insulin was 
emphasized. 
 
Study endpoints 
Insulin secretion and sensitivity was measured during a combined 
euglycemic-hyperinsulinemic and hyperglycemic clamp procedure (Figure 
2.2) (15, 16). First and second phase C-peptide secretion was calculated as 
AUC180-190min and AUC190-260min. Arginine stimulated C-peptide secretion 
(AIRarg) was calculated as the incremental AUC260-270min above the fasting C-
peptide concentration. Arginine was administered during hyperglycemic 
clamp to measure maximum insulin secretory capacity at a steady-state 
glucose concentration of 15 mmol/L (17). Clamps were performed prior to 
randomization, following 52-weeks of treatment, and after a 4-week off-drug 
period. Following an overnight fast, an indwelling cannula was inserted into 
an antecubital vein for infusion of glucose and insulin. To obtain arterialized 
venous blood samples, a cannula was inserted in a retrograde fashion into a 
dorsal hand or wrist vein and maintained in a heated box at 50° Celsius. 
During the clamp at week 52, patients randomized to exenatide, were given 
the study drug 15 minutes prior to the onset of the hyperglycemic clamp and 
patients randomized to insulin glargine received their last insulin dose the 
night before at bed time. 
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Figure 2.2 Clamp design. 
 
HbA1c (normal range: 4!3 to 6!1%, DCCT standardized Biorad assay) was 
measured using the, fasting plasma glucose, and safety parameters were 
measured prior to randomization and during each follow-up visit until the 
end of the 12-week off-drug period by a central laboratory (Quintiles, 
Livingston, UK). Patients were instructed to record seven-point (fasting, 2 
hours after breakfast, before lunch, 2 hours after lunch, before dinner, 2 
hours after dinner, and at bedtime) SMBG profiles using an OneTouch 
Ultra blood glucose meter (Lifescan, Milpitas, CA) prior to each visit. 
Plasma glucose concentrations during the clamp were measured using an 
YSI 2300 STAT Plus (YSI, Yellow Springs, OH) in Sweden and the 
Netherlands, and using a Beckman-Coulter Glucose Analyser 2 (Beckman-
Coulter, Fullerton, CA) in Finland. C-peptide samples were analyzed at the 
VU University Medical Center using an immunoradiometric assay 
(Centaur; Bayer Diagnostics, Mijdrecht, the Netherlands). 
 
Statistical analysis 
The study’s primary efficacy endpoint is the treatment effect on the beta-cell 
function as measured by the ratio of week 52 combined glucose and 
arginine-stimulated insulin secretion during a hyperglycemic clamp. A 
sample size of 26 patients per group was required to provide 90% power to 
detect a between group significant difference in arginine-stimulated insulin 
secretion between the two treatment groups, assuming the mean iAUC at 
baseline is 200 pmol*min/L for both groups and at week 52, 1100 
pmol*min/L and 300 pmol*min/L for the exenatide and insulin glargine 
groups respectively (11, 18). 
All outcome measures are compared between the two treatment groups 
using an analysis of covariance (ANCOVA) model. The dependent variable 
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used in the model is the loge transformed ratio to pre-treatment for the beta-
cell function parameters (AIRarg, 1st phase, 2nd phase). For all other 
endpoints the dependent value used is the mean at the corresponding visit. 
The model includes factors for treatment group (exenatide/glargine), site 
(NL/SE/FIN), and baseline HbA1c stratum (!8.5%/>8.5%), and the pre-
treatment variable of the corresponding dependent variable as a covariate 
Statistical analysis was done using SAS software (SAS Institute, Inc., Cary, 
North Carolina). All inferential statistical tests were conducted at a 
significance level of 0.05 (two-sided). Unless otherwise stated, data are 
presented as mean (±SEM). 
 
Results 
Patient disposition and baseline clinical characteristics 
Patient disposition and baseline clinical characteristics are shown in Figure 
2.1. Sixty patients completed the 52-week treatment period. Of the patients 
randomized to exenatide 62.1% (n=18) were treated with exenatide 10 µg 
BID at 52-weeks of treatment. Five (17.2%) patients were using 20 µg TID, 
2 (6.9%) 10 µg TID, 1 (3.4%) 15 µg BID, and 1 (3.4%) 15 µg TID. The daily 
exenatide dose was reduced to 5 µg BID in two patients (6.9%). Despite this 
increase in daily exenatide dose none of these patients reached the HbA1c 
target of <7.1%. At 52-weeks the mean±SEM insulin glargine dose used 
was 33.6±3.5 units per day. The corresponding fasting SMBG in the insulin 
glargine treated group was 5.6±0.2 mmol/L. 
 
Hemoglobin A1c and fasting plasma glucose 
Exenatide and insulin glargine treatment resulted in a similar reduction in 
HbA1c (0.8±0.1% and 0.7±0.2%, respectively; p=0.55) with both groups 
achieving a mean HbA1c of 6.8% at 52-weeks. The insulin glargine group 
showed a significantly greater reduction in FPG as compared to exenatide (-
2.9±0.4 versus -1.6±0.3 mmol/L; p<0.0001; respectively), while SMBG 
profiles demonstrated significantly greater reductions in postprandial glucose 
excursions in the exenatide treated patients (Figure 2.3C-D). During the 
off-drug period, both HbA1c and FPG increased in both groups and were 
not significantly different compared to pre-treatment values after 12 weeks 
off-drug (Figure 2.3A-B). 
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Figure 2.3A-D Time course for HbA1c (A) and fasting plasma glucose (B). Data are 
mean (SEM). Black circles = exenatide; white circles = insulin glargine. Self-
monitored blood glucose concentrations before (C) and after (D) 52-weeks 
treatment. Data are mean (SEM). Black circles = exenatide; white circles = insulin 
glargine. 
 
Body weight and insulin sensitivity 
Fifty-two weeks of exenatide treatment resulted in a lowering of body weight 
of -3.6±0.6 kg, while treatment with insulin glargine resulted in a body 
weight increase of +1.0±0.8 kg (between group difference, -4.6±1.1 kg; 
p<0.0001; Figure 2.3E). During the 12-week off-drug period body weight 
trended toward baseline values with both therapies (between group 
difference: -2.4±1.1 kg; p=0.03). At baseline, insulin-mediated glucose 
uptake did not differ between the two treatment groups (Figure 2.3F). 
Treatment with exenatide and insulin glargine improved insulin sensitivity 
to the same extent by 0.9±0.3 and 1.1±0.3 mg/min/kg, respectively 
(p=0.49). After 4-week discontinuation of study medication, the M-value 
was not significantly different from pre-treatment values in the insulin 
glargine treated group, while it remained significantly higher in the 
exenatide-treated group (between group difference 0.8±0.4 mg/min/kg, 
p=0.03). 
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Figure 2.3E-F Change in body weight (E) and insulin sensitivity measured as M-
value (F). Data are mean (SEM). Black circles = exenatide; white circles = insulin 
glargine; black bars = pre-treatment; white bars = 52-weeks on-drug; hatched bars 
= 4-weeks off-drug. 
 
Hyperglycemic-clamp derived measures of beta-cell function 
At baseline, both glucose and arginine stimulated C-peptide secretion did 
not differ between the two treatment groups (Table 2.1; Figure 2.4A-D). 
After 52-weeks of treatment, the exenatide group demonstrated a significant 
increase in all measures of beta-cell function. Accordingly, exenatide 
treatment significantly increased first and second phase glucose-stimulated 
C-peptide secretion by 1.53±0.11 and 2.85±0.22 fold, respectively 
(p<0.0001), compared to insulin glargine. The C-peptide response to 
arginine during hyperglycemia increased 3.19±0.24 fold from pre-treatment 
in the exenatide group compared to 1.31±0.07 fold increase in the insulin 
glargine group (between group difference 2.46±0.20 fold; p<0.0001). After 4 
weeks discontinuation of the study medication, measures of beta-cell 
function returned to pre-treatment values in both groups. 
 
Adverse effects and tolerability 
The most frequently observed adverse event in exenatide-treated patients 
was mild-to-moderate nausea (50%). Other gastrointestinal adverse events 
were reported more commonly in exenatide treated patients including 
vomiting, diarrhea and abdominal distension. Biochemically confirmed 
hypoglycemia (<3.3 mmol/L) was observed more frequently in the insulin 
glargine group (24.2%), as compared to the exenatide treated patients 
(8.3%). There was no severe hypoglycemia with either treatment. Other 
adverse events observed more frequently in the insulin glargine group 
included influenza and gastroenteritis. One patient randomized to exenatide 
developed pancreatitis which resolved after withdrawal of study medication. 
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Figure 2.4A-D C-peptide concentrations during hyperglycemic clamp and ratio-
to-pre-treatment in the exenatide (A and C) and insulin glargine (B and D) treated 
group. Data represent mean (SEM) in Figure 2.3A-B and geometric mean (SEM) 
in Figure 2.3C-D. AIRarg, C-peptide response to arginine at 15 mmol/L glucose 
concentration; 1st phase, first-phase C-peptide response to glucose; 2nd phase, 
second-phase C-peptide response to glucose. See methods section for calculations of 
beta-cell function measures. Black circles and black bars = pre-treatment; white 
circles and white bars = 52-weeks on-drug; black squares and hatched bars = 4-
weeks off-drug. 
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Discussion 
This study demonstrates that 52-weeks of treatment with exenatide 
significantly improves beta-cell function as compared to insulin glargine in 
metformin-treated type 2 diabetic patients. Additionally, exenatide 
treatment achieved similar improvements in glycemic control, reduced body 
weight and resulted in fewer hypoglycemic events. Both exenatide and 
insulin glargine resulted in similar improvements in whole body insulin 
sensitivity. After cessation of both treatments, endpoint measures returned to 
pre-treatment values. 
 
In type 2 diabetes defects in beta-cell function include an absent first phase 
insulin response and a gradually diminishing second phase response to 
glucose (1). This progressive loss of beta-cell function is regarded to be the 
main factor responsible for the gradual increase of glycemia over time, 
regardless of the therapy used (3). Acute and chronic exposure to exenatide 
has shown to improve beta-cell function (4-6, 8). However, there have been 
no studies comparing beta-cell function after long-term exposure to 
exenatide or other glucose lowering therapies. In the current study, one-year 
exenatide therapy significantly improved beta-cell function compared with 
titrated insulin glargine, in the presence of comparable improvements in 
glycemic control. 
 
A number of prior studies have demonstrated that exenatide is non-inferior 
to insulin regimens as a glucose lowering treatment option in inadequately 
controlled patients with type 2 diabetes (8-10). These previous insulin 
comparator trials have been criticized for not achieving optimal insulin 
doses in the comparator arm of the study (19) despite mean reductions in 
HbA1c levels that were within the range of reductions observed in 
comparable insulin trials. In the current study, insulin titration resulted in a 
mean daily insulin dose of 34±19 units. Although this insulin glargine dose is 
lower than that utilized in other studies of type 2 diabetes (20, 21) SMBG 
targets were achieved in the current study suggesting that insulin doses were 
appropriately titrated in the majority of patients. Additionally, the intensive 
treatment with both therapies reduced mean HbA1c values after 52 weeks to 
6.8%. In the LANMET study (22) where, comparable to our study, insulin 
glargine was added to metformin monotherapy in patients with type 2 
diabetes, a higher dose of insulin glargine (68 U/day) was used. These 
apparent differences in insulin glargine dose may be attributed to the 
relatively good baseline HbA1c in our population compared to the 
LANMET participants (HbA1c 9.5%).  
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One limitation of the current study should be highlighted; exenatide was 
given 15-minutes prior to the start of the hyperglycemic clamp study. We 
therefore cannot discriminate between acute and long-term effects of 
exenatide on beta-cell function. The current study does, however, support 
the observation that longer-term treatment with exenatide does not 
attenuate the known acute effects of this therapy on beta-cell function while 
active insulin therapy did not improve beta-cell function to the same degree. 
As the primary study objective was to determine the effects of both active 
exenatide and insulin therapy on beta-cell function in type 2 diabetic 
patients, we decided to perform the tests on therapy, in accordance with 
previous studies (18, 23, 24). These findings support the idea that longer-
term exenatide treatment could have an enduring effect on beta-cell 
function.  
 
In the current study, treatment with both exenatide and insulin glargine 
resulted in a similar reduction in HbA1c.  Of interest, the two therapies 
achieved this result through different ways: exenatide primarily affected 
postprandial glucose excursions, with a modest effect on fasting glucose, 
whereas insulin glargine predominantly reduced fasting plasma glucose, 
without influencing postprandial glucose elevations. The resultant average 
glucose concentrations are similar in both treatment groups, as reflected by 
the HbA1c concentration. Albeit modest, the improved glycemic control in 
either group may have lowered the hyperglycemia associated oxidative stress 
burden, which in part may explain the modest improvement of beta-cell 
function in the insulin glargine group (25). Obviously, patients treated with 
exenatide showed a greater improvement in acute beta-cell function, which 
is considered as the result of binding to the beta-cell glucagon-like peptide-1 
(GLP-1) receptor (13). These findings are consistent with work in a number 
of animal models, in which exenatide or GLP-1 have been shown to 
increase beta-cell mass and to reduce apoptosis (13). Collectively, these 
observations lead to the question whether long-term exenatide 
administration to patients with type 2 diabetes may restore some of the beta-
cell functionality that is lost as part of the natural history of the disease. 
 
In our study the improved beta-cell function at 52-weeks was lost 4-weeks 
after cessation of either study treatment, and this was accompanied by an 
increase in plasma glucose and HbA1c to pre-treatment values in both study 
arms. Interestingly, insulin sensitivity remained significantly improved after 
4-weeks cessation of treatment in the exenatide treated group only. This 
may suggest additional effects of exenatide, possibly mediated by weight loss, 
which may be of longer duration. Whether longer-term exposure to 
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exenatide can alter functional beta-cell mass in the absence of active 
exenatide treatment will require further study. These effects may be 
dependent on other factors including diabetes duration, the amount of 
functional beta-cells present at the initiation of therapy and overall achieved 
metabolic control. To study a possible preserving effect on beta-cell 
function, an additional two-year extension trial is currently ongoing. 
 
Both titrated exenatide and insulin glargine were generally well tolerated 
with >80% of patients completing one-year of therapy in both groups. 
These therapeutic approaches differed in that the most common side effect 
with exenatide were of gastro-intestinal origin, occurring in a similar 
proportion of patients as reported in previous studies (4-10). Mild-to-
moderate nausea (47%) was the most commonly reported adverse event 
with exenatide. In contrast, hypoglycemia was the most common adverse 
event reported in 25% of the insulin glargine treated patients. 
 
In conclusion, this study uniquely demonstrates that one-year of treatment 
with exenatide significantly improved, beta-cell function and reduced body 
weight in the face of similar improvement in glycemic control compared to 
insulin glargine. Following cessation of therapy, the beneficial effects on 
beta-cell function, glycemic control and body weight were not sustained, 
suggesting that active treatment is necessary to maintain these beneficial 
effects of exenatide in patients failing oral blood glucose lowering therapy. 
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Abstract 
Background: The objective of the present study was to investigate the effects of 
one-year treatment with exenatide or insulin glargine, followed by a 5-week 
off-drug period, on postprandial lipidemia, glycemia and measures of 
oxidative stress. 
Methods: Sixty-nine metformin-treated patients with type 2 diabetes were 
randomized (using a permuted block randomization scheme stratified by site 
and baseline HbA1c stratum (! 8.5% or > 8.5%) of which 60 completed 
(exenatide n=30; insulin glargine n=30) the pre-treatment and on-drug meal 
test. Postprandial glucose, lipids and lipoproteins, and oxidative stress 
markers were studied at week -1, 51, and after a 5-week off-drug period 
following a breakfast and lunch mixed-meal containing 50g fat, 75g 
carbohydrates, and 35g protein.  
Results: 51-week exenatide treatment resulted in a significant reduction of 
prandial glucose, triglycerides, apo-B48, calculated VLDL-C, FFA and 
MDA excursions whereas insulin glargine predominantly reduced fasting 
glucose, FFA and MDA. Changes in markers of oxidative stress were related 
to changes in postprandial glucose and triglyceride excursions, independent 
of treatment arm. All postprandial measures returned to pre-treatment 
values in both groups after 5-week cessation of study treatment. 
Conclusions: Exenatide showed beneficial effects on postprandial glycemia 
and lipidemia, and these effects were related to changes in the oxidative 
stress markers MDA and oxLDL during 1-year of treatment as compared to 
insulin glargine. Following cessation of both exenatide and insulin glargine 
measures returned to pre-treatment values, suggesting that ongoing 
treatment is necessary to maintain the beneficial effects of either therapy. 
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Introduction 
Patients with type 2 diabetes have a two to fourfold increased risk of 
cardiovascular disease (CVD) as compared to non-diabetic subjects (1). 
Dyslipidemia is an established risk factor for CVD in patients with type 2 
diabetes, as well as in non-diabetic subjects (2). Diabetic dyslipidemia is a 
specific cluster of potentially atherogenic plasma lipid and lipoprotein 
abnormalities including increased plasma triglycerides, reduced HDL 
cholesterol concentrations, and small, dense LDL particles (2). 
In addition to fasting dyslipidemia, exaggerated postprandial 
hypertriglyceridemia characterize patients with type 2 diabetes when 
compared to age- and weight- matched controls (3). After a meal there is an 
abundance of circulating Triglyceride Rich Lipoproteins (TRLs), which 
comprise both intestine-derived, apolipoprotein (apo)-B48-containing 
chylomicrons and liver-derived, apo-B100-containing very-low-density 
lipoprotein (VLDL) particles (4). Postprandial dyslipidemia is characterized 
by high concentrations of chylomicrons and VLDL remnants in plasma.  
Both postprandial hyperglycemia and hypertriglyceridemia lead to 
mitochondrial free radical production and subsequent oxidative stress, 
which in turn may contribute to the development of microvascular and 
macrovascular complications (5). 
Exogenous insulin therapy reduces fasting hypertriglyceridemia in patients 
with type 2 diabetes (6). The concentration of HDL cholesterol remains 
either unchanged or increases slightly during exogenous insulin therapy (7), 
but insulin therapy has been shown to change the composition of HDL 
particles in an anti-atherogenic direction (8).  
Exenatide is a GLP-1 receptor agonist, which stimulates endogenous insulin 
secretion and suppresses glucagon secretion in a glucose-dependent manner, 
slows gastric emptying and reduces appetite (9). These actions contribute to 
a robust lowering of postprandial glucose concentrations (10). Short-term, 
placebo controlled, treatment of patients with type 2 diabetes with exenatide 
has been shown to reduce postprandial triglyceride concentrations (11) but 
there are, to our knowledge, no data on the effects of exenatide on 
postprandial lipoprotein metabolism and markers of oxidative stress.  
The aim of the current study was to assess the effects of treatment with 
exenatide or insulin glargine on postprandial glycemia, lipid profiles and 
markers of oxidative stress after one year of treatment and during a 5-week 
off-drug period in metformin-treated patients with type 2 diabetes. 
Chapter 3 
 
56 
Research design and methods 
Subjects 
Details on study design were reported previously (12) (Figure 3.1A). Briefly, 
69 patients were randomized (using a permuted block randomization 
scheme stratified by site and baseline HbA1c stratum (! 8.5% or > 8.5%) at 
the three study sites, in Finland, Sweden and the Netherlands. Sixty patients 
(exenatide n=30; insulin glargine n=30) completed both the pre-treatment 
and on-drug meal test and are included in the current analysis (evaluable 
population); 47 patients participated in the off-drug meal test (exenatide 
n=25; insulin glargine n=22). HMG-CoA reductase inhibitors (statins) were 
allowed when used in a stable dose "2 months prior to screening; no other 
lipid-lowering agents or change in statin dosage were allowed. 
Patients randomized to exenatide initiated treatment at a dose of 5 µg twice 
daily (BID) for a period of 4 weeks, followed by dose increase to 10 µg BID. 
If needed, exenatide was titrated to a maximum dose of three times (TID) 
20 µg, or the maximum tolerated dose, when the HbA1c value at two 
consecutive visits ranged between 7.1 and 7.5%, or when the HbA1c was 
"7.6% at any given visit. Patients randomized to insulin glargine started 
with an initial dosage of 10 U once daily (QD) at bedtime, followed by self-
adjustment of the daily dose according to a fixed-dose treat-to-target (FPG 
<5.6 mmol/L) algorithm, as previously described (12). At 52 weeks the 
mean±SEM insulin glargine dose used was 33.6±3.5 U per day. The 
corresponding fasting SMBG in the insulin glargine treated group was 
5.6±0.2 mmol/L (12). The study protocol was approved by each site’s 
ethical review committee and was in accordance to the principles described 
in the declaration of Helsinki. Patients were recruited at the local sites and 
through advertising. All participating patients gave their written informed 
consent prior to screening. This study is registered with ClinicalTrials.gov 
number NCT00097500. 
 
Standardized mixed-meal test 
The overall meal test design is shown in Figure 3.1B. Patients arrived in 
the study center after an overnight fast. A cannula was inserted into the non-
dominant dorsal hand or wrist vein and maintained in a heated box at 50°C 
for blood collections. Two sequential mixed meal tests (breakfast and lunch, 
4 hours apart; each test meal containing 50g of fat, 75g of carbohydrates, 
and 35g protein) were performed prior to randomization, after 51 weeks of 
treatment, and after a 5-week off-drug period. Subjects were requested to 
eat the test meal within 10 minutes. During the meal test at week 51, 
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patients received their study medication at the protocol-specified time, i.e. 
patients randomized to exenatide were given the study drug 15 minutes 
prior to breakfast and patients randomized to insulin glargine received their 
last insulin dose the night before at bedtime. 
 
Figure 3.1A-B Study profile (A) and meal test design (B). 
 
Blood sampling and analysis 
Plasma glucose concentrations were measured at bedside using an YSI 2300 
STAT Plus (Yellow Springs Instruments, Yellow Springs, OH) in Sweden 
and the Netherlands, and using a Beckman Coulter Glucose Analyzer 2 
(Beckman Coulter, Fullerton, CA) in Finland. Serum ((s-) for analysis of 
lipids) and EDTA plasma ((p-) for analysis of oxidative stress markers) were 
separated by centrifugation (1300-1500 g) and stored at -80°C until analysis. 
Total cholesterol (s-TC) was measured using a cholesterol oxidase method 
(Roche Diagnostics, Penzberg, Germany). Enzymatic colorimetric assays 
were used to measure s-HDL-C, s-LDL-C, triglycerides (s-TG) (all Roche 
Diagnostics, Penzberg, Germany), and free fatty acids (s-FFA) (Wako 
Chemicals, Neuss, Germany). Immunoturbidimetric methods were used to 
measure s-apo-AI (Thermo Electron, Vantaa, Finland), s-apo-AII and s-apo-
CIII (Wako Chemicals, Neuss, Germany), and s-apo-B (Thermo Electron, 
Vantaa, Finland). Malondialdehyde (HbA1c(normal range: 4.3 to 6.1%, 
DCCT standardized Biorad assay), FPG, and serum safety parameters were 
preformed by a central laboratory (Quintiles International, Livingston, 
United Kingdom). 
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Statistics 
All outcome measures, which include the change from pre-treatment (week -
1) incremental AUC (iAUC) and ratio to pre-treatment (week -1) area under 
the curve (AUC) for postprandial concentrations are compared between the 
two treatment groups using an analysis of covariance (ANCOVA) model. 
The model includes factors for treatment group (exenatide/glargine), site 
(NL/SE/FIN), and baseline HbA1c stratum (!8.5%/>8.5%), and the pre-
treatment variable of the corresponding dependent variable as a covariate. 
The AUC and iAUC were calculated using the trapezoidal rule. Log-
transformation was applied to the AUCs before fitting the ANCOVA 
model. Within treatment group comparison was performed using the paired 
t-test. Partial correlations between markers of oxidative stress and glucose or 
triglyceride excursions adjusting for treatment groups were calculated. 
Statistical analysis was performed using SPSS 16.0 for Mac OS X (SPSS, 
Chicago, IL, USA). All inferential statistical tests were conducted at a 
significance level of 0.05 (two-sided). 
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Results 
Prior to treatment no differences between the exenatide and insulin 
glargine-treated groups were observed (Table 3.1). Unless otherwise stated, 
data are presented as mean±SEM. 
 
 
Exenatide  
(n=36) 
Insulin 
Glargine (n=33) 
Age (years) 58.4±1.4 58.3±1.3 
Male sex (n (%)) 23 (63.9) 22 (66.7) 
Caucasian race (n (%)) 36 (100) 32 (97.0) 
Duration of type 2 diabetes (years) 5.7±0.8 4.0±0.6 
Daily metformin dose (mg) 2058±117 1798±147 
Statin use (n (%)) 16 (44.4) 20 (60.6) 
   
Body weight (kg) 90.6±2.1 92.4±2.4 
BMI (kg/m2) 30.9±0.7 30.1±0.6 
HbA1c (%) 7.6±0.1 7.4±0.1 
Fasting plasma glucose (mmol/L) 9.4±0.4 8.9±0.4 
   
Completed study (n (%)) 30 (83.3) 30 (90.9) 
Discontinued study (n (%)) 6 (16.7) 3 (9.1) 
Discontinued study due to adverse events (n (%)) 5 (13.9) 1 (3.0) 
Table 3.1 Pre-treatment characteristics and patient disposition. Data represent 
mean±SEM or n (%). 
Effects on postprandial plasma glucose concentrations 
Postprandial plasma glucose and insulin profiles are shown in Figure 3.2A-
B. One-year treatment with exenatide significantly reduced postprandial 
glucose excursions, whereas insulin glargine did not, which resulted in a 
significant between-group difference in least-squares (LS) mean iAUC0-
8h±SEM change from pre-treatment: -13.14±2.10 mmol*h/L; p<0.001. 
The observed effect was predominantly a result of the effect of exenatide on 
the breakfast meal (between-group difference LS mean iAUC0-4h±SEM: -
8.65±1.16 mmol*h/L; p<0.001). No between-group difference in glucose 
excursions following the lunch meal was observed (between-group difference 
LS mean iAUC4-8h±SEM: 0.74±1.25 mmol*h/L, p=0.559). As exenatide 
predominantly lowers postprandial glucose excursions and insulin glargine 
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lowers fasting glucose concentrations (10) no between-group difference was 
observed in the total meal test glucose exposure (between-group ratio of 
geometric LS mean AUC±SEM ratio to pre-treatment: 0.96±0.04; 
p=0.310). No correlation was found between (changes in) body weight and 
postprandial glucose excursions. 
 
 
Figure 3.2A-B Postprandial concentration profiles of glucose (A), insulin (B) before 
and after 51 weeks of treatment. Grey squares/line = pre-treatment all subjects; 
black circles, solid line = exenatide; open circles, hatched line = insulin glargine. 
Data represent mean±SEM. 
 
Effects on postprandial serum lipids and lipoprotein 
concentrations 
No between-group differences in fasting lipid parameters were observed 
after 1 year intensified treatment (data not shown). Exenatide administration 
had clear effects on lipid profiles following the mixed meal test (Figure 
3.2C-F), and had a predominant effect on s-TG, s-apo-B48 and s-FFA 
concentrations after the breakfast meal (between-group difference LS mean 
iAUC0-4h±SEM change from pre-treatment: 2.3±0.4 mmol*h/L; p<0.001, -
16.6±3.0 µg*h/mL; p<0.0001, and -897±294 µmol*h/L; p=0.004, 
respectively). These strong post-breakfast effects were sustained after 
exposure to the lunch meal (Table 3.2), although the curves did show a rise 
in these parameters towards the end of our 8-h postprandial follow-up 
period (Figure 3.2C-F). 
Additionally, exenatide-treated patients showed a smaller postprandial 
decline in HDL-C, and a smaller increase in calculated VLDL-C (Figure 
3.2E), compared to insulin glargine-treated patients (between-group 
difference iAUC0-8h±SEM change from pre-treatment: +0.33±0.11 
mmol*h/L; p=0.005, and -0.98±0.34 mmol*h/L; p=0.006, respectively). 
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No between-group differences on 8h postprandial s-TC, s-LDL-C, s-apo-
A1, s-apo-A2, s-apo-B100, s-apo-C3 concentrations and LDL particle size 
were observed (Table 3.2). No correlations were found between (changes 
in) body weight and postprandial lipid and lipoprotein excursions. 
 
 
Figure 3.2 C-F Postprandial concentration profiles of triglycerides (TG) (C), 
apolipoprotein-B 48 (apo-B48) (D), very low-density cholesterol (VLDL-C) (E), and 
free fatty acids (FFA) (F) before and after 51 weeks of treatment. 
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Effects on postprandial circulating markers of oxidative stress 
Post-meal profiles of oxidative stress markers are shown in Figure 3.3. 
Exenatide treatment led to significantly lower p-MDA profiles, whereas 
insulin glargine did not have such an effect (mean iAUC0-8h change from 
pre-treatment: -9.1±2.1 µmol*h/L, p<0.001 and +1.5±2.4 µmol*h/L, 
respectively, p=0.527), resulting in a significant between-treatment group 
difference (Table 3.2). As shown with postprandial glucose this effect was 
mainly due to a strong effect following the breakfast meal (between-group 
difference LSmean iAUC0-4h±SEM change from pre-treatment -8.8±1.4 
µmol*h/L, p<0.001). The postprandial OxLDL-to-LDL-C ratio was 
significantly reduced following exenatide treatment whereas insulin glargine 
did not affect this oxidative stress marker (mean iAUC0-8h change from pre-
treatment: -16.3±6.6 U*h/mmol, p=0.019 and +2.6±6.9 U*h/mmol, 
respectively, p=0.711). However, no significant between-group difference in 
postprandial OxLDL:LDL-C excursions was observed (between-group 
difference LS mean iAUC0-8h change from pre-treatment -10.5±7.8 
U*h/mmol, p=0.184; Table 3.2).Partial correlation analysis, adjusted for 
treatment group, showed significant linear associations between the plasma 
glucose and p-MDA concentrations at the time of the peak glucose 
concentration (t=120 minutes) and between the triglyceride and OxLDL-to-
LDL-C ratio at the lowest TG concentration (t=240 minutes). For both 
measures of oxidative stress (r=0.92; p<0.001 and r=0.44, p=0.001 
respectively; Figure 3.3). 
 
Effects on fasting plasma glucose and serum lipid 
concentrations 
As shown previously (12), both exenatide and insulin glargine treatment 
reduced FPG concentrations. As a result of the treat to FPG <5.6 mmol/L 
the observed decrease was statistically significant greater in the glargine 
treated patients. In both treatment groups the decrease in FPG was 
accompanied by a decrease in plasma MDA concentrations. There was a 
strong correlation between FPG and p-MDA concentrations after 52-weeks: 
r= 0.82, p<0.001. No between-group differences in any of the fasting lipid 
parameters were observed after 1 year intensified treatment (Table 3.3). 
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65  Figure 3.3 Postprandial concentration profiles for malondialdehyde (MDA) (A) 
and oxidized low-density lipoprotein (OxLDL) to low-density lipoprotein cholesterol 
(LDL-C) ratio (C) and relationships between peak postprandial glucose and MDA 
excursions at t=120 minutes (B) and relationships between nadir postprandial 
plasma triglycerides and oxidized low-density lipoprotein-to-low-density lipoprotein 
cholesterol ratio at t=240 minutes during the on-drug meal test (week 51). Grey 
squares/line = pre-treatment all subjects; black circles, solid line = exenatide; white 
circles, hatched line = insulin glargine. Data represent mean±SEM, partial 
correlation coefficient (r) and p-value. 
 
Effects after 5-week cessation of study treatment 
Following 5 weeks discontinuation of exenatide and insulin glargine 
treatment, all postprandial measures returned back to pre-treatment values, 
with no statistically significant between-group difference remaining. 
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Adverse effects and tolerability 
The most frequently observed adverse event in exenatide-treated patients 
was mild-to-moderate nausea, observed in 50% of the patients treated with 
exenatide. Biochemically confirmed hypoglycemia (<3.3 mmol/L) was 
observed more frequently in the insulin glargine group (24.2%), as 
compared to the exenatide treated patients (8.3%). There was no severe 
hypoglycemia with either treatment (12). 
 
Discussion 
Our study is the first to show that one-year exenatide treatment reduces 
postprandial serum triglycerides, apolipoprotein-B48, calculated VLDL-C 
and FFA excursions to a greater extent than with insulin glargine, against a 
background of similar glycemic control. Exenatide also reduced the 
postprandial oxidative stress markers p-MDA and p-oxLDL. These data 
confirm our earlier finding that exenatide primarily reduces postprandial 
glucose excursions, whereas insulin glargine lowers fasting glucose 
concentrations (10), and extend these with the strong observed correlation 
between plasma glucose and MDA concentrations, predominantly following 
the first meal after the exenatide injection. 
Postprandial hyperglycemia, dyslipidemia and oxidative stress have all been 
associated with risk of cardiovascular disease, and are known to be present 
in patients with type 2 diabetes (1). Previous studies have shown 
postprandial hypertriglyceridemia to be associated with endothelial 
dysfunction and elevated oxidative stress parameters in patients with type 2 
diabetes and recent data suggest that apo-B48 and apo-B100-containing 
lipoproteins are equally atherogenic (2). 
GLP-1 receptor agonists influence postprandial glucose and lipid 
metabolism through several mechanisms (15). In the current study, 
exenatide significantly decreased postprandial glucose, triglycerides and apo-
B48 (the structural lipoprotein in chylomicrons) excursions compared to 
insulin glargine. In the postprandial state, intestinal lipids are absorbed from 
the small intestinal lumen as fatty acids and cholesterol, esterified to 
triglycerides and cholesterol esters, and secreted as chylomicrons to the 
surrounding lymph ducts. Animal studies have demonstrated that GLP-1 
slows intestinal uptake of triolein and decreases intestinal lymph flow (16). 
Additionally, a recent study showed that the GLP-1 receptor signaling is 
essential for postprandial lipoprotein synthesis and secretion, and reduces 
intestinal secretion of triacylglycerol, cholesterol and apo-B48 (17). Also, 
fatty acid binding protein 2 (FABP2) is required for the formation of apo-
B48-containing chylomicrons and is influenced by various intestinal 
hormones, such as GLP-1 (18). Combined, these data suggest that, 
 Exenatide and postprandial metabolism 
 
69 
additional to the effect on gastric emptying, GLP-1 reduces intestinal lipid 
production and absorption, preventing the postprandial increase in 
triglyceride levels (16,17). Unfortunately, as a result of blood volume 
restrictions by our ethical review board we did not measure glucagon 
concentrations in the current study. The glucagon-suppressing effects of 
GLP-1RA such as exenatide are well-known and have been reported from 
many different studies (9). 
 
We found postprandial calculated VLDL-C concentrations to be lower in 
exenatide-treated patients without a between-group difference in 
postprandial apo-B100 concentrations. Hepatic overproduction of apo-
B100-containing VLDL1 particles is regarded as the dominant feature of 
diabetic dyslipidemia driven primarily by liver fat and hyperglycemia (19). 
Surprisingly, in both treatment arms, no improvement in postprandial apo-
B100 levels was observed (Table 3.2). Calculated VLDL-C should be 
interpreted as non-HDL/LDL particle cholesterol, which includes 
chylomicron cholesterol. As we showed a vast reduction in the apo-B48 
concentration, the reduction in calculated VLDL-C may merely be a result 
of this observed decrease in apo-B48, an observation that is strengthened by 
the unchanged apo-B100 concentrations in both treatment groups.  
Low fasting HDL-C is an important feature of diabetic dyslipidemia and 
cardiovascular risk factor, which is reduced further during the postprandial 
period (1). This study shows that exenatide diminishes the postprandial 
reduction in HDL-C without having an effect on apo-A1, the predominant 
lipoprotein in HDL particles. The between-group difference in postprandial 
triglycerides may contribute to this difference in HDL-C. Plasma 
triglycerides drive the exchange of lipids between triglyceride-rich 
lipoproteins (such as VLDL) and HDL particles. Also, triglycerides in HDL 
particles are a good substrate for hepatic lipase and the hydrolysis produces 
smaller particles and free HDL apo-A1 that is subsequently cleared by the 
kidneys (2).  
This study confirms our earlier findings that exenatide lowered postprandial 
glucose excursions compared to insulin glargine, using a 4-hour mixed-meal 
test (10). We extended this finding by showing that the total glucose 
excursion remained significantly lower with exenatide compared to insulin 
glargine during an 8-hour mixed-meal test, even after ingestion of an 
additional lunch meal, 4 hours after the (pre-breakfast) exenatide dose. Even 
though glucose excursions following the lunch meal were equal in both the 
exenatide and insulin glargine group, the total glucose exposure during the 
whole 8-hour meal test was significantly lower in the exenatide treated 
patients. Decreased gastric emptying, a reduction in endogenous (hepatic) 
glucose production and potentiation of beta-cell function have been 
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attributed to reduce postprandial glucose excursions (9, 20). Although, the 
total 8-h p-glucose, s-TG, and s-apo-B48 excursions (measured as iAUC) 
remain lower in the exenatide treated patients, a rise following the second, 
lunch meal appeared to be present, resulting in higher concentrations in the 
exenatide group after 8-h of follow-up. An explanation for this phenomenon 
may be that the lipid particles are sequestrated in the gut during the first 
meal and gradually become available during the second meal (20). Whether, 
and for how long, this increase continues after the second meal need further 
study using 24-h meal tests. 
In addition, recent findings attribute a role to portal vein GLP-1 receptors in 
increasing postprandial glucose clearance independent of islet hormones 
(21). Postprandial improvement in several model-derived measures of beta-
cell function has been described for exenatide (22) as well as for other 
incretin-based therapies (23,24). Whether these improvements in 
postprandial beta-cell function extend to after a second lunch meal, 4-h after 
exenatide administration, and possible explaining mechanisms as the Staub-
Traugott effect (25) need further investigation. 
 
Both postprandial hyperglycemia and hypertriglyceridemia lead to 
mitochondrial free radical production and subsequent oxidative stress, 
which in turn may contribute to the development of microvascular and 
macrovascular complications (5). Reducing postprandial glucose and lipid 
excursions has been suggested to be included in the treatment guidelines for 
type 2 diabetes (26). Our data show that attenuating postprandial with 
exenatide and fasting glucose excursions with insulin glargine are related to 
beneficial effects on malondialdehyde, as is the case for triglyceride and 
oxidized LDL concentrations. Also, this observed correlations suggest that 
lowering of glucose and triglyceride excursions may positively affect 
malondialdehyde and oxidized LDL concentrations. The observed findings 
may result in favorable effects on individual cardiovascular risk, which is 
suggested by a recent meta-analysis of exenatide clinical trial data (27). 
 
In summary, the current study showed that one-year treatment with 
exenatide, as compared to insulin glargine, had beneficial effects on 
postprandial glycemia, dyslipidemia and measures of oxidative stress in 
patients with type 2 diabetes. Whether long-term treatment with GLP-1 
receptor agonists, such as exenatide, leads to a decrease in diabetes-related 
cardiovascular complications can only be answered by a prospective long-
term outcomes study. 
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Orleans, Louisiana, 5-9 June 2009. 
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Abstract  
Background: To study the effect of exenatide on body composition and 
circulating cardiovascular risk biomarkers. 
Methods: Metformin-treated patients with type 2 diabetes (N=69) were 
randomized to exenatide or insulin glargine and treated for one-year. Body 
composition was evaluated by Dual-Energy X-ray Absorptiometry. 
Additionally, body weight, waist circumference and cardiovascular 
biomarkers were measured. 
Results: One-year treatment with exenatide significantly reduced body 
weight, waist circumference, total body and truncal fat mass by 6%, 5%, 
11% and 13%, respectively. In addition, exenatide increased total 
adiponectin by 12%, and reduced hsCRP by 61%. Insulin glargine 
significantly reduced endothelin-1 by 7%. These changes were statistically 
independent of the change in total body fat mass and body weight. 
Conclusions: Exenatide treatment for 1 year reduced body fat mass and 
improved the profile of circulating biomarkers of cardiovascular risk. No 
significant changes were seen with insulin glargine except a trend for 
reduced endothelin-1 levels. 
Exenatide, body composition, and cardiovascular risk markers 
  
97 
Introduction 
Abdominal obesity is associated with both type 2 diabetes and metabolic 
complications (1), including elevations in several circulating biomarkers of 
cardiovascular risk (2). Most pharmacologic glucose-lowering treatments 
increase body weight (3). Therefore, treatments that not only reduce 
glycated hemoglobin A1c, but also improve other associated changes such as 
abdominal obesity are urgently needed (4). 
 
We previously reported in that exenatide improves glycemic control to the 
same extent as insulin glargine, while exenatide decreased and insulin 
glargine raised body weight (5). Herein we present additional data on 
associated changes in body composition and circulating levels of biomarkers 
of cardiovascular risk following one-year’s treatment. 
Research design and methods 
Details on study design were reported previously (5). Patients were 
randomized to exenatide (n=36) or insulin glargine (n=33) added to their 
ongoing metformin therapy (Figure 5.1). The study protocol was approved 
by each site’s ethical review committee and was in accordance with the 
principles described in the declaration of Helsinki and all participating 
patients gave their written informed consent prior to screening. This study is 
registered with ClinicalTrials.gov number NCT00097500. 
 
Dual-Energy X-ray Absorptiometry (DEXA) scan 
Lean body and fat mass was assessed using Dual Energy X-ray 
Absorptiometry (DEXA) scans (Delphi A, Hologic, Waltham, MA) at 
baseline, and after treatment. Trunk (abdominal) and limb (hip/leg) regions 
of interest were determined from a total body scan. Waist circumference was 
measured at the midline of the interval between iliac crest and lowest rib 
using the mean of two measurements prior to the DEXA scan. 
 
Biochemical analyses 
Cardiovascular risk biomarkers were collected at baseline and after one-year 
of treatment. Serum was separated by centrifugation and stored at -80°C 
until analysis. All serum samples were analyzed in the Lundberg Laboratory 
for Diabetes Research using a single batch. Total adiponectin, high 
molecular weight (HMW) adiponectin, resistin, leptin, high-sensitive C-
reactive protein (hsCRP), interleukin (IL)-6, monocyte chemotactic protein 
(MCP)-1, endothelin-1 were determined by commercial ELISA’s (R&D 
Systems, Abingdon,UK). 
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Figure 5.1 Protocol flow chart and baseline characteristics of the study population. 
Data represent mean±SEM. 
 
Statistical analysis 
Non-normally distributed data was log-transformed prior to statistical 
analysis, after which the approximated the normal distribution. All outcome 
measures are compared between the two treatment groups using an analysis 
of covariance (ANCOVA) model including factors for treatment, 
investigative site and baseline HbA1c stratum (!8.5% or >8.5%) and 
baseline values of corresponding outcome measure as a covariate (5). 
Statistical analysis was performed using SPSS 16.0 for Mac OS X (SPSS, 
Chicago, IL, USA). All inferential statistical tests were conducted at a 
significance level of 0.05 (two-sided). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Randomized 
69 
 
 
(N = 45) 
Completed On-Drug Period 30 (83.3%) 
Withdrew prior to week 52   6 (16.7%) 
Withdrawal of consent   1   (2.8%) 
Adverse event    5 (13.9%) 
 
Completed Off-Drug Period 25 (69.4%) 
Withdrew between week 52-64   5 (30.6%) 
Withdrawal of consent   2   (5.6%) 
Loss of glucose control   3   (8.3%) 
 
Exenatide 
Intent-to-treat (ITT) 36 
Insulin glargine 
Intent-to-treat (ITT) 33 
Completed On-Drug Period 30 (90.9%) 
 Withdrew prior to week 52   3  (9.1%) 
Withdrawal of consent   1  (3.0%) 
Investigator decision   1  (3.0%) 
Lost to follow-up   1  (3.0%) 
 
Completed Off-Drug Period 26 (78.8%) 
Withdrew between week 52-64   4 (21.2%) 
Withdrawal of consent   1   (3.0%) 
Loss of glucose control   2   (6.1%) 
Investigator decision   1   (3.0%) 
 
 
Screened 
150 
 
 
(N = 45) 
Screen failure   76  (50.6%) 
 
Did not meet inclusion criteria 71   (47.3%) 
Withdrawal of consent    1     (0.7%) 
Protocol violation    3     (2.0%) 
Lost to follow-up    1     (0.7%) 
 
  
Early term prior to randomization  5 (3.3%) 
 
Withdrawal of consent      3 (2.0%) 
Investigator decision      2 (1.3%) 
 
Demographics 
Male Sex (%)    63.9 
Age (y):     58.4±1.4 
Weight (kg)    90.6±2.1 
Body-Mass Index (kg/m
2
)   30.9±0.7 
Duration of diabetes (y)      5.7±0.8 
Daily metformin dose (mg)              2094±120 
HbA1c         7.6±0.1 
Fasting Plasma Glucose (mmol/L)   9.4±0.4 
Fasting Insulin (pmol/L)       87±12 
Fasting C-peptide (nmol/L)     0.9±0.1 
C-peptide response to arginine 
at 15 mmol/L glucose (nmol*min/L)  19.7±2.1 
Demographics 
Male Sex (%)    66.7 
Age (y):     58.3±1.3 
Weight (kg)    92.4±2.4 
Body-Mass Index (kg/m
2
)   30.1±0.6 
Duration of diabetes (y)      4.0±0.6 
Daily metformin dose (mg)              1768±149 
HbA1c         7.4±0.1 
Fasting Plasma Glucose (mmol/L)    8.9±0.4 
Fasting Insulin (pmol/L)       76±12 
Fasting C-peptide (nmol/L)     0.8±0.1 
C-peptide response to arginine 
at 15 mmol/L glucose (nmol*min/L)  20.0±2.5 
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Results 
One-year treatment with exenatide resulted in a statistically significant 
reduction in total body fat mass (Table 5.1), mainly in the abdominal 
region, as illustrated by the decrease in trunk fat mass and waist 
circumference, in contrast to insulin glargine. Neither treatment significantly 
affected lean body mass. 
In univariate analysis, the reduction in body weight in the exenatide arm 
was significantly correlated with the changes in leptin (r=0.580, p=0.001) 
and hsCRP (r=-0.590, p=0.001). No statistical significant univariate 
correlation was found between changes in body weight and other 
biomarkers. Interestingly, changes in all circulating biomarkers did not 
correlate with the changes in total body fat mass (total adiponectin: 
Pearson’s r=-0.224, p=0.106; HMW adiponectin: r=0.057, p=0.694; leptin: 
r=0.229, p=0.106; hsCRP: r=-0.023, p=0.872). 
Following multivariate analysis, statistical adjustment for body weight 
change, exenatide increased total adiponectin, and decreased hsCRP 
concentrations, whereas insulin glargine did not (Table 5.1). Insulin 
glargine reduced endothelin-1 concentrations, whereas exenatide did not 
have such an effect. No statistically significant effects of either treatment on 
HMW adiponectin, IL-6, MCP-1, and resistin was observed. 
The crude between treatment group differences remained statistically 
significant after additional multivariate adjustment for total body fat mass 
change: total adiponectin +16% (95%CI:+5%; +28%), p=0.004; leptin -
20% (-34%;-2%), p=0.028; hsCRP -48% (-69%;-13%), p=0.015; and  body 
weight change (Table 5.1): total adiponectin +17% (95%CI:+6%;+30%), 
p=0.004; leptin -19% (-34%;-0%), p=0.045; hsCRP -52% (-71%;-19%), 
p=0.008. 
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Discussion 
This study showed that exenatide reduced body fat mass and improved the 
profile of circulating cardiovascular biomarkers. The changes in the different 
biomarkers could not be fully attributed to the observed changes in body fat 
mass and body weight. Direct effects of GLP-1 receptor agonists on 
adipocyte function have been described in both animal experimental studies 
as in in-vitro studies in normal human adipocytes (for review see reference 6), 
however as a significant univariate correlation between change in body 
weight (not with fat mass) change and cardiovascular biomarkers was 
present, our relatively small population may influence the statistical power of 
our study. 
 
Animal studies have also demonstrated beneficial effects of exenatide on 
visceral fat mass (7) and circulating adiponectin (8), leptin (9), and CRP (10) 
concentrations. However, to the best of our knowledge, controlled clinical 
studies on the long-term effects of GLP-1 receptor agonists on body 
composition and biomarkers of cardiovascular risk have not previously been 
reported. 
A recent 3-month study comparing exenatide to insulin glargine in 56 
patients with type 2 diabetes has a design comparable to our one-year study. 
Similar to our findings, this study showed that exenatide treatment was 
associated with reduced hsCRP, without affecting the IL-6 levels (11).  
 
Sub-analysis of the LEAD-3 data reported that liraglutide, treatment for 52 
weeks compared to glimepiride reduced DEXA measured total fat tissue 
mass (12). Lean tissue mass was also reduced after one-year treatment, but 
as glimepiride also reduced lean tissue mass, this reduction was not 
statistically significantly different between the groups. 26-week data from the 
LEAD-2 study was used to show that the observed reduction in fat mass was 
mainly a result of a reduction in visceral fat (12). Unfortunately, this study 
did not report the effects of body composition on circulating biomarkers. 
Serum leptin, hsCRP, and IL-6 concentrations did not change in a 14-week 
placebo-controlled study with liraglutide 1.9 mg (13). 
 
Of particular interest in our study was the finding that the changes in 
biomarkers of cardiovascular risk appeared to be independent of the 
changes in body fat mass. Recently, Chung and colleagues reported 
exendin-4 directly increased adiponectin mRNA levels and secretion in 
3T3-L1 adipocytes (14). In that study, exendin-4 also decreased mRNA 
levels of IL-6 and MCP-1 (14). Additionally, we (15), and others (10), have 
previously reported beneficial effects of exenatide on hepatic steatosis, which 
also may contribute to a reduction in CRP. 
Exenatide, body composition, and cardiovascular risk markers 
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In conclusion, we found that exenatide treatment for one-year led to a 
reduced total fat mass, including visceral fat, while lean body mass was not 
significantly altered. Additionally, the circulating levels of adiponectin, 
leptin, and hsCRP showed an improved profile, which appeared to be 
independent of the changes in fat mass. In contrast, no significant changes in 
body composition or circulating biomarkers were seen with insulin glargine. 
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Abstract 
Background: Previously we showed that exenatide enhanced insulin secretion 
after 1-year treatment, relative to insulin glargine, with a similar glucose-
lowering action. These effects were not sustained after a 4-week off-drug 
period. Here we report the results after additional 2 years of exposure. 
Methods: Sixty-nine metformin-treated patients with type 2 diabetes were 
randomized to exenatide or insulin glargine. Forty-six patients entered the 
2-year extension study in which they continued their allocated therapy. 
Thirty-six completed (exenatide n=16; insulin glargine n=20) the 3-year 
exposure period. Insulin sensitivity (M-value) and beta-cell function were 
measured by euglycemic hyperinsulinemic clamp followed by hyperglycemic 
clamp with arginine stimulation at pre-treatment, week 52, and 4 weeks 
after discontinuation of study medication at week 56, and week 172. First-
phase glucose stimulated C-peptide secretion was adjusted for M-value and 
calculated as the disposition index (DI). 
Results: At 3-years, exenatide and insulin glargine resulted in similar levels of 
glycemic control: 6.6±0.2% and 6.9±0.2%, respectively (P=0.186). 
Exenatide compared to insulin glargine significantly reduced body weight (-
7.9±1.8 kg; P<0.001). After the 4-week off-drug period, exenatide increased 
the M-value by 39% (p=0.006) while insulin glargine had no effect 
(p=0.647). Following the 4-week off-drug period, the DI, compared to pre-
treatment, increased with exenatide, but decreased with insulin glargine 
(+1.43±0.78 and -0.99±0.65, respectively; P=0.028).  
Conclusions: Exenatide and insulin glargine sustained HbA1c over 3-year 
treatment, while exenatide reduced, and insulin glargine increased body 
weight. Following 3-year treatment with exenatide the DI was sustained 
after a 4-week off-drug period. These findings suggest a beneficial effect on 
beta-cell health. 
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Introduction 
Type 2 diabetes is characterized by progressive beta-cell dysfunction against 
a background of obesity-related peripheral and hepatic insulin resistance (1). 
Current treatment guidelines promote a step-wise approach, starting with 
lifestyle and metformin, and adding a next agent, as soon as target HbA1c 
values cannot be sustained below 7% (2). None of the presently advocated 
pharmacological interventions, most of which were already used in the 
UKPDS (3), address the underlying pathophysiological factors of type 2 
diabetes, especially beta-cell function (4). Due to this progressive decline of 
beta-cell function, in the presence of additional glucose toxicity, the majority 
of patients will require polypharmacy and eventually insulin therapy to 
maintain acceptable glycemic control (4). Therefore, novel treatment 
options specifically addressing the beta-cell function defect are eagerly 
awaited. 
Exenatide is the first-in-class glucagon-like peptide-1 receptor agonist (GLP-
1RA), which improves blood glucose in patients with type 2 diabetes by 
many different mechanisms (5). Exenatide predominantly lowers 
postprandial glucose by a glucose-dependent stimulation of insulin-secretion, 
inhibition of an inappropriate glucagon secretion and by slowing down 
gastric emptying (6). Additionally, exenatide promotes satiety, decreases 
food intake and reduces body weight (6). 
Previously, we showed exenatide, as compared to insulin glargine, improved 
pancreatic beta-cell secretory function against a background of similar 
glycemic control (7). However, these findings were not sustained after a 4-
week off-drug period, thus it was not possible to demonstrate disease 
modification (7). 
The aim of this extension study was to assess the long-term effects of 
exenatide and insulin glargine on glycemic control, body weight, and safety, 
after an additional 2-year treatment period and during a 12-week off-drug 
period. During the off-drug period, clamp derived measures of beta-cell 
function and insulin sensitivity were assessed after 4 weeks. 
Research design and methods 
The study was performed between September 2004 and December 2009 at 
three study sites, in Sweden, Finland and the Netherlands. The one-year 
data were reported previously (7). In total, 150 patients were screened of 
which 69 patients were randomized using a permutated block 
randomization scheme stratified by site and screenings HbA1c to receive 
exenatide or insulin glargine, in addition to ongoing metformin treatment. 
Inclusion criteria were: age 30-75 years, HbA1c 6.5-9.5%, body mass index 
25-40 kg/m2, and metformin treatment at a stable dose for at least 2 
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months. No other blood glucose lowering agents were allowed within 3 
months prior to screening. The study protocol was approved by each site’s 
ethics review committee and was in accordance with the principles described 
in the declaration of Helsinki. All participating patients gave their written 
informed consent prior to screening. This study is registered with 
ClinicalTrials.gov number NCT00097500. 
 
Experimental design 
Patients randomized to exenatide (n=36) initiated treatment at a dose of 5 
µg twice daily (BID), injected 15-min before breakfast and dinner, for a 
period of 4 weeks, followed by dose increase to 10 µg BID. Exenatide was 
titrated to a maximum dose of three times (TID) 20 µg, or the maximum 
tolerated dose, when HbA1c ranged 7.1-7.5% at two consecutive visits, or 
when HbA1c was !7.6% at any given visit. Patients randomized to insulin 
glargine (n=33) started at an initial dose of 10 IU once daily (QD), injected 
at bedtime. Patients were instructed to increase the daily dose based on their 
fasting self-monitored blood glucose (SMBG) levels (<5.6 mmol/L), 
according to a pre-specified treat-to-target algorithm (8). When necessary, 
the importance of proper titration of insulin was emphasized. 
After completing the one-year main treatment period of the study, patients 
were asked to return to their randomly assigned study medication for an 
additional 104-weeks of treatment, followed by a 12-week off-drug period 
(Figure 6.1). Forty-six patients gave their written consent to participate in 
the extension phase and continued their allocated treatment with exenatide 
(n=21) or insulin glargine (n=25). During the extension phase patients 
visited the study centers at 12-week intervals until the end of the treatment 
period (week 168). At this point they stopped the exenatide or insulin 
glargine treatment and continued their ongoing metformin treatment, which 
they had been using in an unchanged dose during the total 168-week 
treatment period. After a 4-week off-drug period, patients returned to the 
center for their final combined euglycemic hyperinsulinemic and 
hyperglycemic clamp with arginine stimulation. The final study visit was at 
week 180 (approximately 3.5 years after randomization). 
 
 
Figure 6.1 Study design. 
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Combined euglycemic hyperinsulinemic and hyperglycemic 
clamp with arginine stimulation 
Insulin sensitivity and C-peptide secretion measures were measured during a 
combined euglycemic hyperinsulinemic and hyperglycemic clamp 
procedure, as described previously (Figure 6.2) (9, 10). Clamps were 
performed prior to randomization, following 52-weeks of treatment, after a 
4-week off-drug period (week 56), and finally after a 4-week off-drug period 
following the total 3 years of treatment (week 172) as described previously 
(7). During the clamp at week 52, patients randomized to exenatide, were 
given the study drug 15 minutes prior to the onset of the hyperglycemic 
clamp and patients randomized to insulin glargine received their last insulin 
dose the night before at bed time. During the clamp at week 56 and week 
172, patients did not receive either exenatide or insulin glargine. Arginine 
was administered at t=260 minutes, during the hyperglycemic clamp to 
estimate maximum insulin secretory capacity at a steady-state glucose 
concentration of 15 mmol/L (11). Whole body insulin-mediated glucose 
uptake (M-value) was calculated as the mean glucose infusion rate during 
the last 30 minutes of the euglycemic-hyperinsulinemic clamp between 90-
120 minutes (9). First and second phase C-peptide secretion was calculated 
as area-under-the-curve (AUC) 180-190min and AUC190-260min, 
respectively. Arginine-stimulated C-peptide secretion (AIRarg) was 
calculated as the incremental AUC260-270min above the C-peptide 
concentration prior to the start of the hyperglycemic clamp (t=175 minutes). 
The disposition index (DI), a measure of beta-cell function, adjusted for 
insulin sensitivity, was calculated by multiplying the first-phase incremental 
C-peptide secretion with the M-value (AIRgluc*M) (12). 
 
Figure 6.2 Clamp design. At week 52, exenatide injection at t=165 minutes, 
insulin glargine at bed time. At week 56 and week 172, no exenatide- or insulin 
glargine injection. 
 
Biochemical analysis 
HbA1c (normal range: 4.3 to 6.1%, DCCT standardized Biorad assay), 
fasting plasma glucose (FPG), and safety parameters were measured prior to 
randomization and during each follow-up visit until the end of the 12-week 
off-drug period by a central laboratory (Quintiles, Livingston, UK). Plasma 
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glucose concentrations during the clamp were measured using an YSI 2300 
STAT Plus (YSI, Yellow Springs, OH) in Sweden and the Netherlands, and 
using a Beckman-Coulter Glucose Analyzer 2 (Beckman-Coulter, Fullerton, 
CA) in Finland. C-peptide samples were analyzed at the VU University 
Medical Center using a single batch immunoradiometric assay 
(Centaur; Bayer Diagnostics, Mijdrecht, the Netherlands). 
 
Statistical analysis 
The extension study’s primary efficacy endpoint was the treatment effect on 
the beta-cell function, measured as the 1st-phase glucose-stimulated C-
peptide secretion adjusted for the M-value. Non-normally distributed data 
were base-e transformed prior to statistical analysis. Outcome measures 
were compared between the two treatment groups using an analysis of 
covariance (ANCOVA) model. The dependent variable used in the model 
was the change from pre-treatment for the beta-cell function parameters 
(AIRarg, 1st phase, 2nd phase). For all other endpoints the dependent value 
used was the mean at the corresponding visit. The model included factors 
for treatment group (exenatide/insulin glargine), site (NL/SE/FIN), and 
baseline HbA1c stratum (!8.5%/>8.5%), and the pre-treatment variable of 
the corresponding dependent variable as a covariate. If the parameter did 
not approximate the normal distribution after base-e transformation a non-
parametric test was used (DI statistics using Mann-Whitney test). Statistical 
analysis was performed using SPSS 16.0 for Mac OS X (SPSS, Chicago, IL, 
USA). All inferential statistical tests were conducted at a significance level of 
0.05 (two-sided). Unless otherwise stated, data are presented as mean 
(±SEM). 
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Figure 6.3 Protocol flow chart and baseline characteristics of the study population. 
Data represent mean ± SD. 
 
Results 
Patient disposition and baseline clinical characteristics 
Extension phase patient disposition and baseline clinical characteristics are 
shown in Figure 6.3. No significant between treatment group differences 
were presents at baseline. At the end of the one-year main study phase five 
patients withdrew their consent and did not participate in the extension 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Randomized 
69 
 
 
(N = 45) 
Completed 1st On-Drug Period 30 (83.3%) 
Withdrew prior to week 52   6 (16.7%) 
Withdrawal of consent   1   (2.8%) 
Adverse event    5 (13.9%) 
 
Completed 1st Off-Drug Period 25 (69.4%) 
Withdrew between week 52-64   5 (30.6%) 
Withdrawal of consent   2   (5.6%) 
Loss of glucose control   3   (8.3%) 
Entered extension period 21 (58.3%) 
 
Completed 2nd On-Drug Period 16 (83.3%) 
Withdrew between week 64-168   5 (16.7%) 
Withdrawal of consent   1   (4.8%) 
Adverse event    2   (9.5%) 
Loss of glucose control   2   (9.5%) 
 
Completed 2nd Off-Drug Period 16 (83.3%) 
Withdrew between week 168-180   0   (0.0%) 
 
Exenatide 
Intent-to-treat (ITT) 36 
Insulin glargine 
Intent-to-treat (ITT) 33 
Completed 1st On-Drug Period 30 (90.9%) 
 Withdrew prior to week 52   3  (9.1%) 
Withdrawal of consent   1  (3.0%) 
Investigator decision   1  (3.0%) 
Lost to follow-up   1  (3.0%) 
 
Completed 1st Off-Drug Period 26 (78.8%) 
Withdrew between week 52-64   4 (21.2%) 
Withdrawal of consent   1   (3.0%) 
Loss of glucose control   2   (6.1%) 
Investigator decision   1   (3.0%) 
Entered extension period 25 (75.8%) 
 
Completed 2nd On-Drug Period 20 (83.3%) 
Withdrew between week 64-168   5 (20.0%) 
Withdrawal of consent   3 (12.0%) 
Adverse event    1   (4.0%) 
Loss of glucose control   1   (4.0%) 
 
Completed 2nd Off-Drug Period 16 (64.0%) 
Withdrew between week 168-180   4 (30.6%) 
Withdrawal of consent   2   (8.0%) 
Loss of glucose control   2   (8.0%) 
 
Screened 
150 
 
 
(N = 45) 
Screen failure   76  (50.6%) 
 
Did not meet inclusion criteria 71   (47.3%) 
Withdrawal of consent    1     (0.7%) 
Protocol violation    3     (2.0%) 
Lost to follow-up    1     (0.7%) 
 
  
Early term prior to randomization  5 (3.3%) 
 
Withdrawal of consent      3 (2.0%) 
Investigator decision      2 (1.3%) 
 
Demographics 
Male Sex (%)    63.9 
Age (y):     58.4±1.4 
Weight (kg)    90.6±2.1 
Body-Mass Index (kg/m2)   30.9±0.7 
Duration of diabetes (y)      5.7±0.8 
Daily metformin dose (mg)              2058±117 
HbA1c         7.6±0.1 
Fasting Plasma Glucose (mmol/L)   9.4±0.4 
Fasting Insulin (pmol/L)       87±12 
Fasting C-peptide (nmol/L)     0.9±0.1 
C-peptide response to arginine 
at 15 mmol/L glucose (nmol*min/L)  19.7±2.1 
Demographics 
Male Sex (%)    66.7 
Age (y):     58.3±1.3 
Weight (kg)    92.4±2.4 
Body-Mass Index (kg/m2)   30.1±0.6 
Duration of diabetes (y)      4.0±0.6 
Daily metformin dose (mg)              1798±147 
HbA1c         7.4±0.1 
Fasting Plasma Glucose (mmol/L)    8.9±0.4 
Fasting Insulin (pmol/L)       76±12 
Fasting C-peptide (nmol/L)     0.8±0.1 
C-peptide response to arginine 
at 15 mmol/L glucose (nmol*min/L)  20.0±2.5 
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phase (one in the insulin glargine group and four in the exenatide group), 
because of the demanding study procedures. Thirty-six patients completed 
the 168-week treatment period. Of the patients randomized to exenatide 
69% (n=11) were treated with exenatide 10 µg BID at 168-weeks of 
treatment. 1 (6.25%) patient was using 20 µg BID, 1 15 µg TID, 1 a 
combination of 4QD/8BID, and 1 a combination of 6QD/8QD. The daily 
exenatide dose was reduced to 5 µg BID in 1 (6.25%) patient. At 168-weeks 
the mean±SEM daily insulin glargine dose used was 33.7±4.0 units.  
 
Glycemic control  
At three-years glycemic control was still comparable for exenatide and 
insulin glargine treatment: the HbA1c values were 6.6±0.2%, and 6.9±0.2% 
at 168-weeks (between group difference: P=0.186, Figure 6.4A). Due to the 
treat-to-target titration, the insulin glargine group showed a significantly 
greater reduction in FPG as compared to exenatide (-2.0±0.4 versus -
0.2±0.5 mmol/L; P<0.0001, respectively, Figure 6.4B). After 12 weeks off-
drug both HbA1c and FPG increased in both groups to pre-treatment values 
(Figure 6.4A-B). 
 
Body weight and insulin sensitivity 
After 168-weeks of treatment exenatide reduced body weight by -5.7±1.3 
kg, while treatment with insulin glargine resulted in a body weight increase 
of 2.1±1.3kg (between group LSmean difference, -7.9±1.8 kg; P<0.001 
Figure 6.4C). During the 12-week off-drug period body weight slightly 
trended back toward baseline values in both treatment groups, leaving a 
statistical significant difference at the end of the study in favor of exenatide 
(between group difference at week 180: -5.5±1.7 kg; P=0.004 Figure 
6.4C). 
Before randomization, whole-body insulin-mediated glucose uptake did not 
differ between the two treatment groups. Three-year treatment with 
exenatide improved the M-value by 39% (p=0.006) while insulin glargine 
had no effect (p=0.647). 
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Figure 6.4A-C Time course for HbA1c (A), fasting plasma glucose (B), and change 
in body weight (C). Data are mean (SEM). White circles = exenatide; black circles = 
insulin glargine. Vertical hatched line at week 52, 64 and 168 represents cessation 
and restart of study medication. 
Measures of beta-cell function 
At week 0, both glucose and arginine stimulated C-peptide secretion did not 
significantly differ between the two treatment groups (Figure 6.5A). 
Exenatide significantly improved beta-cell function during 52-week of active 
treatment compared with titrated insulin glargine (Figure 6.5B, Figure 
6.5E-F). After 4-week cessation of both exenatide and insulin glargine 
therapy, beta-cell function returned to pretreatment values at week 56 
(Figure 6.5C, Figure 6.5E-F), as reported previously (7). 
A
B
C
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Following three-year treatment with either exenatide or insulin glargine and 
a 4-weeks off-treatment period the glucose- and arginine stimulated C-
peptide secretion, as compared to baseline remained similar: 1.02 ±0.11 and 
1.06 ±0.10 for exenatide and insulin glargine, relative to baseline, 
respectively (Figure 6.5E-F) between treatment group comparison 
P=0.665). Interestingly, first and second phase glucose stimulated C-peptide 
responses were significantly lower in the exenatide treated patients after 3-
years of treatment when compared to insulin glargine (Figure 6.5D): 1st 
phase relative to pre-treatment exenatide 0.88±0.09, insulin glargine 1.08 
±0.10, P=0.038, and 2nd phase relative to pre-treatment exenatide 
0.97±0.08, insulin glargine 1.17 ±0.08, P=0.017. However, the DI change 
from pre-treatment showed a sustained effect on beta-cell function 4-weeks 
after cessation of treatment in the exenatide treated patients whereas a 
reduction was observed in the insulin glargine treated patients (Figure 
6.5G-H: +1.43±0.78 and -0.99±0.65 respectively; between group 
difference P=0.028). This is in contrast to the one-year data, where no 
sustained effect on the DI was observed after cessation of treatment. No 
statistical significant between treatment group difference was observed in the 
DI calculated over the second phase C-peptide secretion (+36.89±17.51 and 
+25.02±14.24 for exenatide and insulin glargine respectively; between 
group difference P=0.763). 
 
Adverse events and tolerability 
During the extension phase, most common adverse events with exenatide 
treatment were gastrointestinal in nature (42.9%) and mild-to-moderate in 
intensity: nausea: 38.1%, vomiting 9.5%, abdominal distention 4.8%, and 
diarrhea 4.8%.  In the exenatide treated group, 2 patients (9.5%) withdrew 
their consent as a result of nausea or vomiting. 19% of exenatide-treated 
subjects experienced treatment-emergent minor hypoglycemia, defined as a 
self-measured blood glucose concentration <3.0 mmol/L. At week 168, 
31% of exenatide-treated subjects (5/16) had detectable anti-exenatide 
antibody titers, with the majority (4/5) of titers in the low range (<1/25 
titer). The anti-exenatide antibodies had no predictive effect on the 
magnitude of an individual’s glycemic response or the incidence of adverse 
events. Most reported adverse events with insulin glargine treatment were: 
treatment-related minor hypoglycemia 28%, gastrointestinal disorders 16%, 
vomiting 8.0%. No major hypoglycemia and no treatment-related 
withdrawal due to hypoglycemia were observed in both the exenatide and 
insulin glargine group. In the insulin glargine treated group, one patient 
(4.0%) withdrew his consent as a result of a cerebrovascular incident. 
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Figure 6.5A-H Beta-cell function parameters during 3-years of exenatide (n=16) 
and insulin glargine (n=20) treatment. Serum C-peptide concentrations during 
hyperglycemic clamp are shown at week 0 (Figure 6.5A), week 52 (Figure 6.5B), 
week 56 (Figure 6.5C), and week 172 (Figure 6.5D). White circles = exenatide; 
black circles = insulin glargine. Beta-cell secretory capacity ratio-to-pre-treatment in 
the exenatide (Figure 6.5E) and insulin glargine (Figure 6.5F) treated group. 
Black bars = week 0 (pre-treatment); blocked bars = week 52 (on-drug); horizontal 
lined bars = week 56 (off-drug); white bars = week 172 (off-drug). Mean Disposition 
Index the exenatide and insulin glargine treated group (Figure6.5G). Black square = 
A B
DC
FE
G H
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exenatide week 0 (pre-treatment); white square = exenatide week 172 (off-drug); 
black circle = insulin glargine week 0 (pre-treatment); white circle = insulin glargine 
week 172 (off-drug). Disposition Index change from pre-treatment (Figure 6.5H). 
White bars = exenatide, black bars = insulin glargine. Data represent mean (SEM) 
Figure6.5A-D & Figure 6.5G-H, and geometric mean (SEM) in Figure 6.5E-F. 
AIRarg, C-peptide response to arginine at 15 mmol/L glucose concentration; 1st 
phase, first-phase C-peptide response to glucose; 2nd phase, second-phase C-peptide 
response to glucose. See methods section for calculations of beta-cell function 
measures. 
 
Discussion 
The main result of this 3-year follow-up study in patients treated with 
exenatide is the sustained improvement in first-phase glucose-stimulated C-
peptide secretion, adjusted for prevailing insulin sensitivity (the DI), 4 weeks 
after discontinuation of treatment. No significant effect was seen in the 
insulin glargine treated patients, despite achievement of similar glycemic 
control. Additionally, exenatide treatment was associated with continued 
weight loss and improvement in whole-body insulin sensitivity. Both 
exenatide and insulin glargine were generally well tolerated with nausea and 
minor hypoglycemia being the most frequently reported adverse event in the 
exenatide and insulin glargine group, respectively. 
 
Although human data is not available, exposure to GLP-1 and GLP-1RA in 
the pre-clinical setting results in beta-cell proliferation, islet neogenesis, and 
inhibition of beta-cell apoptosis in (human) cell lines, primary rodent islets 
and in vivo in different rodent species (13). It has therefore been 
hypothesized, although human islet-cell biology differs widely from that in 
rodents, that long-term GLP-1RA treatment may enhance beta-cell mass or 
health in humans, thereby potentially modifying the progressive course of 
type 2 diabetes (14). The current study, particularly the 3-year data 
presented herein, reports that exenatide treatment may lend some support 
to this idea, whereas following one-year exenatide exposure; the treatment-
related improvement of beta-cell function was lost after 4-week drug 
cessation (7).  
The current 3-year treatment data shows a small, but statistically significant, 
effect on the DI following a 4-week off-therapy period. Our results therefore 
suggest that a 3-year treatment with a GLP-1RA (such as exenatide) is 
necessary to delineate an effect on beta-cell function. This beneficial effect 
was not enough to sustain glycemic control. Additional factors, such as 
duration of type 2 diabetes, and achieved glycemic control and body weight 
reduction may play a role in the ultimate efficacy of the GLP-1RA. An even 
longer treatment or intervention at an earlier stage of the disease may 
3-year exenatide and beta-cell function 
 
119 
probably be necessary, given the chronic nature of the disease. Additionally, 
our results confirm findings in diabetic fatty Zucker rats, that prolonged 
exenatide treatment in humans does not result in tachyphylaxis (15). 
 
Prolonged exposure to elevated glucose and lipid concentrations is 
detrimental to beta-cell function (16). These combined glucolipotoxic effects 
result in impaired insulin secretion and beta-cell apoptosis, and may 
contribute to the loss of beta-cell function in the pathogenesis of type 2 
diabetes (17). Our results show a similar reduction in hyperglycemia, i.e. 
glucose toxicity, in the exenatide and insulin glargine group after 3-year 
treatment. Although we did find a 0.2% greater HbA1c reduction in the 
exenatide treated group, this finding did not reach statistical significance, 
due to the decreased number of participants left in the study. Since glycemic 
control was similar for both treatments, this improvement cannot be solely 
attributed to an improvement of glycemic control, and therefore a GLP-
1RA related factor should be considered. 
 
In as much as beta-cell function integrity is determined by the combined 
effects of variables related to beta-cell stress versus beta-cell health, it is 
important to note that 3-year exenatide versus insulin glargine treatment 
resulted in body weight reduction of approximately 8 kg, with concomitant 
improvement of insulin sensitivity. Body weight reduction per se has been 
shown to improve beta-cell function in subjects with and without type 2 
diabetes (18, 19). Interestingly, the improvement in beta-cell function 
reported in our manuscript cannot be explained fully by the reduction in 
body weight alone. Most patients treated with exenatide experienced a 
reduction in body weight. However, about half of the patients treated with 
exenatide a combined improvement in body weight and disposition index 
was observed. Additionally, there appeared to be no statistical correlation 
between the body weight reduction and the disposition index improvement 
in both exenatide and insulin glargine treated patients. Unfortunately, 
additional post-hoc analysis is not possible due to the small sample size.  
We recently demonstrated that exenatide predominantly reduces truncal fat 
mass, whereas lean body mass was not affected (20). The observed 39% 
improvement in M-value may at least partly be due to a lowering of the 
(truncal) body fat mass. Obesity-related insulin resistance is a key feature of 
type 2 diabetes and is associated with metabolic and cardiovascular 
complications (16). The landmark study by Zander and colleagues was the 
first to report a beneficial effect of continuous GLP-1 infusion on clamp-
measured beta-cell function as well as insulin sensitivity, in the presence of 
concomitant weight loss of 1.9 Kg, in spite of the mere 6-week duration (21). 
Subsequent clinical studies, using the euglycemic hyperinsulinemic, insulin-
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modified frequently sampled intravenous glucose tolerance test (FSIGT), or 
HOMA-IR, do not provide a clear view of the effects GLP-1RA on insulin 
sensitivity, and suggest that such an effect may be secondary to the weight 
reduction (22, 23).  
 
Since insulin sensitivity and beta-cell secretory function are closely 
interrelated it is essential to measure both when studying (long-term) 
therapeutic interventions that may affect insulin secretion and body weight 
(1). The DI adjusts for the interaction between changes in insulin sensitivity 
and insulin secretion, as differences in insulin sensitivity must be balanced by 
reciprocal changes in insulin release in order to maintain glucose tolerance 
(and prevent hypoglycemia). In the case of exenatide, given the observed 
weight-loss related improvement in insulin sensitivity (+39%), one may have 
expected that, if beta-cell secretory function had remained unaltered, the C-
peptide response to rather decline. However, inasmuch as the C-peptide 
remained substantially unaltered (compared to pre-treatment), one may 
conclude that beta-cell function following 3-year of exenatide exposure was 
improved (1). Additionally, no correlation was observed between treatment-
related changes in DI and body weight (Figure 6.6).  
 
 
Recently, DeFronzo and associates demonstrated a similar phenomenon 
following 20-week exenatide mono-therapy, as compared with the 
combination of exenatide and rosiglitazone (22). The DI was similar in the 
exenatide alone and exenatide/rosiglitazone groups, although the amount of 
insulin secreted in response to glucose alone or with arginine during the 
hyperglycemic clamp was markedly reduced in the group receiving 
exenatide/rosiglitazone combination therapy. These findings are in 
agreement with our results. Interestingly, DeFronzo and colleagues also 
Figure 6.6 Scatter plot 
showing the relation 
between treatment-induced 
change in body weight and 
change in disposition index, 
calculated for the week 172 
hyperglycemic clamp test. 
White circles = exenatide; 
black circles = insulin 
glargine. 
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showed an improvement in the DI calculated from the second phase C-
peptide secretion, a finding we did not observe in our study. In contrast to 
the former study, we did not administer exenatide prior to the 
hyperglycemic clamp. This differential study design may account for the 
observed difference. Additionally, a DI that is not derived from the rapid C-
peptide response to intravenous glucose may not present correct physiology 
(1, 12). 
 
The strength of our study is the long-term follow-up and the use of state-of-
the-art gold-standard methodology to quantify of insulin sensitivity and 
beta-cell function in the study population. Additionally, as patients did not 
receive study medication prior to the hyperglycemic clamp at the end of the 
extension phase, the effects of a 3-year treatment period on beta-cell health 
were measured rather than the acute effects of exenatide administration. 
One limitation of our study is the relatively modest proportion of 
randomized patients who completed the entire study. Fifty-two percent 
(36/69) of all randomized patients completed the entire 3-year treatment 
period. Of the original 51 patients who completed the 64-week main study, 
46 agreed to participate in the extension phase. From these, 78% completed 
the additional 2-year treatment period, with similar numbers remaining in 
each of both treatment arms. Most patients withdrew their consent and did 
not participate in the 2-year extension phase of the study because of the 
demanding nature of the study protocol, including long-term follow-up, 
which included a total of 30 visits (during 3.5 years) to the study center. The 
proportion of patients who did enter the additional 2-year treatment period, 
show characteristics comparable to those participating in large intervention 
studies in patients with type 2 diabetes (24, 25). Only 3 patients discontinued 
the 2-year extension phase because of loss of glycemic control (exenatide 
n=2, insulin glargine n=1). Finally, 3 patients dropped-out as a result of an 
adverse event: one patient randomized to insulin glargine experienced an 
ischemic stroke, and two patients randomized to exenatide dropped-out as a 
result of nausea following reinitiating of exenatide treatment during the first 
weeks of the extension period. Generally, both exenatide and insulin 
glargine were well tolerated during the 3-year study period, and reported 
adverse events were mainly mild-to-moderate in intensity, confirming 
previous long-term study tolerability results (6). No renal function 
deterioration and no pancreatitis were observed. Interestingly, no patients 
randomized to exenatide withdrew their consent during the 3-month off-
drug period, whereas four patients in the insulin glargine group did. After 
cessation of insulin glargine, patients continued their SMBG measurements. 
30.6% of patients randomized to insulin glargine did not want to continue 
with the off-drug period of the study as they observed an increase in SMBG, 
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confirming the important role self-monitoring of blood glucose plays in the 
treatment of patients with type 2 diabetes. 
 
In conclusion, 3-year exenatide treatment in metformin-treated patients 
with type 2 diabetes resulted in sustained improvement in beta-cell function 
and progressive weight reduction. Long-term follow-up in a wide variety of 
patients at earlier stages of type 2 diabetes is needed to study possible disease 
modifying effects of GLP-1RA. 
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Abstract 
Background: preclinical studies suggest that incretin-based therapies may be 
beneficial for the bone, however, clinical data are largely lacking. We 
assessed whether the differential effects of these therapies on body weight 
differed with respect to their effect on bone mineral density (BMD) and 
markers of calcium homeostasis in patients with type 2 diabetes. 
Methods: sixty-nine metformin-treated patients with type 2 diabetes were 
randomized to exenatide twice daily (n=36) or insulin glargine once daily 
(n=33). Total body BMD, measured by dual-energy X-ray absorptiometry 
and serum markers of calcium homeostasis were assessed before and after 
44-weeks treatment.  
Results: exenatide versus insulin glargine decreased body weight by 6%. 
Endpoint BMD was similar in both groups after 44-weeks therapy 
(LSmean±SEM between group difference -0.002±0.007 g/cm2; P=0.782). 
Fasting serum alkaline phosphatase, calcium, and phosphate remained 
unaffected.  
Conclusion: forty-four weeks exenatide or insulin glargine had no adverse 
effects on bone density in patients with type 2 diabetes, despite differential 
effects on body weight. 
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Introduction 
Diabetes is associated with an increased risk of bone fractures (1). Although 
patients with type 2 diabetes have a higher bone mineral density compared 
to non-diabetic age-matched controls, this does not confer a lower fracture 
risk (1). Higher bone mineral density was protective in obese individuals 
with impaired glucose metabolism or those with recently diagnosed diet-
treated patients with type 2 diabetes (1). However, in more advanced 
diabetes fracture risk was increased, due to factors including hyperglycemia 
and neuropathy, all of which may alter bone quality while leaving bone 
density unchanged (1). To date, the use of metformin, sulphonylurea and 
insulin does not seem to negatively affect bone health (1, 2).  
Recently, the thiazolidinediones have been implicated in increased bone 
fracture risk in patients with type 2 diabetes (3). Body weight reduction is 
advocated in most type 2 diabetes patients to improve their cardiovascular 
risk profile, however, it may decrease bone density and increase bone 
turnover (4,5). Therefore, type 2 diabetes therapies should not only lower 
cardiovascular risk but also be safe for the bone, also given their chronic use.  
Preclinical data suggest that gut hormones are associated with bone 
turnover, such that enhanced activity of these hormones has anabolic effects 
on the bone (6-8). We previously showed that 1-year treatment with the 
glucagon-like peptide (GLP)-1 receptor agonist exenatide reduced, while 
insulin glargine increased body weight in patients with type 2 diabetes (9).  
Here, we assessed whether the differential effects of these therapies on body 
weight differed with respect to their effect on bone mineral density and 
markers of calcium homeostasis in these patients. 
 
Research design and methods  
Details on study design were reported previously (9). Sixty-nine metformin-
treated patients with type 2 diabetes (45 males, 24 females; mean±SD: 
age 59±8y; HbA1c 7.5±0.8%; weight 91.5±13.1kg; BMI 31±4kg/m2) were 
randomized to exenatide (n=36) or titrated insulin glargine (n=33) added to 
their ongoing metformin therapy. The study protocol was approved by each 
site’s ethical review committee and was in accordance to the principles 
described in the declaration of Helsinki and all participating patients gave 
their written informed consent prior to screening. This study is registered 
with ClinicalTrials.gov number NCT00097500. 
Bone mineral density was assessed using Dual Energy X-ray Absorptiometry 
scans (Delphi A, Hologic, Waltham, MA) at baseline, and after 44 weeks. 
Fasting serum alkaline phosphatase, calcium, and phosphate were 
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measured, as markers of bone metabolism and calcium homeostasis were 
determined using standard ELISA’s on the same day, prior to scanning. 
All outcome measures are compared between the two treatment groups 
using an analysis of covariance (ANCOVA) model as reported previously 
(9). The model includes factors for treatment group (exenatide/glargine), site 
(NL/SE/FIN), and baseline HbA1c stratum (≤8.5%/>8.5%), and the pre-
treatment variable of the corresponding dependent variable as a covariate. 
Statistical analysis was performed using SPSS 16.0 for Mac OS X (SPSS, 
Chicago, IL, USA). All inferential statistical tests were conducted at a 
significance level of 0.05 (two-sided). 
 
Results 
At baseline no between treatment group differences in outcome measures 
was present (Table 7.1).  
 
 
Exenatide  
(n=36) 
Insulin Glargine 
(n=33) 
Age (years) 58.4±1.4 58.3±1.3 
Sex, M/F (n) 23/13 22/11 
Caucasian race (n(%)) 36 (100) 32 (97.0) 
Duration of type 2 diabetes (years) 5.7±0.8 4.0±0.6 
Daily metformin dose (mg) 2058±117 1798±147 
Body weight (kg) 90.6±2.1 92.4±2.4 
BMI (kg/m2) 30.9±0.7 30.1±0.6 
HbA1c (%) 7.6±0.1 7.4±0.1 
Fasting plasma glucose (mmol/L) 9.4±0.4 8.9±0.4 
Bone mineral density (g/cm2) 1.189±0.026 1.230±0.024 
Calcium (mmol/L) 2.37±0.11 2.36±0.10 
Phosphate (mmol/L) 1.14±0.16 1.10±0.19 
Alkaline phosphatase (IU/L) 2.37±0.11 2.36±0.10 
   
Completed study (n (%)) 30 (83.3) 30 (90.9) 
Discontinued study (n (%)) 6 (16.7) 3 (9.1) 
Discontinued study due to adverse events (n (%)) 5 (13.9) 1 (3.0) 
Table 7.1 Pre-treatment characteristics and patient disposition. Data represent 
mean±SEM or n (%). 
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At 44 weeks, exenatide versus insulin glargine, significantly decreased body 
weight (LSmean change from baseline±SEM: exenatide -3.5±0.9, insulin 
glargine  +0.3±0.9 kg; difference -3.8 kg; P<0.001). No effects on total body 
bone mineral density was observed with either exenatide or insulin glargine. 
Endpoint bone mineral density was similar in both groups after 44-weeks 
therapy (adjusted LSmean±SEM: exenatide 1.213±0.006 g/cm2, insulin 
glargine 1.215±0.006 g/cm2; difference -0.002±0.007 g/cm2; P=0.782) 
(Figure 7.1A). Additionally, adjustment for gender did not alter the results 
(Figure 7.1B-C). Serum alkaline phosphatase, calcium, and phosphate also 
remained unaffected following 44-weeks treatment (adjusted between group 
LSmean±SEM difference: +0.26±2.87 IU; p=0.929, +0.02±0.04 mmol/L; 
p=0.596 and -0.03±0.03 mmol/L; p=0.368, respectively) (Figure 7.1D-F). 
No bone fractures were reported during the follow-up of our study. 
As reported previously, exenatide and insulin glargine treatment was 
generally well tolerated (9). Mild-to-moderate hypoglycemia (exenatide 
8.3%; insulin glargine 24.2%) and nausea (exenatide 50%; insulin glargine 
0%) were the most frequently reported adverse events. There were no major 
hypoglycemic events observed during this study. 
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Figure 7.1A-F Bone mineral density in all patients (A), in male patients (B), in 
female patients (C), calcium (mmol/L) (D), phosphate (mmol/L) (E), and alkaline 
phosphatase (IU/L) (F) before and after 44 weeks of treatment. White box = 
exenatide; black box = insulin glargine. Data represent mean±SEM. 
 
Discussion 
Our study is the first to show that 44-week exenatide treatment does not 
affect bone mineral density and markers of bone metabolism and calcium 
homeostasis in patients with type 2 diabetes in spite of the body weight 
reducing effects of exenatide. Indeed, many studies have shown that 5-10% 
weight loss is associated with a decrease in bone mass and an increase in 
bone resorption, especially in obese postmenopausal women (4,5). Whereas 
insulin may reduce bone resorption and its weight-gain promoting effects 
may indirectly increase bone mineral density (6), the mechanisms underlying 
the bone mass-sparing effects of exenatide in the face of body weight 
reduction are unclear. Long-term exposure of type 2 diabetic patients to 
exenatide did not increase bone fracture risk, despite the progressive weight 
loss: at 82 weeks weight reduction was progressive and averaged 4.4 kg, with 
a mean of 11.9 kg in the highest weight-loss quartile (i.e. 11.4% of baseline 
body weight) (10). 
Pre-clinical studies have shown gut hormones, in particular GLP-2 and 
glucose-dependent insulinotropic peptide (GIP), to play an important role in 
bone metabolism (9). Postprandial GIP and GLP-2 elevations suppress meal-
related bone resorption (6). GIP also increases bone density in 
ovariectormized rats, a rodent model for postmenopausal osteoporosis, and 
functional GIP-receptors have been found on osteoblast-like cells (6). 
Unfortunately, the design of our study did not include measurement of GIP 
or GLP-2.  
More recent data suggest GLP-1 to be involved in bone metabolism as well 
(7). GLP-1 receptor knock-out versus wild-type control mice showed 
increased bone resorption and had lower bone mineral density (6). Three-
day exendin-4 treatment exerted osteogenic effects in rat models of insulin 
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resistance and type 2 diabetes, as quantified by markers of bone turnover 
and micro-CT assessment of bone structure (8). More recently, a GLP-1 
receptor was found to be present in an osteoblastic cell line, that seemed 
independent of the cAMP-linked GLP-1 receptor (7). However, these 
findings need to be confirmed in vivo, particularly in humans. 
In conclusion, 44-week exenatide treatment did not lead to significant 
changes in total body bone mineral density in men and women with type 2 
diabetes, despite a marked reduction in body weight. Additionally, serum 
markers of bone metabolism and calcium homeostasis also remained 
unaffected. Long-term studies are needed to assess whether prolonged GLP-
1 receptor agonist treatment can off-set the weight-loss related decline in 
bone mineral density, but more importantly, whether it may confer 
protection against bone fractures in type 2 diabetic patients. 
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Abstract 
Background: Fat accumulation in the liver or non-alcoholic fatty liver disease 
(NAFLD) is regarded as a key pathogenic factor and component of the 
metabolic syndrome. It was reported that administration of the incretin 
mimetic exenatide reversed hepatic steatosis in an obese mouse model. We 
had the opportunity to study the effect of additional exenatide 
administration on liver fat content in a patient with type 2 diabetes. 
Case report: A 59-year-old male with poorly controlled type 2 diabetes was 
treated with exenatide in addition to metformin monotherapy. Following 44 
weeks of exenatide treatment mean the liver fat measured by liver 
spectroscopy declined from 15.8% to 4.3%. This dramatic decrease in liver 
fat was accompanied by significant beneficial changes in several 
cardiovascular disease risk factors and improvement of all liver enzymes, in 
particular alanine aminotransferase, the most important marker of liver 
steatosis. 
Conclusion: This case report suggests that the incretin mimetic exenatide 
decreases hepatic fat accumulation and may play a role in the future 
treatment of NAFLD, and the associated insulin resistance and 
cardiovascular risk factors in an ever-growing high-risk population. 
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Introduction 
The metabolic syndrome, a cluster of cardiovascular disease factors, is 
present in the majority of obese type 2 diabetic patients (1). Currently, fat 
accumulation in the liver or non-alcoholic fatty liver disease (NAFLD) is 
regarded as a key pathogenic factor and component of this syndrome (2). 
Therapies aimed at reducing liver fat have been shown to concomitantly 
improve the risk profile in this high-risk population. For example, both 
lifestyle interventions resulting in weight loss and administration of 
thiazolidinediones, which is associated with weight gain, have been 
associated with decreased liver fat and improvement of (hepatic) insulin 
sensitivity (3, 4). Furthermore, these studies suggested that the presence of 
risk factors for cardiovascular disease, in particular low HDL cholesterol and 
high triglycerides, is strongly related to the amount of liver fat. 
Glucagon-like peptide 1 (GLP-1) is an incretin hormone that is secreted by 
the L cells of the intestine upon meal ingestion. In type 2 diabetic patients, 
GLP-1 lowers blood glucose levels in a glucose-dependent manner, by 
potentiating meal-induced insulin production and secretion by the 
pancreatic beta-cells, by slowing gastric emptying and by inhibiting 
glucagon secretion. Also, GLP-1 induces weight loss, possibly because of 
central inhibition of appetite, and may also improve insulin sensitivity (5). 
However, GLP-1 has a very short half-life as it is degraded by the ubiquitous 
enzyme dipeptidyl-peptidase-4 (DPP-4). The long-acting, DPP-4-resistant 
GLP-1 receptor agonist or incretin mimetic exendin-4 (exenatide, synthetic 
exendin-4) is a 39 amino-acid peptide that binds with high affinity to the 
GLP-1 receptor. Recently, exenatide was introduced, to the market in the 
United States as a blood-glucose-lowering-agent. The full scope of the effects 
of incretin mimetics still needs to be elucidated and the almost ubiquitous 
presence of the GLP-1 receptor in the human body implies many potential 
actions. Recently, it was reported that exenatide administration in an obese 
mouse model reversed hepatic steatosis. This effect was attributed to 
increased fatty acid oxidation and/or inhibition of de novo lipogenesis (6). 
At present, it is not clear whether incretin mimetics also affect liver fat 
content in obese type 2 diabetes patients. 
 
Case report 
A 59-year-old Caucasian male with type 2 diabetes, treated with metformin, 
was prescribed exenatide 20 ug twice daily, because of poor control (HbA1c: 
8.7%; reference values: 4–6%). He was a retired craftsman and had no 
history of alcohol abuse or viral hepatitis. At baseline, his body weight was 
88.5 kg (BMI 28.7 kg/m2), his waist circumference was 98.5 cm and his 
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blood pressure was 157/87 mmHg. The fasting laboratory values were as 
follows: plasma glucose 14.5 mmol/l, total cholesterol 4.82 mmol/l, HDL 
cholesterol 1.04 mmol/l, LDL cholesterol 3.29 mmol/l, triglycerides 1.46 
mmol/l, alanine aminotransferase (ALT) 46 IU/l, aspartate 
aminotransferase (AST) 18 IU/l, gamma-glutamyltranspeptidase (GGT) 28 
IU/l (reference values: 6–48; 10–45; 7–51 IU/l, respectively) and insulin 
resistance estimated by homeostasis assessment model (HOMA-IR) of 6.36. 
Following 44 weeks of exenatide therapy, HbA1c decreased to 8.4% and 
fasting plasma glucose to 9.9 mmol/l. His body weight fell by 4.7%, from 
88.5 to 84.3 kg, and his waist circumference by 2.5 cm. 
 
Liver fat accumulation was quantified in the fasting state using proton 
magnetic resonance spectroscopy (1H-MRS), a method that has been shown 
to correlate excellently with liver fat as measured in biopsy samples (7). At 
three positions (right anterior, right posterior and medial or left anterior), a 
15 cm3 spectroscopic volume of interest was positioned, avoiding major 
blood vessels, intra-hepatic bile ducts and the lateral margin of the liver. 
Areas of resonances from protons of water and methyl and methylene 
groups in fatty acid chains of the hepatic triglycerides were evaluated with 
LCModel (8). Surprisingly, the mean liver fat (average of the three volumes 
of interest) declined from 15.8% before to 4.3%, i.e. by 73%, after 44 weeks 
of exenatide therapy (Figure 8.1). This dramatic decrease in liver fat was 
accompanied by significant beneficial changes in several cardiovascular 
disease risk factors: blood pressure decreased to 140/85 mmHg, fasting LDL 
cholesterol to 2.67 mmol/l, triglycerides to 0.69 mmol/l, HOMA-IR to 
2.51, while HDL cholesterol increased to 1.27 mmol/l. In accordance with 
the MRS findings, all liver enzymes, and in particular ALT, the most 
important marker of liver steatosis (9), improved. This value decreased from 
46 to 20 IU/l, while AST decreased from 18 to 13 IU/l, and GGT from 28 
to 23 IU/l. 
 
Discussion 
Experimental evidence indicates that exenatide, by activating the GLP-1 
receptors, effectively reverses hepatic steatosis. This is the first report 
describing a marked reduction in liver fat accumulation following treatment 
with the incretin mimetic exenatide in humans. Although this effect may be 
indirect, because of concomitant systemic metabolic improvement, it is very 
likely that exenatide may also act directly on the liver, as a GLP-1 receptor 
is present on liver cells (6). A direct effect is even more likely in the present 
case, as additional exenatide treatment in our patient did not lead to 
significant improvement of glycemia, nor did it result in relevant weight loss, 
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both of which are treatment effects that are known to reduce liver fat (3, 4). 
In vitro studies in hepatocytes demonstrated that exposure to synthetic 
exendin-4 resulted in an up-regulation of PPARgamma mRNA, a key 
element in â-oxidation of free fatty acids, and in a down-regulation of sterol 
regulatory element binding protein (SREBP-1c) and stearoyl-CoA 
desaturase (SCD1), both critical regulators of de novo hepatic lipogenesis. As 
exenatide stimulates insulin secretion, and in turn inhibits lipolysis, the 
delivery of FFA to the liver will be diminished. This probably also 
contributes to the lowering of liver fat content. 
 
 
 
Figure 8.1 Abdomen magnetic resonance imaging scans indicating volume of 
interest in the anterior left hepatic lobe from which proton magnetic resonance 
spectra (CH2 peak at 1.3 p.p.m. is the main signal of lipids) were obtained before (A) 
and after (B) exenatide treatment. 
 
Incretin mimetics have already been demonstrated to influence beneficially 
a variety of abnormalities in type 2 diabetes, including defective insulin 
secretion, hyperglucagonemia as well as excessive body weight and appetite 
(5). Now it seems that incretin mimetics also have salient effects on NAFLD 
and the associated cardiovascular risk factors. Future long-term intervention 
studies are required to confirm these findings. 
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This final chapter summarizes the main findings of the work presented in 
this thesis and also provides some methodological considerations and 
backgrounds. The primary objective of the studies presented in this thesis 
was to assess and compare the effects of long-term treatment with the GLP-1 
receptor agonist exenatide versus insulin glargine on different parameters of 
pancreatic beta-cell function, in patients with type 2 diabetes who had not 
achieved an HbA1c of ≤ 6.5% using metformin mono-therapy. In addition, 
treatment effects on postprandial lipid levels, body composition, circulating 
cardiovascular risk biomarkers, and safety were assessed. 
 
Primary study endpoints: beta-cell function 
parameters  
Type 2 diabetes is characterized by a progressive beta-cell defect in the 
presence of obesity-related insulin resistance (1, 2). The former is thought to 
be primarily responsible for the progressive nature of the disease (3, 4). The 
capacity to secrete insulin is thought to be related to functional beta-cell 
mass, which is determined by the balance of the rate of beta cell neogenesis 
and apoptosis (5), and is showed to be reduced in patients with type 2 
diabetes (6). Until beta-cell volume can be quantified reliably and non-
invasively, we will need to rely on the ability of glucose, with or without 
other secretagogues, to potentiate insulin release as the best surrogate 
estimate of the number of beta-cells (7). However, an attempt to estimate 
beta-cell mass based simply on the use of a functional test as a surrogate 
measure cannot, by nature, be complete and will therefore be imprecise (7). 
 
A number of different functional indexes have been proposed to estimate 
beta-cell function in vivo (7-9). Hyperglycemic clamps and experiments in 
isolated pancreatic islets have demonstrated that glucose administration 
induces insulin secretion in a biphasic pattern: an initial component (first 
phase), which develops rapidly but lasts only a few minutes, followed by a 
sustained component (second phase) (8, 10). Loss of first phase glucose 
stimulated secretion and a reduction in second phase glucose stimulated, 
and combined glucose and arginine stimulated insulin secretion are 
characteristic features of type 2 diabetes mellitus (10, 11). It is known that a 
decrease in first phase glucose stimulated insulin secretion is found in the 
early stage of type 2 diabetes and also in patients with impaired glucose 
tolerance (12, 13). Detailed assessment of beta-cell function will therefore be 
useful to identify early stages of type 2 diabetes, but also to evaluate (the rate 
of) disease progression, and to monitor the effects of pharmacological 
interventions (14). 
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Evidence supporting the rationale and design of the current study included 
the demonstration in preclinical models of diabetes, and in in vitro assays, 
that GLP-1 and the GLP-1 receptor agonist exenatide improved beta-cell 
function, promoted beta-cell health and preserved or increased beta-cell 
mass (15-19). Initial, often short-term, studies in healthy humans and 
patients with type 2 diabetes, showed improvement of (surrogate) markers of 
beta-cell function following exenatide treatment (20-26). 
 
Beta-cell function measures using the hyperglycemic clamp 
In chapter 2 we studied whether 52 weeks of treatment with exenatide or 
insulin glargine significantly improved beta-cell function, measured with the 
hyperglycemic clamp with additional arginine stimulation. Furthermore, 
durability of treatment effect on beta-cell function was assessed after a 4-
week off-drug period. We showed that exenatide administration, relative to 
insulin glargine, significantly improved first and second phase glucose-
stimulated insulin secretion by 53% and 185%, respectively. The combined 
glucose and arginine stimulated insulin secretion increased by 146%, when 
compared to insulin glargine, while on active treatment (Table 2.1).  This 
beneficial effect on beta-cell function was accompanied by an improvement 
in glycemic efficacy (Figure 2.3). 
 
Pancreatic beta-cells contain at least two pools of insulin secretory granules, 
that differ in release pattern, which account for biphasic insulin secretion. A 
small pool available for immediate exocytosis and a reserve pool which 
accounts for the vast majority of granules, and needs to be mobilized to 
being available for secretion (8, 27). The prevailing hypothesis is that 
granules from the readily releasable pool account for the first phase of 
glucose-stimulated insulin secretion, and that mobilization of a subsequent 
supply of new granules from the reserve pool accounts for the second phase 
(27-29). GLP-1 receptor agonists, such as exenatide, bind to a specific G-
protein coupled receptor resulting in the activation of adenylate cyclase and 
an increase in cAMP generation (30, 31). In the beta-cell, cAMP binds and 
modulates activities of both protein kinase A (PKA) and cAMP-regulated 
guanine nucleotide exchange factor II (Epac2), thereby increasing 
intracellular Ca2+ concentrations and enhancing glucose-dependent insulin 
secretion (10, 30, 32). It is postulated that Epac2 signaling increases the size 
of the readily releasable pool and PKA signaling may increase the size of the 
reserve granule pool (10). Through these mechanisms exenatide treatment 
may have contributed to the increase in first and second phase insulin 
secretion as described in chapter 2. 
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Ward and Porte introduced the glucose-dependent arginine stimulation test 
(33). It is a method which gives thorough information on islet function as it 
measures both basal and “maximal” alpha-cell and beta-cell secretion (34). 
Unfortunately, we did not measure glucagon release as a measure of alpha-
cell (dys)function in our study. It has been shown that combined glucose and 
arginine stimulated insulin release increases when arginine is administered at 
higher clamp glucose concentrations (33). During the design of our study we 
deliberately chose to test glucose-dependent arginine stimulation at 
moderately elevated glucose concentrations (15 mmol/L), as used by Ward 
(33) and Larsson (34). An intravenous glucose infusion rate to achieve higher 
glucose concentrations, for example 25 mmol/L, during the hyperglycemic 
clamp was expected not to be feasible while on active exenatide treatment. 
Therefore, the reported acute insulin responses to arginine (AIRarg) in 
chapters 2 and 6 cannot be interpreted as the real “maximum acute 
insulin responses” (AIRmax) in our population. 
 
Following our initial one-year study the improved beta-cell function at 52 
weeks was lost 4 weeks after cessation of exenatide and insulin glargine, 
suggestion an acute pharmacological effect of either treatment (Figure 2.4, 
Table 2.1). Interestingly, insulin sensitivity remained significantly improved 
after 4 weeks cessation of exenatide treatment. We did not observe this 
finding in the insulin glargine group (Figure 2.3F). This observation led to 
the idea that extra-pancreatic effects of exenatide, such as weight loss and 
the associated improvement in insulin sensitivity, might last longer. We 
concluded that the possible effects on preservation of beta-cell function 
might be dependent on other (additional) factors including: 1) diabetes 
duration, 2) the amount of functional beta-cells present at the initiation of 
therapy, 3) overall metabolic control achieved and 4) treatment duration. To 
study the possible preserving effect of exenatide on beta-cell function, 
patients were asked to participate in an additional 2-year extension trial, and 
restart their originally assigned treatment at the end of our original one-year 
study. The results of this extension study are presented in chapter 6. 
 
At the end of the 3-year treatment period, exenatide and insulin glargine 
treatment was stopped and patients were only treated with their original 
metformin dose. As a result of strict regulations by the ethical review board 
we were not able to measure beta-cell function both on and off active 
exenatide or insulin glargine treatment. To answer the durability questions, 
which were raised following the one-year treatment period, we chose to only 
measure beta-cell function following a 4-week off-drug period. After 3 years 
of treatment, beta-cell secretory function measured as first and second phase 
glucose-stimulated insulin secretion showed a statistically significant 
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reduction in exenatide treated patients as compared to the insulin glargine 
treated patients (Figure 6.5). Interestingly, insulin sensitivity remained 
significantly improved during the 4-week off-drug period in the exenatide 
treated patients. As insulin sensitivity and insulin secretion are closely 
interrelated this means that the proper assessment and interpretation of 
beta-cell function parameters requires the incorporation of both insulin 
sensitivity and the insulin response measures (35). The following paragraph 
will discuss this relationship in greater detail. 
 
The relation between insulin sensitivity and insulin secretion 
The relationship between insulin sensitivity and insulin secretion follows a 
hyperbolic function, such that the product of the two variables (called the 
disposition index) remains a constant (35, 36) (Figure 9.1). By 
acknowledging this hyperbolic relationship, beta-cell function measures 
should include measures of   glucose-stimulated insulin first phase insulin 
release and insulin sensitivity (37). In response to the decrease in insulin 
sensitivity as observed in obesity (36), puberty (38) and pregnancy (39), 
human beta-cells increase insulin release to levels four to fivefold higher than 
in insulin sensitive individuals (2). As long as this compensatory insulin 
secretion is sufficient, resulting in a normal disposition index, glucose 
tolerance remains unaffected. Individuals predisposed to type 2 diabetes 
show a reduced beta-cell compensatory response to obesity-related insulin 
resistance and will subsequently develop impaired glucose tolerance, and 
type 2 diabetes (40).  
 
In chapter 6 we showed that 3-year long treatment with exenatide results 
in a 7.9 kg reduction in body weight as compared to insulin glargine 
(Figure 6.4C). Probably as a consequence of this, insulin sensitivity 
remained improved by 39% in the exenatide treated patients after 4-week 
cessation of treatment. Insulin secretion responses to glucose and arginine 
cannot be interpreted without taking the changes in insulin sensitivity into 
account. Following 4-week cessation of exenatide treatment the disposition 
index increased significantly. In the insulin glargine treated patients, the 
disposition index decreased (Figure 6.5E-H).  
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Figure 9.1 In people with normal glucose tolerance (1) a non-linear, hyperbolic 
relation between insulin sensitivity and beta-cell insulin release exists. The product 
of insulin release and insulin sensitivity is called disposition index (DI), and is 
assumed to be a constant. Healthy subjects react to a decrease in insulin sensitivity 
by a reciprocal increase in beta-cell insulin release (2), and vice versa (3). Patients 
with impaired tolerance (5) and type 2 diabetes (6) are not able to compensate for 
the decrease in insulin sensitivity. In situation 2, beta-cell insulin release is increased 
but the DI is normal. In 4, beta-cell insulin release appears normal but the DI is 
reduced. This hyperbolic relationship means that assessment of beta-cell function 
requires knowledge of both insulin sensitivity and the insulin response. Impaired 
glucose tolerance (IGT). Adapted from Kahn (2), Cobelli (8), and Stumvoll (1). 
 
Body weight reduction per se has been shown to improve beta-cell function 
in subjects with and without type 2 diabetes (41, 42). It is possible that 
factors secreted from adipose tissue, such as free fatty acids and 
adipocytokines such as IL-6, TNF-α, or adiponectin, may directly or 
indirectly impact beta-cell function (43). In chapter 5 we showed exenatide 
beneficially affected some of these adipocyte-derived proteins. In our 3-year 
extension study, the improvement in disposition index appears to be driven 
by the improvement in insulin sensitivity (Figure 6.5G). Interestingly, the 
improvement in disposition index reported in chapter 6 cannot be fully 
explained by the reduction in body weight (and subsequent improvement in 
insulin sensitivity) alone. Most patients treated with exenatide experienced a 
reduction in body weight. However, about half of the patients treated with 
exenatide a combined improvement in body weight and disposition index 
was observed (Figure 6.6). Additionally, there appeared to be no statistical 
correlation between the body weight reduction and the disposition index 
improvement in both exenatide and insulin glargine treated patients. A 
more specific GLP-1 receptor agonist related factor could therefore not be 
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excluded. Unfortunately, more post-hoc analyses were not possible due to 
the small sample size. 
 
As acknowledged in chapter 2, residual beta-cell function and mass may be 
an important determinant of the efficacy of GLP-1 receptor agonist therapy 
(44). Based on homeostasis model assessment (HOMA) data from the UK 
Prospective Diabetes Study (UKPDS), it has been suggested that in patients 
with type 2 diabetes, beta-cell function is already reduced by 50% at the 
time of diagnosis (45), and that loss of beta-cell function begins 10–12 years 
before diagnosis (14, 46). The data presented in chapter 2 and chapter 6 
may suggest that a temporary improvement in pancreatic beta-cell function 
may be achieved following prolonged treatment with a GLP-1 receptor 
agonist. The observed improvement in disposition index was not 
accompanied by a lasting improvement in glycemic efficacy measures; the 
HbA1c concentration returned to pre-randomization levels following the 12-
week off-drug period (Figure 2.3A and Figure 6.4A). It has been shown 
that glucose control is closely related to pancreatic beta-cell function in 
humans (47). It may be that the improvement of the DI was not big enough 
in these patients with established type 2 diabetes to affect glycemic control. 
Pharmacological interventions aimed to preserve beta-cell function probably 
need to be initiated at an earlier stage. Additional studies are needed in 
patients at high-risk, for example patients with impaired glucose tolerance, 
to test this hypothesis (48).  
 
Beta-cell function measured using the mixed-meal test 
As mentioned in chapters 2 and chapter 6, the euglycemic-
hyperinsulinemic clamp and the hyperglycemic clamp are currently 
regarded gold-standard methods for measuring insulin sensitivity and beta-
cell function respectively. However, these techniques also have 
disadvantages. The clamp technique is technically challenging, a burden to 
patients and time consuming. Additionally, the invasive nature of the clamp 
may not mirror ‘real life’ situations. Although fasting indices (such as the 
HOMA (49)) are frequently used as surrogate estimates of insulin sensitivity 
and insulin secretion, fasting concentrations only reflect a single point on the 
complex glucose-insulin dose-response curve, and thus cannot provide 
insight regarding the dynamics of the beta-cell in response to changing 
glucose concentrations such as typically occur in daily life (8). Therefore, for 
epidemiologic studies, and for the follow-up of individual changes in insulin 
sensitivity and insulin secretion, measurements derived from simpler 
methods such as the oral glucose tolerance test (OGTT) are often used (50, 
51). The insulinogenic index, calculated as the ratio of the 30-minute 
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increment in insulin to glucose concentration (52), is widely used to estimate 
glucose responsiveness of the beta-cell following the OGTT. Despite its 
simplicity, this index is able to detect anomalies in beta-cell function in many 
circumstances (52). Nevertheless, it needs to be acknowledged that 
correlations between OGTT derived and intravenous derived measures of 
beta-cell function are not perfect (r values between 0.5-0.7) (53). Being a 
composite index, it does not reflect specific mechanisms of insulin secretion 
(for instance, the first phase insulin secretion as assessed with the 
hyperglycemic clamp) (9). In the interpretation of the OGTT beta-cell 
indices, it must be kept in mind that giving glucose through the oral route 
results in a potentiated secretory response due to the activation of the 
entero-insular axis, which does not occur with the hyperglycemic clamp (9). 
By design, the hyperglycemic clamp uses intravenous administration of 
glucose and other secretagogues (i.e. amino acids or GLP-1) to test beta-cell 
secretory function (33, 54, 55). Since the primary goal of most studies is to 
determine how alterations in beta-cell function and insulin action influence 
human metabolism, ideally these should be assessed under physiologic 
conditions by using simple tests, i.e. mixed-meals that provide 
carbohydrates, fats and amino acids (8). 
 
Over recent years, several mathematical models have been developed to 
quantify the beta-cell response following an OGTT or standardized mixed-
meal test (8, 56). A common aspect of these models is a dose-response 
function representing the relationship between the circulating glucose 
concentration and subsequent insulin secretion rate (ISR) (8, 53, 56). The 
simplest models are confined to just the dose response relationship between 
the glucose and insulin concentration (57), whereas others are more 
sophisticated (58-62). Insulin and C-peptide are equimolarly secreted from 
the beta-cell and pass through the liver, where insulin, but not C-peptide, 
undergoes hepatic extraction (63). Therefore more recently developed 
models rely on C-peptide deconvolution (64) rather than insulin 
concentrations per se. Although more models exist, two are now frequently 
used in the literature (58, 59, 61, 62). In these models insulin secretion is 
represented as the sum of two main compartments: 1) the glucose/insulin 
dose-response relations, and 2) one accounting for the observation that rapid 
changes in glucose concentration enhance insulin release (53) (for review see: 
(8, 56)). These models share common features, the models mainly differ by 
the way they interpret the potentiation of insulin secretion (8, 53). For the 
study presented in chapter 4 we have chosen for the model by Mari et al. 
(61, 62) (Figure 9.2). Since this model has been used frequently in other 
studies using GLP-1 (65), exenatide (26), liraglutide (66), and the DPP-4 
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inhibitor vildagliptin (67, 68), it facilitates the comparison with other 
incretin-based therapies. 
 
Figure 9.2 Block diagram of the beta-cell model and illustration of the role of the 
insulin secretion components during an oral glucose tolerance test. The central 
compartment of the model is the glucose/insulin dose-response relation, which 
describes the rise and fall of insulin secretion that parallels the rise and fall of the 
glucose concentration. From the glucose/insulin dose-response relation 2 
parameters are calculated: 1) the insulin secretion rate at reference glucose 
concentration (ISR@Gref) and 2) beta-cell glucose sensitivity which is represented 
by the slope of the glucose/insulin dose-response relation. The dose-response 
relation is modulated by the potentiation factor, which is a positive function over 
time and has been constrained to have a time average of 1 during the experiment. 
The potentiation factor explains the sustained insulin secretion usually seen at the 
end of an OGTT or meal test when the circulating glucose concentration already 
has returned to baseline values. Finally, rate sensitivity is introduced into the model: 
an early insulin secretion component, which quantifies the sensitivity of the insulin 
response to the initial rapid glucose rise. The black arrows represent the effects of 
one-year treatment with exenatide on the specific model-derived measure as 
compared to insulin glargine. Adapted from Mari (56). 
 
The main findings of the study assessing one-year treatment with exenatide, 
as compared to insulin glargine, on meal derived measures of beta-cell 
function are presented in chapter 4. One-year treatment with exenatide 
resulted in a significantly greater upward shift in the glucose/insulin dose-
response relation, and increased potentiation after both breakfast and lunch.  
Notwithstanding the fact that the potentiation factor has been criticized for 
being a time-varying correction term that mathematically compensates for 
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the difference between the observed ISR and the ISR derived from the 
glucose/insulin dose response relation (8), Ferrannini postulates that 
potentiation should be considered as an independent parameter of beta-cell 
function (69). The strong initial increase in potentiation (Figure 4.4C) may 
represent the strong stimulating effect on insulin secretion following the 
exenatide injection prior to the breakfast meal. Additionally, both exenatide 
and insulin glargine treatment equally improved glucose sensitivity, 
representing the ability of the beta-cell to adjust the ISR to the change in 
prevailing glucose concentration. Finally, the beneficial effects on the 
glucose/insulin dose response relationship were sustained after a 5-week off-
treatment period in both the exenatide and insulin glargine treated groups. 
As the improvement in beta-cell glucose sensitivity, and the lasting effect on 
glucose/insulin dose response relationship after cessation of treatment, was 
found in both treatment groups a more general mechanism, possibly 
reduction of glucose toxicity (70) may explain these findings. 
 
Interestingly, the rate sensitivity significantly decreased in exenatide-treated 
patients when compared to insulin glargine. Rate sensitivity appreciates the 
relationship between the early, fast rise in plasma glucose concentrations 
and the subsequent change in insulin secretion. When the time derivative of 
the glucose concentration is negative, the derivative component equals 0 (61, 
62). The observed delta in glucose concentration is negative in the exenatide 
group (Figure 4.3A). This reduction in postprandial glucose concentration 
may account for the between-group difference in rate sensitivity, as this 
parameter is automatically set to be 0 in many exenatide treated patients. 
Insulin glargine did not have such an effect on the postprandial glucose 
concentration, and hence on rate sensitivity. These findings are consistent 
with observations made in similar experiments with GLP-1 infusion (65) and 
the GLP-1 receptor agonist liraglutide (66).  
 
Secondary study endpoints: cardiovascular 
disease risk markers 
Today, it is well recognized that type 2 diabetic patients have an increased 
risk of developing micro and macrovascular disease. Mortality from 
cardiovascular disease (CVD) is 2-4 fold increased in persons with diabetes 
compared with the general population (71). Although it has been shown that 
an intensified multifactorial intervention reduces macrovascular and 
microvascular events by about half, it is still considerably higher than in the 
background population, leaving room for much improvement (72, 73). 
Hyperglycemia is associated with cardiovascular risk in patients with type 2 
diabetes. However, there is less compelling evidence that glucose lowering 
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therapy reduces CVD risk. Data from the original United Kingdom 
Prospective Diabetes Study (UKPDS) cohort did not exhibit a reduction in 
CVD events, apart from a small subgroup of obese patients treated with 
metformin that experienced a CVD benefit. (74). However, the Diabetes 
Control and Complications Trial/Epidemiology of Diabetes Interventions 
and Complications trial (DCCT/EDIC) showed that glucose lowering was 
associated with a long-term cardiovascular complications benefit in patients 
with type 1 diabetes (75, 76). Over the last few years data from ACCORD 
(77), ADVANCE (78), and the Veterans Affairs Diabetes Trial (79), did not 
demonstrate a significant reduction of cardiovascular events in the groups 
randomized to intensive glucose-lowering therapy as compared to the 
standard therapy group. More recently the United Kingdom Prospective 
Diabetes Study Post-Trial (UKPDS post-trial) showed a benefit of glycemic 
control after 10 years of post-trial follow-up (a so-called ‘legacy effect’) (80). 
These observations support the concept to treat patients to target as early as 
possible following diagnosis (81,82).  
 
Effects on postprandial dysmetabolism 
Both postprandial hyperglycemia and hypertriglyceridemia lead to 
mitochondrial free radical production and subsequent oxidative stress, 
which in turn may contribute to the development of both micro and 
macrovascular complications (81, 83-85) (Figure 9.3). It has been suggested 
to include the reduction of postprandial glucose and lipid excursions as 
treatment targets in the treatment guidelines for type 2 diabetes (86).  
To our knowledge, studies on the effects of exenatide on postprandial 
cardio-metabolic parameters have used a single meal study design (23, 24, 
26, 88-92). It is known that postprandial glucose and lipid responses differ 
following subsequent meals in patients with the metabolic syndrome and 
type 2 diabetes  (82, 84, 93). To simulate the real-life daily food intake we 
used two consecutive meals in our study. 
In chapter 3 the effects of one-year exenatide treatment on postprandial 
glucose and lipids are presented. One-year exenatide resulted in a significant 
reduction of prandial glucose, triglycerides, apo-B48, VLDL-C, HDL-C, 
free fatty acid and MDA excursions (Table 3.2). Additionally, we found a 
statistically significant correlation between the reduction in postprandial 
glucose and lipid excursions, and different markers of oxidative stress 
(Figure 3.3).  
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Figure 9.3 Type 2 diabetes is characterized by high circulating levels of 
atherogenic lipid particles due to an increased supply of fatty acids to the liver and 
defective hepatic clearance of lipoproteins. In the postprandial state, the lipid 
abnormalities are further exaggerated, with an additional adverse effect of meal-
induced hyperglycemia. These postprandial metabolic derangements increase the 
production of reactive oxygen species causing oxidative stress. Collectively, 
postprandial dysmetabolism and the associated oxidative stress may link type 2 
diabetes to cardiovascular disease. Adapted from Tushuizen (87). 
 
Gastric emptying is an important determinant of postprandial glucose and 
lipid excursions in healthy subjects and type 2 diabetes (94, 95). Studies 
using the acetaminophen technique (96-99) and scintigraphy (100) have 
shown that exenatide slows gastric emptying in both healthy subjects and 
subjects with type 2 diabetes. Unfortunately, we did not measure gastric 
emptying rates in our study. However, is appears to be reasonable to assume 
that gastric emptying significantly contributed to the reduction in 
postprandial glucose and lipid excursions. The reduction in postprandial 
glucose excursions was previously shown to be related to the slowing of 
gastric emptying during exenatide treatment (100). However, other data 
suggest that, exenatide may lower postprandial glycemia via a novel 
mechanism independent of islet hormones and slowing of gastric emptying 
(101). Although the effects of exenatide on the second meal were attenuated 
as compared to the first meal, the total glucose and triglyceride excursion 
remained significantly lower with exenatide compared to insulin glargine 
during the entire 8-hour mixed-meal test, even after ingestion of an 
additional lunch meal, 4 hours after the (pre-breakfast) exenatide dose. 
Combined, our meal test findings may suggest a beneficial effect on the 
Central obesity, insulin resistance, type 2 diabetes
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Hyperglycemia 
Hyperlipidemia
Oxidative stress
Coagulation activation
Inflammation activation
Endothelial dysfunction
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cardiovascular risk profile of exenatide as compared to insulin glargine as 
epidemiological (102) and interventional studies (103) have suggested that 
postprandial glucose are stronger predictors of CVD than fasting plasma 
glucose in patients with diabetes.  
 
Effects on body composition 
Estimates indicate that approximately 60% of all cases of type 2 diabetes can 
be attributed to weight gain (104). Pharmacological interventions in patients 
with type 2 diabetes should therefore also target obesity (105). The clustering 
of cardiovascular risk factors with abdominal obesity is well established 
(106). The term metabolic syndrome captures a wide spectrum of factors 
thought to increase the risk of CVD and type 2 diabetes. This syndrome 
now includes amongst others: abdominal obesity, hypertension, abnormal 
plasma glucose, microalbuminuria, elevated levels of cytokines, and insulin 
resistance (107, 108).  
Computed tomography (CT) and magnetic resonance imaging (MRI) 
technologies are regarded the gold standard for measuring body 
composition in vivo. However, as they are expensive and cumbersome, dual-
energy X-ray absorptiometry (DEXA) provides a reliable alternative for 
regional body composition analysis in large-scale follow-up studies (109). 
Effects of exenatide and insulin glargine administrations on body 
composition assessed with DEXA are discussed in chapter 5. We showed 
that exenatide reduces body weight mainly as a result of a reduction of 
truncal fat mass and waist circumference. Additionally, circulating 
concentrations of leptin, adiponectin, and hsCRP were beneficially 
influenced. Adiponectin and CRP are thought to be independent key 
molecules in type 2 diabetes related cardiovascular disease (110, 111). 
Although the combination of a reduction in truncal fat mass and waist 
circumference may suggest a reduction in metabolically active visceral fat 
mass, a recent uncontrolled study did not show an effect of exenatide 
treatment on visceral fat measured with computed tomography (112). 
Therefore additional studies to assess the effects of exenatide on body 
composition and body fat distribution are needed. 
 
Disproportionate accumulation of intra-abdominal and/or hepatic fat may 
explain variations in serum triglyceride, HDL-cholesterol, and hepatic 
insulin sensitivity, supporting the assumption that both fat deposits are 
important determinants of these components of the metabolic syndrome 
(113). According to the American Association for the Study of Liver 
Diseases, non-alcoholic fatty liver disease (NAFLD) is defined as fat 
accumulation in the liver exceeding 5% to 10% (114). In Chapter 8 we 
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describe the possible effects of exenatide treatment on hepatic fat content in 
one patient participating in our study. Following approximately 10 months 
of exenatide treatment the liver fat content measured by liver MRI-
spectroscopy declined from 15.8% to 4.3%.  
 
Diabetic dyslipidemia is a cluster of potentially atherogenic lipid and 
lipoprotein abnormalities that are metabolically interrelated. Recent 
evidence suggests that a fundamental defect is an overproduction of large 
very low-density lipoprotein (VLDL) particles, which initiates a sequence of 
lipoprotein changes, resulting in higher levels of remnant particles, smaller 
and denser LDL particles, and lower levels of high-density lipoprotein 
(HDL) cholesterol (82, 115, 116). In addition, a fatty liver may further 
contribute to the CVD risk by a higher production of glucose, CRP, and 
coagulation factors (117).  Chapter 3 and chapter 5 present data on the 
effects of exenatide on metabolic factors that are thought to be related to the 
amount of liver fat. Hepatic overproduction of apo-B-containing VLDL 
particles is regarded as the dominant feature of diabetic dyslipidemia driven 
primarily by liver fat and hyperglycemia (115). Although the reduction in 
truncal fat mass may play an important role in the in the observed reduction 
in atherogenic lipid particles and circulating CRP levels, we showed that the 
reduction in CRP was partially independent of changes in body weight and 
truncal fat mass changes. This may be attributed to a possible reduction in 
liver fat content following exenatide treatment. 
The combined findings of chapter 3, chapter 5 and chapter 8 may 
suggest favorable effects on cardiovascular risk in type 2 diabetes treated 
with exenatide. A recent meta-analysis of exenatide clinical trial data 
supports this interpretation of our findings (118). 
 
Secondary study endpoints: treatment safety 
The exenatide therapy associated adverse event profile as reported in this 
thesis is similar to earlier published studies. The most common adverse 
events associated with exenatide treatment were mild-to-moderate 
gastrointestinal side effects (including nausea, diarrhea, vomiting), which are 
dose-dependent, more common during drug initiation and decrease over 
time (119). The risk of hypoglycemia is not increased when exenatide is 
combined with metformin (88). During our study no major hypoglycemic 
events occurred in either randomization arm.   
In our study one patient randomized to exenatide developed pancreatitis 
while on active treatment, which resolved after cessation of the study 
medication. This adverse event is referred to in chapter 2. Cases of acute 
pancreatitis have been reported in patients treated with exenatide BID (120, 
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121), liraglutide (122), and vildagliptin (123). Recently published data 
showed that exenatide use was not associated with an increased risk of acute 
pancreatitis (124). Additionally, exenatide does not evoke pancreatitis and 
attenuates chemically induced pancreatitis in normal and diabetic rodents 
(125). 
Type 2 diabetes is associated with an increased risk of bone fractures (126). 
Thiazolidinediones have been suggested in increased bone fracture risk in 
female patients with type 2 diabetes (127). Body weight reduction is 
advocated in most type 2 diabetes patients to improve their cardiovascular 
risk profile, however, it may decrease bone density and increase bone 
turnover (128, 129). Therefore, type 2 diabetes therapies should not only 
lower cardiovascular risk but also be safe in terms of bone health, also given 
their chronic use. In chapter 7 we show that exenatide treatment does not 
affect bone mineral density despite the significant reduction in body weight. 
Final conclusion 
In addition to an acute pharmacological effect, the studies presented in this 
thesis showed that exenatide treatment, as compared to insulin glargine, 
beneficially affects metabolic parameters, which are thought to play an 
important role in the pathogenesis of type 2 diabetes (Figure 9.4).   
 
Figure 9.4 Model for the effects of body fat content on insulin sensitivity and  beta-
cell function in the pathogenesis of type 2 diabetes. Adapted from Cnop (130). 
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Taken together the following hypothesis could be suggested. Prolonged, 
multi-year, exenatide treatment leads to: 
• a reduction in body weight by lowering truncal fat mass (chapter 
5); 
• subsequently, circulating adipocytokines (i.e. leptin and adiponectin) 
and inflammatory biomarkers, and insulin sensitivity will improve 
(chapter 2, chapter 5 and chapter 6); 
• exenatide treatment reduces liver fat content (chapter 8);  
• together these metabolic effects lead to a more favorable (prandial) 
lipid and lipoprotein profile and a reduction in oxidative stress 
(chapter 3); 
• which in turn lead to an amelioration of beta-cell function and 
glucose tolerance (chapter 2, chapter 4, and chapter 6).  
 
However in our studies, the glucometabolic improvements were not 
persevered following a 12-week off-drug period suggesting multi-year 
treatment may be necessary for these effects to happen. Beta-cell preserving 
pharmacotherapeutic interventions should preferably start early to ensure 
that sufficient residual beta-cell function is still present. It has been proposed 
to start early in the disease pharmacological intervention to prevent the 
further deterioration of beta-cell function using a combination of metformin, 
thiazolidinediones, and exenatide, preferably in patients with impaired 
glucose tolerance (i.e. pre-diabetes) (48, 105). Against this background, 
future long-term pharmacotherapeutic interventions in patients with pre-
diabetes are needed to study whether GLP-1 receptor agonists (such as 
exenatide) might favorably alter the progressive nature of type 2 diabetes. 
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Samenvatting voor de geïnteresseerde leek 
Gedurende de laatste decades is diabetes mellitus type 2 (DM2) veranderd 
van een relatief onschuldige aandoening van de, met name de oudere, mens 
in een ziekte die een gevaar is voor de volksgezondheid. Door verandering 
in levensstijl neemt het aantal mensen met DM2 zeer snel toe, niet alleen in 
de westerse wereld, maar juist ook in opkomende economieën. De 
Wereldgezondheidsorganisatie van de Verenigde Naties (WHO) heeft 
berekend dat er in het jaar 2030 wereldwijd 350 miljoen mensen met DM2 
zullen zijn. Voor Nederland is berekend dat het aantal mensen met DM2 zal 
toenemen van 670.000 in 2008 naar ongeveer 1.3 miljoen in 2025. 
 
Wat is diabetes mellitus type 2? 
DM2 is een progressieve ziekte van de koolhydraatstofwisseling. De 
koolhydraatstofwisseling is een belangrijk proces, waarmee het lichaam 
energie maakt. In dit proces spelen een aantal in het bloed circulerende 
voedingsstoffen en hormonen (signaalstoffen) een belangrijke rol. Glucose 
(suiker) is een voedingsstof die in de lichaamscellen wordt gebruikt om 
energie te verkrijgen. Om glucose vanuit de bloedbaan in de lichaamscel te 
krijgen is het hormoon insuline nodig. Insuline wordt aangemaakt door de 
zogenaamde beta-cellen in de alvleesklier. In de normale situatie zal na het 
eten van een maaltijd de hoeveelheid glucose in het bloed stijgen. De 
alvleesklier zal hierop een stijging van de hoeveelheid glucose in het bloed 
waarnemen. Deze stijging is voor de alvleesklier het signaal om insuline uit 
te scheiden. Door het loslaten van insuline in de bloedbaan zal glucose de 
cel in worden getransporteerd, waarna de glucose kan worden gebruikt voor 
de productie van energie. Bij mensen met DM2 is deze 
koolhydraatstofwisseling op twee manieren verstoord:  
• zij zijn ongevoeliger voor de werking van het hormoon insuline 
• zij kunnen onvoldoende insuline produceren om deze 
ongevoeligheid te compenseren. 
 
Insulinegevoeligheid en insuline-afgifte 
In de westerse consumptiemaatschappij eten we meer voedingstoffen dan 
nodig is voor normaal functioneren van het menselijk lichaam. Het 
overschot aan voedingsstoffen wordt door het lichaam opgeslagen in 
vetcellen en daar bewaard voor tijden waarin minder voedingsstoffen 
beschikbaar zijn (perioden van schaarste en honger). Het gevolg hiervan is 
dat het lichaamsgewicht, en met name het lichaamsvetgehalte, toeneemt. 
Naast deze opslagfunctie voor energie maken vetcellen allerlei signaalstoffen 
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aan. Deze signaalstoffen zijn belangrijk voor de regulering van o.a. de 
voedingstoestand van het lichaam. Een aantal van de, door vetcellen 
gemaakte, signaalstoffen hebben echter een schadelijk effect als zij in 
overvloed gemaakt worden. Een van deze (schadelijke) effecten is dat zij de 
werking van het hormoon insuline verminderen. Wij noemen dit insuline 
ongevoeligheid of insulineresistentie. Door deze ongevoeligheid is meer 
insuline nodig om dezelfde hoeveelheid glucose uit het bloed de cel in te 
transporteren en het bloedglucosegehalte binnen de normaalwaarden te 
houden. Onderzoek laat zien dat mensen met overgewicht en obesitas 
hogere insuline waarden in het bloed hebben in vergelijking met mensen 
zonder overgewicht. Op deze manier zijn zij in staat normale bloedglucose 
waarden in stand te houden. Dit geldt voor de meeste mensen met 
overgewicht: door meer insuline te produceren en af te geven zullen deze 
mensen normale bloedglucose waarden houden en geen DM2 ontwikkelen. 
Echter niet alle mensen zijn in staat om voldoende insuline vanuit de 
alvleesklier te produceren en op deze manier voldoende te compenseren 
voor de ontstane ongevoeligheid voor het hormoon insuline. Wat hiervan de 
precieze oorzaak is, is nog niet bekend, maar een erfelijke aanleg lijkt een 
belangrijke rol te spelen. Als gevolg van het onvermogen de 
insulineresistentie te compenseren met een verhoogde uitscheiding van 
insuline door de alvleesklier zal uiteindelijk het bloedglucosegehalte stijgen 
en DM2 ontstaan.  
 
Traditionele behandeling 
De hoeksteen van de behandeling van DM2 is verandering van 
leefgewoonte. Hiermee bedoelen we minder eten en meer bewegen. 
Hierdoor zal lichaamsgewicht afnemen en, als gevolg hiervan, zal de 
gevoeligheid van het lichaam voor het hormoon insuline weer toenemen. 
Gezamenlijk leidt dit tot een afname van het bloedglucosegehalte. Echter 
voor veel mensen met DM2 zal deze aanpak onvoldoende effect hebben en 
zal een behandeling met geneesmiddelen noodzakelijk zijn.  
Traditioneel beschikbare geneesmiddelen voor de behandeling van DM2 
proberen het bloedglucosegehalte binnen de daarvoor geldende 
normaalwaarden te houden. Dit doen zij op een aantal manieren. Sommige 
geneesmiddelen proberen de gevoeligheid van het lichaam voor het 
hormoon insuline te vergroten, andere geneesmiddelen proberen de 
hoeveelheid insuline die door de alvleesklier wordt afgegeven te vergroten. 
Het gevolg van beide manieren is dat het bloedglucosegehalte zal dalen.  
Studies in grote groepen mensen met DM2 laten echter zien dat deze 
traditionele geneesmiddelen het progressieve karakter van DM2 niet 
ongedaan kunnen maken. Gedurende het ziektebeloop zal op den duur de 
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dosering van de gebruikte geneesmiddelen moeten worden verhoogd. Vaak 
moeten meerdere geneesmiddelen worden gecombineerd om het 
bloedglucosegehalte binnen de daarvoor geldende normaalwaarden te 
houden. Deze aanpak, in combinatie met de eerder genoemde verandering 
van leefgewoonte, kan lang voldoende resultaat hebben. Helaas zal voor een 
groot deel van de mensen deze behandeling niet voldoende zijn, waardoor 
uiteindelijk insuline zal moeten worden geïnjecteerd. Daarnaast laten studies 
zien dat de huidig beschikbare traditionele geneesmiddelen de aan DM2 
gerelateerde complicaties, zoals hart- en vaatziekten, onvoldoende 
voorkomen. Daarom zijn nieuwe geneesmiddelen noodzakelijk die het 
progressieve karakter en de complicaties van DM2 kunnen voorkomen. 
 
Glucagonachtig peptide-1 (GLP-1) 
Zoals eerder aangegeven zal na een maaltijd het glucosegehalte in het bloed 
stijgen, waarna de alvleesklier het hormoon insuline aan de bloedbaan zal 
afgeven. Dit is een gecompliceerd proces, waar meerdere signaalstoffen, 
maar ook b.v. het zenuwstelsel, een rol in spelen. Een van de signaalstoffen 
die een belangrijke rol speelt in de regulatie van de insulineproductie en -
afgifte na een maaltijd is de signaalstof glucagonachtig peptide-1, ook wel 
GLP-1 genoemd. GLP-1 wordt na de maaltijd in delen van de darm aan de 
bloedbaan afgegeven. In de alvleesklier zal dit afgegeven GLP-1 de aanmaak 
en afgifte van insuline stimuleren. Wetenschappelijk onderzoek heeft laten 
zien dat de GLP-1 productie bij mensen met DM2 is verminderd vergeleken 
met gezonde mensen. Echter, de werking van GLP-1 in de alvleesklier van 
mensen met DM2 is ongestoord. Dit heeft er toe geleid dat er GLP-1 achtige 
stoffen zijn ontwikkeld die als geneesmiddel kunnen worden gebruikt voor 
de behandeling van mensen met DM2. Het in dit proefschrift gebruikte 
geneesmiddel exenatide is zo'n, van GLP-1 afgeleide, stof. 
 
Exenatide 
Exenatide lijkt erg op GLP-1 zoals dat door de mens wordt gemaakt. Het is 
echter op een aantal punten verschillend, waardoor het een langere 
werkingsduur heeft (i.v.m. menselijk GLP-1). Wetenschappelijk onderzoek 
bij knaagdieren met DM2 heeft laten zien dat exenatide mogelijk de 
insulineproductie door de beta-cellen in de alvleesklier zou kunnen 
herstellen. Of behandeling met exenatide het progressieve karakter van 
DM2 ook in mensen gunstig zou kunnen beïnvloedden was bij aanvang van 
het in dit proefschrift beschreven onderzoek nog niet geheel duidelijk. 
Echter, eerder verricht wetenschappelijk onderzoek heeft laten zien dat 
behandeling van mensen met DM2 met exenatide leidt tot een acute 
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toename van insulineproductie door de alvleesklier. Als gevolg hiervan zal 
exenatidebehandeling in mensen met DM2 het bloedglucosegehalte 
verlagen. Naast deze gunstige effecten op de insulineproductie en 
bloedglucosegehalte toonde onderzoek ook aan dat mensen die met 
exenatide behandeld werden, minder gingen eten en hierdoor 
lichaamsgewicht verloren. Vermindering van lichaamsgewicht is in mensen 
met DM2 een belangrijke stap voor het verminderen van de kans op hart- 
en vaatziekten. Zoals eerder gezegd, is het met traditionele geneesmiddelen 
niet mogelijk het progressieve karakter van DM2 een halt toe te roepen. Na 
de ontdekking van de nieuwe, op GLP-1 gebaseerde, geneesmiddelen rees 
de vraag of dit met deze nieuwe groep geneesmiddelen wel tot de 
mogelijkheden behoorde. 
 
Bovenstaande leidde tot het in dit proefschrift beschreven onderzoek. De 
belangrijkste onderzoeksvragen van de studies beschreven in dit proefschrift 
waren: 
1. Leidt behandeling met exenatide, gedurende 1, dan wel 3 jaar, in 
mensen met DM2 tot een verbetering in insuline-afgifte? 
2. Zo ja, blijft deze verbetering in insuline-afgifte bestaan na het staken 
van de behandeling met exenatide? 
 
Daarnaast hebben wij geprobeerd antwoord op vier additionele vragen te 
verkrijgen. 
1. Leidt behandeling met exenatide tot een gunstige beïnvloeding van 
de koolhydraat- en vetstofwisseling na een maaltijd? 
2. Leidt behandeling met exenatide tot een verandering in 
lichaamssamenstelling en -vetgehalte? 
3. Leidt behandeling met exenatide tot een gunstige beïnvloeding van 
stoffen in het bloed die samenhangen met het risico op hart- en 
vaatziekten? 
4. Is behandeling met exenatide veilig? 
 
Om deze onderzoeksvragen te beantwoorden werden 69 mensen (45 
mannen en 24 vrouwen) met DM2 door loting toegewezen aan een 
behandeling met exenatide (36 mensen) of insuline glargine (33 mensen). 
Alleen mensen die behandeld werden met het orale bloedglucose verlagende 
geneesmiddel metformine werden tot de studie toegelaten. Daarnaast moest 
het bloedglucosegehalte van de deelnemers, ondanks de behandeling met 
metformine, bij aanvang van de studie niet binnen internationaal gestelde 
behandeldoelen (HbA1c <6.6%) zijn.  
Er werd gekozen om exenatide te vergelijken met het langwerkende 
insulinepreparaat glargine. Insuline glargine wordt in de regel 
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voorgeschreven als de behandeling met orale geneesmiddelen alleen 
onvoldoende behandeleffect laten zien. 
Deelnemers werden gedurende 1 jaar behandeld met exenatide of insuline 
glargine. Aan het einde van de behandelperiode werd de studiemedicatie 
gestaakt en werden de deelnemers gedurende 12 weken alleen nog 
behandeld met metformine. Voor en na de behandelperiode, en gedurende 
de 12 weken met alleen metformine behandeling, werd het effect van de 
behandeling op de bovengenoemde onderzoeksvragen gemeten. 
 
In hoofdstuk 2 werd het effect van 1 jaar behandeling met exenatide op 
insuline-afgifte, bloedglucosegehalte, lichaamsgewicht en 
insulinegevoeligheid onderzocht. In vergelijking met insuline glargine zagen 
wij een toename van de insuline-afgifte en een afname van het 
lichaamsgewicht. Het bloedglucosegehalte verbeterde in gelijke mate in de 
exenatide en de insuline glargine behandelde mensen. Er werd geen verschil  
in bloedglucosegehalte waargenomen tussen de twee behandelgroepen. Na 
het staken van de behandeling met exenatide, of insuline glargine, was er 
geen effect op de insuline-afgifte meer waarneembaar, gemeten vier weken 
na het stoppen van de studiemedicatie. Interessant was de bevinding dat de 
insulinegevoeligheid in de mensen behandeld met exenatide verbetert in 
vergelijking met de mensen behandeld met insuline glargine. Dit effect was 
mogelijk een gevolg van de nog steeds waarneembare afname in 
lichaamsgewicht, vier weken na het staken van de studiemedicatie. Het 
bloedglucosegehalte verslechterde geleidelijk gedurende de periode waarin 
de studiemedicatie was gestopt. Twaalf weken na het stoppen van de 
studiemedicatie was het bloedglucosegehalte gelijk aan het gehalte 
voorafgaand aan de studie. De conclusie van hoofdstuk 2 is dat 1 jaar 
exenatidebehandeling in mensen met DM2 leidt tot een toename in de 
insuline-afgifte, een afname in lichaamsgewicht en een verbetering in 
bloedglucosegehalte, maar dat deze toename niet blijvend is na staken van 
de studiemedicatie. Als mogelijkheid hiervan worden o.a. DM2 ziekteduur 
of een te korte behandelperiode genoemd. Om deze laatste mogelijkheid te 
onderzoeken is een langere behandelduur van in totaal drie jaar op de 
insuline-afgifte onderzocht. Resultaten van deze drie jaar durende 
behandelperiode worden beschreven in hoofdstuk 6. 
 
In hoofdstuk 3 werd het effect van 1 jaar exenatide behandeling op de 
koolhydraat- en vetstofwisseling na een vetrijke maaltijd onderzocht. 
Deelnemers kregen een hamburgermaaltijd als ontbijt en als lunch. Na 
inname van de maaltijden onderzochten wij de verandering in het 
bloedglucose- en bloedvetgehalte, als mede de mate van zuurstofschade 
veroorzaakt door deze verandering. Zuurstofschade is een riscofactor voor 
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het ontstaan van hart- en vaatziekten. Exenatide behandeling verlaagde het 
bloedglucose- en bloedvetgehalte na de maaltijd in vergelijking met insuline 
glargine. Ook de hoeveelheid zuurstofschade nam af na behandeling met 
exenatide en deze afname was statistisch gekoppeld aan de effecten op het 
bloedglucose- en bloedvetgehalte. 
 
De in hoofdstuk 2 beschreven effecten op de insuline-afgifte werden in een 
laboratoriumopstelling gemeten. De vraag was of de beschreven gunstige 
effecten van exenatide op de insuline-afgifte ook aanwezig zouden zijn 
wanneer gemeten na een maaltijd. De effecten van exenatide op de insuline-
afgifte gemeten na een maaltijd werd onderzocht in hoofdstuk 4. In 
vergelijking met insuline glargine namen verschillende aspecten van maaltijd 
gerelateerde insuline-afgifte toe na 1 jaar behandeling met exenatide. Deze 
bevindingen bevestigde de in hoofdstuk 2 beschreven resultaten en breidde 
deze verder uit. Interessant was dat in zowel de exenatide als in de insuline 
glargine behandelde mensen met DM2 een blijvend effect waarneembaar 
was op de relatie tussen bloedglucose en insuline-afgifte, 5 weken na het 
stoppen van de studiemedicatie.  
 
In hoofdstuk 5 werd het effect van 1 jaar exenatide behandeling op de 
lichaamssamenstelling en bloedrisicofactoren op hart- en vaatziekten 
bestudeerd. In vergelijking met insuline glargine was een afname in 
lichaamsgewicht waarneembaar in exenatide behandelde deelnemers. 
Aanvullend onderzoek naar de veranderingen in lichaamssamenstelling liet 
zien dat de afname in lichaamsgewicht met name veroorzaakt werd door 
een afname van het vetgehalte in de romp. Doordat ook de buikomvang in 
deze deelnemers afnam, mogen wij concluderen dat deze afname 
waarschijnlijk wordt veroorzaakt door een afname van het buikvetgehalte. 
Buikvet is een risicofactor voor het ontstaan van hart- en vaatziekten. Naast 
de beschreven afname in lichaamsvetgehalte zagen wij ook een gunstige 
verandering van in het bloed circulerende stoffen die samenhangen met het 
risico op hart- en vaatziekten. Adiponectine, een eiwit dat een gunstige 
werking heeft op de insulinegevoeligheid, nam toe. CRP, een ander eiwit dat 
door de lever geproduceerd wordt en een maat is voor systemische 
ontsteking, nam af. Deze resultaten suggereren dat exenatide mogelijk een 
gunstige invloed heeft op het ontstaan van hart- en vaatziekten in mensen 
met DM2. Echter, een definitief antwoord op deze vraag kan alleen gegeven 
worden na een langdurige studie met deze specifieke onderzoeksvraag. 
 
In hoofdstuk 6 werden de effecten van exenatide en insuline glargine op 
insuline-afgifte, bloedglucosegehalte, lichaamsgewicht en 
insulinegevoeligheid, na een behandelperiode van 3 jaar onderzocht. In 
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tegenstelling tot de in hoofdstuk 2 beschreven effecten op insuline-afgifte na 
1 jaar behandeling, zagen wij na 3 jaar behandeling een kleine afname in 
insuline-afgifte, 4 weken na het stoppen van de studiemedicatie. Echter, 
omdat er, als gevolg van de exenatidebehandeling, een aanzienlijke 
gewichtsafname had plaatsgevonden, was ook de insulinegevoeligheid 
toegenomen in de met exenatide behandelde deelnemers. Insuline-afgifte en 
insulinegevoeligheid zijn twee mechanismen die elkaar direct beïnvloeden. 
Als de insulinegevoeligheid afneemt zal de insuline-afgifte in gezonde 
mensen toenemen om te voorkomen dat het bloedglucosegehalte (te veel) 
stijgt. Tegenovergesteld, als er teveel insuline afgegeven wordt neemt de 
insuline gevoeligheid af om te voorkomen dat het bloedglucosegehalte te 
veel daalt. Deze relatie wordt beschreven in de dispositie index. In mensen 
met DM2 is deze relatie tussen insulinegevoeligheid en insuline-afgifte (en in 
de dispositie index) verstoord. In hoofdstuk 6 hebben wij laten zien dat als 
wij de afname in insuline-afgifte corrigeerden voor de toename in 
insulinegevoeligheid er een toename was van de dispositie index. Dit effect 
was niet waarneembaar na behandeling met insuline glargine. Omdat na 12 
weken stoppen met de studiemedicatie in beide behandelgroepen het 
bloedglucosegehalte  terug was op het niveau van voor de behandeling mag 
worden verondersteld dat deze verbetering in de dispositie index 
onvoldoende was om een blijvend gunstig effect op de 
koolhydraatstofwisseling te bewerkstelligen. Of dit op een andere manier wel 
mogelijk is, moet toekomstig aanvullend onderzoek aantonen. 
 
In hoofdstuk 7 werd aangetoond dat de behandeling met exenatide geen 
nadelige effecten heeft op de botmineraaldichtheid. Nadelige effecten op de 
gezondheid van de botten werd in eerder onderzoek met de bloedglucose 
verlagende geneesmiddelengroep thiazolidinedione aangetoond. Het is 
hierdoor belangrijk om bij nieuwe middelen voor de behandeling van DM2 
aan te tonen dat zij geen negatieve effecten hebben op o.a. de 
botmineraaldichtheid. 
 
Leververvetting wordt geassocieerd met een toegenomen risico op hart- en 
vaatziekten. In hoofdstuk 8 werd het effect van exenatide op het 
levervetgehalte onderzocht in een van de deelnemers die in de studie 
exenatide kreeg toegewezen. Exenatidebehandeling verlaagde het 
levervetgehalte van 15,8% naar 4,3%, een waarde onder de grens 
waarboven gesproken wordt van leververvetting. Ondanks dat in dit 
hoofdstuk slechts een deelnemer beschreven wordt, laten de resultaten zien 
dat exenatide mogelijk een rol kan spelen in de behandeling van mensen 
met leververvetting.  
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Suggesties voor toekomstig onderzoek 
De resultaten van het in dit proefschrift beschreven onderzoek laat zien dat 
behandeling van mensen met DM2 met exenatide leidt tot een: 
• Toename van de insuline-afgifte; 
• Verlaging van het bloedglucosegehalte; 
• Verlaging van het lichaamsgewicht en lichaamsvetgehalte; 
• Toename van de insulinegevoeligheid; 
• Gunstige beïnvloeding van diverse risicofactoren voor hart- en 
vaatziekten. 
 
Echter de hierboven beschreven (gunstige) effecten verdwenen enige tijd na 
het staken van de behandeling met exenatide. Toch heeft het onderzoek 
beschreven in dit proefschrift laten zien dat   in theorie de insuline-afgifte 
(gemeten als dispositie index) mogelijk blijvend gunstig kan worden 
beïnvloed met behulp van GLP-1 gerelateerde stoffen zoals exenatide. De in 
dit proefschrift gebruikte studiepopulatie was echter mogelijk al te lang 
bekend met DM2. Hierdoor is mogelijk de potentie tot herstel van de 
insuline-afgifte onvoldoende. Toekomstig onderzoek bij mensen met een 
voorstadium van DM2 is nodig om te bestuderen of behandeling met 
exenatide de overgang naar DM2 kan uitstellen of eventueel kan 
voorkomen. Tevens is toekomstig onderzoek nodig om te bepalen of 
langdurig gebruik van exenatide aan DM2 gerelateerde complicaties kan 
voorkomen en veilig is.  
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List of abbreviations 
ACE   Angiotensin converting enzyme 
AIR   Acute insulin response 
AIRarg  Acute insulin response to arginine 
ALT   Alanine aminotransferase 
ANCOVA  Analysis of covariance 
AST   Aspartate aminotransferase 
AUC   Area under the curve 
bGS   Beta-cell glucose sensitivity 
BID   Twice daily 
BMD   Bone mineral density 
BMI   Body mass index 
BW   Body weight 
CI   Confidence interval 
CRP   C-reactive protein 
CVD   Cardiovascular disease 
DCCT  Diabetes control and complications trial 
DEXA   Dual energy x-ray absorptiometry 
DI   Disposition index 
DPP-4   Dipeptidyl peptidase 4 
ELISA   Enzyme-linked immunosorbent assay 
EMA   European medicines agency 
FABP2  Fatty acid binding protein 2 
FDA   Food and drug administration 
FFA   Free fatty acid 
FPG   Fasting plasma glucose 
FSIGT  Frequently sampled intravenous glucose tolerance test 
GGT   Glutamyltranspeptidase 
GI   Gastrointestinal 
GIP   Glucose-dependent insulinotropic polypeptide 
GLP-1   Glucagon-like peptide-1 
GLP-1RA  Glucagon-like peptide-1 receptor agonist 
Hb   Hemoglobin 
HbA1c  Glycated hemoglobin  
HDL   High-density lipoprotein 
HMG-CoA  3-hydroxy-3-methylglutaryl-coenzyme A 
HMW   High molecular weight 
HOMA  Homeostasis Model Assessment 
hsCRP   High-sensitive C-reactive protein 
iAUC   Incremental area under the curve 
IG   Insulin glargine 
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IL   Interleukin 
IQR   Inter quartile range 
ISR   Insulin secretion rate 
LDL   Low-density lipoprotein 
LEAD   Liraglutide effect and action in aiabetes 
LS   Least squares 
MCP   Monocyte chemotactic protein 
MDA   Malondialdehyde 
MET   Metformin 
mRNA  Messenger ribonucleic acid 
N   Number of patients 
NA   Not applicable 
NAFLD  Non-alcoholic fatty liver disease 
NR   Not reported 
oxLDL  Oxidized low-density lipoprotein 
p-   Plasma 
PFR   Potentiation factor ratio 
PPAR   Peroxisome proliferator-activated receptors 
QD   Once daily 
QW   Once weekly 
s-  Serum 
SCD1   Stearoyl-CoA desaturase-1 
SD   Standard deviation 
SEM   Standard error of mean 
SMBG   Self-monitored blood glucose 
SREBP  Sterol regulatory element binding protein 
SU   Sulphonylurea 
TC   Total cholesterol 
TID   Three times daily 
TZD   Thiazolidinedione 
UKPDS  United Kingdom Prospective Diabetes Study 
VLDL   Very-low-density lipoprotein 
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